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Summary 
The work described in this thesis identifies some 
properties of the major polypeptides of pneumonia virus of 
mice (PVM) and of turkey rhinotracheitis (TRT) virus. The 
PVM glycoproteins have been studied in particular detail 
while the results obtained with TRT virus provide a 
preliminary description of the polypeptides of this virus. 
Twelve major PVM specific polypeptides designated L, G1, 
G2, F1, N, 39K, 35K, M, 20K, 19K, 16K and 12K were 
identified. In addition PVM specific polypeptides 
designated 25K, 24K, 23K, 18K and 17K were sometimes 
detected. Monoclonal antibodies directed against the G1/G2, 
39K and M polypeptides were produced. 
The a~ility of a monoclonal antibody to precipitate 
G1 and G2 suggested that these two glycosylated proteins 
were related and this was confirmed by tryptic peptide 
mapping. G2 was shown to be derived from G1 in pulse chase 
experiments and a similar relationship between two higher 
mobility polypeptides synthesized in the presence of 
tunicamycin was observed. The G protein may have a 
precursor since G1 did not appear immediately following a 
pulse labelling. The precursor could not however be 
identified. An additional minor glycosylated polypeptide of 
42K was found to be related to the G protein. 
The F1 protein appeared to be poorly glycosylated and 
a difference in mobility of the polypeptide synthesized in 
the presence of tunicamycin did not appear to be directly 
due to a lack of N-linked oligosaccharides. The polypeptide 
migrated more slowly under non-reducing conditions but no 
evidence of a small disulphide bonded polypeptide was found 
in contrast to the situation with other paramyxoviruses. 
This polypeptide appeared to be the major PVM protein 
expressed on the cell surface and was associated with G1 
and G2 as the major protein in a particulate fraction of 
the infected cell supernatant. 
Tentative relationships were suggested between the 
39K, 35K and 25K polypeptides, the M and 24K polypeptides 
and the 20K and 19K polypeptides. This together with the 
observation that the 12K polypeptide was not a primary gene 
product suggested that there may be about 11 PVM 
polypeptides. The N or 39K and the 20K or 19K polypeptides 
were observed to be phosphorylated. 
Twelve possible TRT virus specific polypeptides of 
150K, 129K, 95K, 83K, 57K, 45K, 38K, 35K, 3DK, 23K, 19K and 
15K were identified. The 150K, 95K, 83K, 57K, 45K and 15K 
polypeptides were glycosylated with the latter three 
polypeptides showing a similar relationship to the F1,2, F1 
and F2 polypeptides of paramyxoviruses. A broad 
glycosylated band designated the 31K polypeptide was 
identified that was similar to a smeared band observed on 
prolonged exposure of immunoprecipitates of PVM 
polypeptides labelled with [3H]-glucosamine. The 35K and 
19K polypeptides were observed to be phosphorylated. 
PVM may be more closely related to RS virus than TRT 
virus since anti-PVM serum irnmunoprecipitated the RS virus 
N polypeptide but not any TRT virus polypeptides. The PVM 
39K polypeptide and the RS virus P protein were recognised 
by a monoclonal antibody providing further evidence of a 
relationship between PVM and RS virus. 
x~i 
INTRODUCTION 
INTRODUCTION 
The genus Pneumovirus is a group of viruses belonging 
to the family Paramyx'ovir idae, the other genera ir.l this 
family being the genus Paramy.wH'irus which includes mumps 
virus and parainfluenza viruses 1, 2, and 3, and the genus 
/'tor b iII i ~I i r us , which includes 
di'stemper virus, rinderpest virus 
ruminants virus (Kingsbury et 
measles virus, 
and peste des 
al . , 1978). 
canine 
petits 
The 
Paramyxov1ridae are classified in group V of the Baltimore 
classification, having a single stranded RNA genome 
complementary to the viral messenger RNA. They are enveloped 
viruses having glycoprotein spikes and an internal 
nucleocapsid structure containing the viral RNA. The genome 
consists of a single RNA molecule which is transcribed from 
a single promoter at the 3' end. The classification of the 
Paramyxoviridae into the three genera is based largely on 
the biological properties of the larger of the two 
glycoproteins and, in the case of the pneumoviruses on the 
dimensions of the nucleocapsid. The large glycoprotein of 
the paramyxoviruses, designated HN, is responsible for 
haemagglutination by the virus and its neuraminidase 
activity, in the morbilliviruses the analogous protein 
designated H has haemagglutinating activity only. 
Respiratory syncytial virus, the type member of the 
Pneumovirus genus lacks both activities. The genus 
Pneu.(wirus has 3 established members, human respiratory 
syncytial virus, bovine respiratory syncytial virus and 
1 
pneumonia virus of mice, (PVM). Recently a fourth virus 
which may be placed in this genus has been described, Turkey 
rhinotracheitis virus (TRT virus). The involvement of these 
viruses in disease of man and animals and a description of 
the genome structure and the virus associated polypeptides 
that have been observed are described below. One of the aims 
of the project was to compare the polypeptides of PVM with 
H 
those of RS virus and so RS virus polypeptides are described 
in some detail. The introduction is concluded with the aims 
of the work described in this thesis. 
1.1 Human respiratory syncytial virus 
Human respiratory syncytial virus is a major cause of 
respiratory disease in young children, being associated with 
bronchiolitis and pneumonia in infants under 1 year of age 
more often than any other agent. The involvement of this 
virus in respiratory disease has been reviewed by Chanock et 
a1. (1976) and Stott and Taylor (1985). The virus was first 
isolated from children with respiratory disease by Chanock 
et al. (1957) and was found to be antigenically related to 
an agent isolated earlier from chimpanzees showing mild 
upper respiratory tract disease (Morris et a1., 1956). The 
name of the virus was given to it because of its cytopathic 
effect on cells in culture. The studies reviewed by Stott 
and Taylor (1985) and Chanock et al. (1976), showed that 
most infants were infected during the first year of life and 
that reinfection was common, most disease in infants being 
observed in the winter months in temperate climates. The 
2 
virus does not usually cause lower respiratory tract disease 
in adults although infection is rarely believed to be 
asymptomatic, usually causing upper respiratory tract 
infection. Infections are more severe in immunocompromised 
patients and the elderly. In old peoples homes and geriatric 
wards for example a disease clinically similar to influenza 
and commonly progressing to bronchopneumonia with 
~ 
significant mortality levels has been observed (Garvie & 
Gray, 1980; PHLS, 1983). Adult volunteers have been infected 
with respiratory syncytial virus despite having serum 
neutralizing antibody (McKay et aJ., personal communication; 
Mills et al., 1971) and in a comparison of consecutive 
natural infections, Beem (1967) failed to detect any 
difference between virus strains using sera from the 
infected individuals although differences were observed 
using ferret sera. In contrast monoclonal antibodies have 
been used to distinguish 2 (Mufson et al., 1985) or 3 
(Anderson et al' J 1985) subgroups of the virus but how 
these relate to the occurrence of reinfections is not clear. 
The A and B subgroups of RS virus differ not only in 
reaction patterns with monoclonal antibodies but also in the 
mobilities of the F and P proteins (Gimenez et al., 1986; 
Norrbyet al., 1986). The gene coding for the G protein, 
which showed the greatest number of differences between 
antigenic sites between the two subgroups (Mufson et al' J 
1985) has been shown to differ significantly in sequence 
between the two subgroups (Johnson et aI., 1987a). Most of 
the data described in the following sections refer to A 
3 
subgroup viruses with which most of the published work was 
carried out. 
1.1.1 Genomic organization of the A subgroup of Respiratory 
syncytial virus. 
The order of the RS virus genes on the genome has 
been determined by comparison of size and sequence homology 
of polycistronic readthrough transcripts identified by 
hybridization of cDNA clones of the viral mRNA molecules 
with Northern blots of infected cell RNA, (Collins & Wertz, 
1983; Collins et aJ., 1984a). The transcription of the genes 
from a single promoter and the order in which the 
transcripts are made have been demonstrated by Dickens et 
al. (1984) using ultraviolet inactivation studies. The two 
maps give the same gene order which is shown in Figure 1 
along with the gene orders of other non-segmented negative 
stranded RNA viruses. The nucleocapsid gene N is the first 
gene to be transcribed in all of the viruses shown in Figure 
1 except for RS virus where two small genes, NSIC and NSIB 
are located immediately after the promoter. Translation of 
viral messenger RNA molecules isolated by hybrid selection 
with the corresponding cDNA clones showed that NS1C and NS1B 
coded for polypeptides migrating in SDS-PAGE with 
mobilities corresponding to ~s of 14.000 and 11,000 
respectively (Collins et al., 1984a). The MrS of these 
polypeptides obtained from sequence data are 15,565 and 
14,674 (Collins & Wertz, 1985c). The messenger RNA molecules 
corresponding to these genes are the most abundant in 
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Figure 1 Gene order of non-segmented negative strand viruses 
This figure, redrawn from Pringle (1987), shows the 
gene order or rhabdoviruses and paramyxoviruses. The'3' 
promoter CPr) is shown at the top and the 5' end of the 
genome at the bottom. Genes present only in some viruses are 
shown in blue, genes encoding a fusion glycoprotein are shown 
in red and genes encoding an attachment glycoprotein are 
shown in orange. The original sources of the gene 
arrangements were as follows:-
VSV Hudson et al. (1986) 
Rabies virus (RV) Tordo et al. (1986) 
Haematopoetic necrosis virus (HNV) Kurath et al. (1985) 
Measles virus (MV) Rima eta 1. (1986 ) 
, 
Dowling et .. 1. (1986) 
Parainfluenzavirus type 1 (PI1) Blumberg et al. (1985a,b) 
Shioda et .. 1. (l986) 
SV5/parainfluenzavirus type 2 (PI2) Paterson et al. (1984) 
Newcastle disease virus (NDV) Chambers et al. (1986a) 
Respiratory syncytial virus (RS) Collins et al. (1984a,b) 
\ 
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infected cells as expected from the predicted attenuation of 
transcription with increasing distance from the promoter 
(Collins & Wertz, 1983). 
The gene order of the N, P, and M genes is similar to 
that observed for other paramyxoviruses and rhabdoviruses. 
The N gene of RS virus has an open reading frame encoding a 
protein of 391 amino acids with a calculated Mr of 42,600. 
~ 
The P gene encodes a polypeptide of Mr 27,150 in the A2 
strain (Satake ~t al., 1984) and 27,166 in the Edinburgh 
strain (Lambden, 1985), both being devoid of cysteine and 
tryptophan residues. The ~ calculated from the sequence is 
less than that observed by SDS-PAGE. This may be due to the 
altered binding of SDS to proteins rich in aspartic acid and 
glutamic acid residues. 
The P gene of the A2 strain of RS virus does not have 
a second open reading frame as has been observed for the 
corresponding gene in vesicular stomatitis virus, (Herman, 
1986; Hudson et al., 1986), measles virus (Bellini et aI., 
1985) and Sendai virus, (Giorgi et al., 1983; Shioda et al., 
1983) or an internal gene at a separate initiation site as 
observed in mumps virus (Herrler & Compans, 1982), Newcastle 
disease virus (Collins ~t al., 1982) and SV5 (Peluso et al., 
1977; Paterson ~t aI., 1984). Lambden (1985) has reported a 
second open reading frame in the Edinburgh strain of RS 
virus which overlaps the 3' end and potentially encodes a 
protein of 65 amino acids. The significance of this is not 
MO~. 
The M gene of RS virus has an open reading frame 
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encoding a polypeptide of 256 amino acids with a calculated 
Mr of 28,717 (Satake & Venkatesan, 1984). The protein has 
two clusters of hydrophobic amino acids in the carboxy 
terminal third of the molecule which could interact with 
membrane components. A second open reading frame in the M 
gene could potentially encode a polypeptide of 75 amino 
acids but this has not been observed and the initiation 
., 
codon, unlike that for the M protein does not lie in a 
conserved sequence found in functional eUkaryotic 
initiation sites. Some recombinant plasmids with M gene 
sequences had been observed to select messenger RNA for M 
and a 15,000 ~ polypeptide but no suitable sites could be 
found in the RS virus sequences known that could act as 
donor sites for a spliced message encoding such a 
polypeptide. 
RS virus has an additional gene located between the 
matrix protein gene and the glycoprotein genes compared with 
the other paramyxoviruses. This gene encodes a polypeptide 
with an Mr of 7536, designated NSIA (Collins & Wertz, 
1985b), which has an apparent Mr of 9500 when it is 
synthesized iTt vitro, (Collins et ;:,1 . , 1984a) . This 
polypeptide has two potential N-linked glycosylation sites 
and exists in infected and uninfected cells in both 
glycosylated and unglycosylated forms (Olmsted et ;:,1 • , 
personal communication). 
The RS virus glycoprotein genes are arranged on the 
genome in a different order compared with those of other 
members of the Para1ftyxoviridae . The fusion protein gene of 
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RS virus has a similar structure to that of other members of 
the Paramyxoviridae, the location of cysteine residues in 
RS virus being similar to that in the Newcastle disease 
virus fusion protein (Chambers et a1. 1986b). The F gene 
encodes a polypeptide of 574 amino acids with a calculated 
~ of 63,453 for the A2 strain (Collins et a1., 1984b) and 
63,417 for the RSS-2 strain (Baybutt & Pringle, 1987). 
Collins et a1. (1984b) identified an amino terminal signal 
sequence at residues 1 to 22, a transmembrane region at 
residues 525 to 550, a cleavage site at position 131 to 136 
and a hydrophobic region at residues 137 to 154 which would 
become the amino terminus of the larger fragment, Fl. The 
amino terminal F2 portion was relatively hydrophilic and had 
4 of the 5 possible N-linked glycosylation sites. The amino 
terminal signal sequence showed less homology between 
strains than the remainder of the F gene sequence. 
The G glycoprotein gene of RS virus differs 
significantly from the analogous gene of other non-segmented 
negative strand viruses. The Mr of the polypeptide coded for 
by the gene for the G glycoprotein is 32,587 compared with 
an estimated size for the glycoprotein in polyacrylamide 
gels of 84,000 to 90,000 (Wertz et a1. J 1985). The sequence 
contains a high proportion of serine and threonine residues 
which are potential acceptor sites for O-linked 
glycosylation, this type of modification being believed to 
account for most of the difference between the predicted 
size of the primary gene product (and that produced iTi 
vitro ) and the estimated size of the polypeptide observed 
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on SDS-polyacrylamide gels. There is no amino terminal 
hydrophobic signal sequence or carboxy terminal hydrophobic 
membrane anchoring region. Wertz et al. (1985) suggest that 
a hydrophobic region near the amino terminus may perform 
both these functions. 
The M2 (22K or 24K), protein gene of RS virus has no 
counterpart in other viruses in the family Paramyxoviridae. 
Viruses of the Lyssavirus genus of the Rhabdoviridae have a 
gene between the glycoprotein gene and the L protein gene 
(Tordo et al., 1986; Kurath et al' J 1985). However this gene 
encodes a non-structural protein in infectious hematopoietic 
necrosis virus and is non-functional in rabies virus. In 
contrast the RS virus M2 protein gene encodes an envelope 
associated protein (Huang et al., 1984, 1985). The sequence 
of the M2 protein gene has been determined for the A2 strain 
by Collins & Wertz (1985a) and for the RSS-2 strain by 
Baybutt & Pringle (1987). The sequences suggest that it is a 
hydrophillic protein and is the most basic of the RS virus 
proteins. The protein coded for by this gene has 194 amino 
acids and a ~ of 22,153 for the A2 strain and 22,140 for 
the RSS-2 strain. A second open reading frame also exists in 
this gene which potentially encodes a protein of 90 amino 
acids, however no protein corresponding to this has been 
observed ir, vivo or iTi ~/itro. 
Only a small part of the sequence of the L gene has 
been determined. This gene is presumed by analogy with the 
largest gene in VSV to encode the virion 
transcriptsse/polymerase. The L gene was found to lack the 9 
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nucleotide start sequence that is conserved between all the 
other RS virus genes (Collins et al., 1987). The start of 
the L gene was found to overlap the end of the M2 gene and 
showed two nucleotide differences from the ,conserved 
sequence at the start of the gene. The most abundant L gene 
transcript was found to be a truncated transcript probably 
due to recognition of the M2 gene transcription termination 
and polyadenylation signals. Readthrough transcripts were 
known to occur for all the RS virus genes and this was 
proposed to be the mechanism for production of full length L 
gene'transcripts. It is not known if the truncated L mRNA is 
simply a by-product of transcriptional attenuation or if it 
is also a functional mRNA since it contains two open reading 
frames (Collins et al. 1987). 
Collins et al. (1986a) have sequenced the intergenic 
regions of RS virus and found no conserved features apart 
from a conserved adenosine at the end. The intergenic region 
between the F and M2 genes is less conserved than the 
sequences of the two genes between the A2 and RSS-2 strains 
(Baybutt & Pringle, 1987). Each gene had a sequence 
5'-GGGGCAAAU-3' at the beginning except for the presumed 
start of the L gene. The gene sequence ended with 
AGUUA(A/C)(A/U)(A/U)(A/U)AAAA for the 1e, N, P, H, lA and G 
genes or AGU(A/U) (A/U) (A/U)AAAA for genes lB, F and H2. 
1.1.2 Polypeptides of human respiratory syncytial virus 
The first experiments carried out to characterize the 
polypeptides of RS virus identified most of the structural 
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proteins of the virus but did not establish the virus 
specificity of the G glycoprotein (Cash et al., 1977; Cash 
et a1., 1979b; Levine, 1977; Peeples & Levine, 1979; Wunner 
& Pringle, 1976). These authors identified polypeptides 
corresponding to the L, F1, N, P, M and M2 polypeptides. 
Levine (1977) and Peeples & Levine (1979) identified the G 
protein in the Long strain of RS virus purified from the 
supernatants of Hela cells infected at high multiplicity. 
They could detect the G polypeptide using either 
[3H]-glucosamine or a 3H amino acid mixture to label the 
polypeptides. Cash et a1. (1977,1979b) and Wunner & Pringle 
failed to identify this protein using [ 35 S]-methionine 
labelling of RS virus polypeptides in BS-C-1 cells infected 
at a low m.o.i with several strains of RS virus. A 
polypeptide with a mobility corresponding to that of the G 
protein was identified using [3H]-glucosamine labelling but 
there was a cellular glycoprotein with the same mobility. It 
has subsequently been found that the virus strain, cell type 
and label used affect the ease with which the G glycoprotein 
can be identified (Dubovi, 1982; Pringle et a1., 1981; 
Routledge et a1 .• 1986). 
The non-structural polypeptides corresponding to the 
produc~s of the NS1A, NSIB and NS1C genes have been observed 
less often partly because many studies concerned the 
polypeptides of partially purified virus. Cash et a1. (1977) 
detected a 10K polypeptide that could have corresponded to 
the 9.5K or 11K polypeptide products of the NSIA or NSIB 
genes. Dubovi (1982) detected a 14K polypeptide that could 
11 
have corresponded to the product of the NS1C gene. Cash et 
al . (1979b) detected a 17K polypeptide amongst the 
polypeptides synthesized in vitro using RNA from RS virus 
infected cells, the nature of which is not clear. The 
products of the NS1A, NS1B and NS1C genes have been observed 
in irl translation experiments (Collins et al., 
1984a).The properties of the RS virus polypeptides that have 
tl 
been described are given below. 
The L polypeptide 
The L polypeptide is not well labelled probably due to 
attenuation of transcription and production of truncated 
mRNA molecules as described above in Section 1.1.1. It has 
been identified both in infected cells (Cash et al., 1977) 
and in purified virus (Peeples & Levine, 1979). Detergent 
and salt treatment of purified virus (Peeples & Levine, 
1979), purification of nucleocapsids from virus on caesium 
chloride gradients (Lambert & Pons, 1983) and isolation of 
nucleocapsids . by gel filtration of clarified cell lysates 
(Huang et al., 1984) have revealed that the L protein is 
nucleocapsid associated. By analogy with the large 
polypeptide of the rhabdovirus VSV it has' been suggested 
that this polypeptide is a component of the viral RNA 
dependent RNA polymerase. An RNA dependent RNA polymerase 
activity has been demonstrated for RS virus in vitro but the 
polypeptides associated with the reaction mixtures were not 
described (Mbuy & Rochovansky, 1984). 
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The G glycoprotein 
The viral specificity of this polypeptide was not at 
first clear as described above. Pringle et al. (1981) showed 
that this polypeptide was not readily labelled with 
[35 S]-methionine but could be readily labelled with 
[3H]-glucosamine. Dubovi (1982) also observed that the G 
protein was not well labelled with [ 35 S]-methionine but 
could be labelled with [3 H]-leucine. This lead to the 
conclusion that the G protein had a low methionine content 
which was confirmed by the sequence of the gene (Wertz et 
al . ,. 1985). Pringle et al. (1981) also observed that the 
intensity of the band representing the mature form of the G 
protein (~ of 80,000 to 90,000), varied depending on virus 
strain and cell type used. In partially purified virus G was 
detected more readily with the Long and A2 strains than with 
the RSN-2 strain and was labelled better when the virus was 
grown in HEp-2 cells than when it was grown in BS-C-l cells. 
Routledge et al. (1986) using monoclonal antibodies to the G 
protein in immunoprecipitation experiments observed two G 
related polypeptides of 50K and 45K as major bands in A2 
strain infected BS-C-l and Vero cells. These bands were not 
so prominent with the 
cells and HEp-2 cells. 
observe any progression 
Long strain and were weak in Bela 
Routledge et al. (1986) did not 
of label between these G related 
polypeptides in a pulse chase experiment so the relationship 
between these forms of the G protein is not known. 
The nature of the oligosaccharides and the processing 
of precursors to give the mature form of the G protein has 
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been described by several authors. The effects of the 
inhibitors and glycosidases used to study virus 
glycoproteins are described in Appendix 1. The size of the 
unglycosylated polypeptide synthesized iT, vitro is only 
about 36K when determined by SDS-PAGE compared with the size 
of the mature glycosylated form of 80-90K (Wertz et al . , 
1985). Fernie et al. (1985) have proposed two possible 
explanations for this. The G protein may consist of a dimer 
of a glycosylated 45K polypeptide or the polypeptide may be 
heavily glycosylated. The latter explanation is considered 
the most likely by most authors. The nature of the 
oligo saccharides has been 
glycosylation inhibitors 
studied 
and 
by the use of 
digestion with 
endoglycosidases. Two types of oligosaccharides have been 
described for the G protein. Fernie et al. (1985), Gruber & 
Levine (1985a), Lambert & Pons (1984) and Wertz et al. 
(1985) showed that treatment of RS virus infected cells with 
tunicamycin resulted in the production of a G protein with a 
slightly increased mobility due to the absence of N-linked 
carbohydrate. It was observed that the G protein was 
labelled with [3H]-glucosamine under these conditions 
indicating that not all of the oligosaccharides of the G 
protein were N-linked. The N-linked carbohydrate of the 
mature form of G was not sensitive to endo-H showing that 
they were of the complex type (Fernie et al., 1985; Gruber & 
Levine, 1985a; Lambert & Pons, 1984). The susceptibility of 
the G protein to digestion with endo-D depended on the cell 
type in which the virus was grown. When CV-l cells were used 
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an increase in mobility of the G protein was observed but 
with HEp-2 cells digestion with neuraminidase as well as 
endo-D was required to produce a mobility change (L~bert & 
Pons, 1984). Neuraminidase also enhanced the action of 
endo-D on the G protein of RS virus grown in CV-l cells. 
This suggests that the presence of neuraminic acid in the 
glycoprotein was cell type specific and inhibited the action 
of endo-D which only cleaves some types of complex N-linked 
oligosaccharides. Endo-F resulted in the disappearance of a 
band corresponding to the mature G protein and the 
appearance of a 43K polypeptide of unknown relationship to 
the G or F protein (Lambert & Pons, 1984). The result of the 
digestions with endo-F has not been studied further and the 
authors did not offer an explanation of the result. 
The presence of Q-linked oligosaccharides on the G 
glycoprotein has been studied indirectly using monensin 
treatment of infected cells to inhibit Golgi apparatus 
functions. Gruber & Levine (1985a) and Fernie et al. (1985) 
observed a marked increase in the mobility of the G protein 
in monensin treated cell lysates. This together with the 
high serine/threonine content of the predicted amino acid 
sequence (Wertz et al' J 1985) has been interpreted as 
evidence for a high degree of Q-linked glycosylation. The 
size of the G related protein in monensin treated RS virus 
infected cells (45K) suggests that a large part of the 
mobility difference between the size of the G protein 
calculated from the predicted amino acid sequence and that 
calculated from the results of SDS-PAGE analysis of the 
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protein is due to Q-linked oligosaccharides. The relatively 
low incorporation of mannose into the G protein described by 
Gruber & Levine (1985a) is al~o consistent with a large 
proportion of Q-linked oligosaccharides which usu~lly lack 
mannose (Kornfield & Kornfield, 1980). 
Synthesis of the G protein in RS virus infected cells 
has been studied in pulse chase experiments by Fernie et al. 
(1985) and Gruber & Levine (1985b). These authors observed 
a precursor of about 45K which decreased in intensity after 
chase periods whereas the G protein increased in intensity 
with increasing length of the chase periods up to about 50 
minutes. Fernie et aI. (1985) also observed a 29K 
polypeptide with [3H]-leucine labelling that decreased in 
intensity with increasing length of the chase period. 
Labelling with [3H]-glucosamine revealed the polypeptides 
described above and several additional polypeptides with 
mobilities intermediate between those of the 29K and 45K 
polypeptides. Monensin was observed to slow down the 
processing of the 45K polypeptide to give the fully 
glycosylated G protein which could only be observed with 
carbohydrate labels. The 45K polypeptide could be identified 
. sH 1 . us~ng - euc~ne label. Labelling with [3H]-glucosamine or 
[3H]-mannose (but not [3H]-fucose or [3H]leucine) revealed a 
ladder of glycosylated polypeptides from 26K to 45K that was 
more evident in samples from monensin treated cells than in 
samples from untreated cells. Unlike the mature G protein 
'the higher mobility polypeptides were endo-H sensitive 
showing that they were not breakdown products of G that were 
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produced during the sample preparation. These polypeptides 
therefore appeared to represent precursors to G that had 
high mannose N-linked oligosaccharides but not complex or 
Q-linked oligosaccharides. Tunicamycin did not inhibit the 
incorporation of [3H]-glucosamine or [3H]-fucose into G 
did inhibit incorporation of [3H]-mannose which 
consistent with the inhibition of addition of N-linked 
but 
was 
but 
not O-linked oligosaccharides to 
polypeptide and a 34K polypeptide 
the G 
that 
protein. A 70K 
chased out in 
tunicamycin treated infected cells probably represented the 
G and 45K polypeptides without their N-linked 
oligosaccharides. These results suggested that addition of 
O-linked oligosaccharides occurred more slowly and 
independently of addition of N-linked oligosaccharides. 
Hendricks et al. (1987) found that the G protein had a 
calculated ~ of 82K in the supernatant compared with 88K 
when it was immunoprecipitated from cell lysates. These 
authors found that the G protein was the glycoprotein most 
readily precipitated from the supernatants of infected cells 
and could be detected at the top of a gradient used to 
separate virus from free polypeptides. They suggested that 
the G protein was released into the supernatant like the G. 
protein of VSV. (The VSV G. protein is a truncated form of 
the viral G protein that is synthesized intracellularly and 
secreted into the medium (Graeve et al., 1986; Chen et al., 
1987).) 
Antibodies directed against the G glycoprotein have 
been found to neutralize plaque formation by RS virus but 
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not to inhibit fusion of RS virus infected cells. Many 
anti-G monoclonal antibodies do not neutralize the virus. 
For example Fernie et al. (1982) found that none of 15 
anti-G protein monoclonal antibodies neutralized the virus. 
Walsh & Hruska, (1983) found that one of two anti-G protein 
monoclonal antibodies neutralized RS virus in the presence 
of complement. Tsutsumi et al. (1987) suggested that the 
type of anti-G monoclonal antibodies produced depended on 
the immunization protocol used. When intraperitoneal 
injections with Freund's adjuvant were used the anti-G 
monoclonal antibodies did not neutralize. When 80rdetella 
pertussis was used as the adjuvant the monoclonal antibodies 
obtained neutralized RS virus although some of them required 
the presence of complement to have this effect. When 
intranasal infection was used all the anti-G monoclonal 
antibodies obtained neutralized RS virus in the absence of 
complement. Three sites were identified on the G protein one 
eliciting production of antibodies that did not neutralize 
and two that elicited production of antibodies that 
neutralized the virus in the absence of complement. One of 
the two sites eliciting production of neutralizing 
antibodies was also present on the 50K G-related 
polypeptide. The overall results of the experiments 
described by these authors, in contrast to all other groups, 
showed that a higher proportion of anti-G protein monoclonal 
antibodies than anti-F protein monoclonal antibodies 
neutralized the virus. Monoclonal antibodies are not ideal 
for determining which proteins induce production of 
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antibodies inhibiting biological properties such as 
infectivity and cell fusion. This is because each monoclonal 
antibody only binds to a single antigenic site which mayor 
may not be involved in the function being, studied. 
Experiments with polyclonal antisera therefore give a better 
overall idea of the functions of the RS virus proteins. 
Walsh et al. (1984a) raised antibody to the G protein 
purified by affinity chromatography using an anti-G protein 
monoclonal antibody. This serum neutralized the virus in the 
absence of complement but did not inhibit fusion. This serum 
also inhibited the bindi~g of purified G protein to HEp-2 
cells. This serum and an antiserum raised against the RS 
virus G protein expressed from a clone of the gene in a 
vaccinia virus vector inhibited the attachment of purified 
[ 35 S]-methionine labelled RS virus to HeLa cells (Levine et 
al .• 1987). These results suggested that the G protein was 
the attachment protein of RS virus. 
The F glycoprotein 
The F glycoprotein of RS virus is a glycosylated 
polypeptide of about 70K that is cleaved to give two 
disulphide bond linked polypeptides of about 45-50K and 
20-25K (Gruber & Levine, 1983; Lambert & Pons, 1983). The 
larger fragment (F1) can be readily labelled with 
[ 35 S]-methionine (Wunner & Pringle, 1976; Cash et al., 
1977). A 140K dimer has also been identified under 
'non-reducing conditions (Lambert & Pons, 1983; Walsh et al .• 
1985; Trudel et al .• 1986). The FO, F1 and F2 related 
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polypeptides were observed to be basic (Dubovi, 1982). A 
rabbit antiserum directed against a preparation of RS virus 
spikes immunoprecipi tated all of 'the F related polypeptides 
as well as the G protein. Walsh & Hruska (1983) o~served a 
speckled immunofluorescence pattern using an anti-F 
monoclonal antibody compared with filament associated 
fluorescence with an anti-G monoclonal antibody suggesting a 
different distribution of the polypeptides in infected 
cells. F2 was observed to show a variation in mobility 
between cell types and to sometimes show two bands on 
SDS-polyacrylamide gels (Lambert & Pons, 1983, 1984). A 
fragment of the F1 polypeptide may also exist since Samson 
et ale (1986) obtained evidence of a polypeptide of about 
20K being recognized by a monoclonal antibody that bound to 
Fl. Samson et al. (1986) suggested that the 20K polypeptide 
was F2 since it was not observed under non-reducing 
conditions. However Norrby et al. (1986) observed a fragment 
of Fl which was also not observed under non-reducing 
conditions. This suggests that the 20K polypeptide 
identified by Samson et al. (1986) may have also been a 
fragment of F1 explaining its identification with an anti-F1 
monoclonal antibody. Hendricks et al. (1987) observed a 
polypeptide of 18K that appeared to be related to the F 
protein in addition to F2. The nature of the various minor F 
related polypeptides is not understood but they are presumed 
to be breakdown products of F1 or F2. 
Tunicamycin has been shown to inhibit glycosylation of 
the F protein suggesting that all of the oligosaccharides 
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were N-linked (Fernie et al., 1985; Gruber & Levine, 1985a). 
A change in migration of F1 and F2 after digestion with 
endo-D was observed similar to that with ~he G protein, 
which was dependent upon the absence of neuraminic acid 
residues as described for the G protein (Lambert & Pons, 
1984). The mature F polypeptides were insensitive to endo-H 
(Gruber & Levine, 1985a). These results suggested that the 
N-linked carbohydrate was of the complex type. Endo-F 
treatment of samples led to an increase in mobility of FO 
and a decreased mobility of F1 (Lambert & Pons, 1984) 
although since F specific antibodies were not used the 
identification of the F specific polypeptides was not 
necessarily correct. 
FO has been observed to be the precursor to F1 and F2 
in pulse chase experiments (Fernie et al., 1985; Gruber & 
Levine, 1985b). A slight increase in the mobility of F1 and 
F2 labelled in RS virus infected cells incubated in the 
presence of monensin was observed (Gruber & Levine, 1985a). 
This effect is probably" due to inhibition of some of the 
later stages of processing of the N-linked oligosaccharides 
in the Golgi apparatus. Monensin treatment of RS virus 
infected cells also caused a partial inhibition of the 
cleavage of FO (Fernie et al., 1985). This suggested that 
cleavage of Fa occurs in the Golgi apparatus or at a later 
stage during transport to the cell surface. Unlike the F1 
and F2 polypeptides Fa was sensitive to digestion by endo-H 
(Gruber & Levine, 1985a). Gruber & Levine (1985b) exposed 
monensin treated, RS virus infected cells to trypsin in 
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order to remove any F protein expressed on the cell surface 
and immunoprecipitated the cell lysates with anti-F protein 
serum. Fl and F2 were still detected and· it was therefore 
concluded that cleavage occurred intracellularly. 
Antibodies to the F protein have been used to show 
that it is involved in fusion of RS virus infected cells and 
that it is a target 
Walsh et al.(1985) 
antigen for neutralizing antibodies. 
raised antisera to F protein that had 
been purified by affinity chromatography. When antiserum was 
raised against the native polypeptide it was found to 
neutralize the virus but not to inhibit fusion. In contrast 
antiserum raised against the reduced polypeptide both 
neutralized the virus and inhibited fusion. The latter 
antiserum had higher levels of antibody recognizing the F2 
protein. Antibodies to F2 are not essential to get a fusion 
inhibiting reaction however because monoclonal antibodies to 
F1 will inhibit fusion (Trudel et al., 1987a). Several 
groups have carried out solid phase competitive binding 
studies to identify -antigenic sites on the F protein 
(Anderson et al., 1986; Fernie et al., 1982; Gimenez et al' J 
1986; Hufson et al., 1985; Norrby et al' J 1986; Orvell et 
a1'J 1987; Routledge et al. J 1986; Samson et al. J 1986; 
Trudel.t al., 1986; Trudel et al., 1987a; Tsutsumi et al., 
1987; Walsh & Hruska, 1983; Walsh et al .• 1986). Since these 
authors used different sets of monoclonal antibodies it is 
not possible to determine the total number of sites that 
-have been described. Five sites bind antibodies inhibiting 
fusion and neutralizing the virus. Two sites bind 
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neutralizing antibodies that do not inhibit fusion and a 
further twelve sites bind neutralizing monoclonal antibodies 
whose reactions in fusion inhibition assays have not been 
reported. Three sites bound antibodies that neither 
inhibited fusion or neutralized the virus. Sixteen sites 
bound non-neutralizing antibodies whose reactions in fusion 
inhibition assays have not been reported. It appears likely 
therefore that only a small proportion of antigenic sites 
are recognized by neutralizing antibodies and a subset of 
these are recognized by fusion inhibiting antibodies. One 
site recognized by fusion inhibiting and neutralizing 
monoclonal antibodies has been found to be resistant to 
denaturation and at least part of he site has been localized 
to a 12 amino acid peptide (Trudel et al., 1987a,b). This is 
therefore a possible candidate for a synthetic peptide 
vaccine. The relevance of solid phase binding studies to the 
, 
situation with native virus particles is not clear since 
Walsh et al. (1986) observed that a polyclonal antiserum 
inhibited binding of a fusion inhibiting monoclonal antibody 
in solid phase binding studies but did not inhibit the 
fusion inhibiting activity of the monoclonal antibody on RS 
virus infected cells in tissue culture. Antisera raised 
against purified F protein or vaccinia virus expressing the 
RS virus F protein did not inhibit attachment of RS virus to 
Bela cells in contrast to sera raised against the G 
glycoprotein suggesting that the F protein was not involved 
, 
in attachment of the virus to cells (Levine et al .• 1987). 
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The N protein 
The N protein migrates on SDS-polyacrylamide gels with 
an estimated Hr of 40K to 44K. It has been identified a~ the 
major nucleocapsid polypeptide (Huang et a1., 1984; Peeples 
& Levine, 1979; Wunner & Pringle, 1976). Cash et a1. (1979b) 
identified a 38K polypeptide that was related to N. The 38K 
polypeptide was not identified in in vitro translation 
experiments but was more readily labelled than N in pulse 
labelling experiments carried out with infected cells. After 
a chase period N became more abundant than the 38K 
polypeptide. The results of experiments with TPCK and/or 
TLCK added during labelling or just during harvesting or 
storage suggested that the 38K polypeptide was derived from 
the N polype~tide by proteolytic cleavage. The explanation 
of these results is not clear. Cash et al. (1979b) suggested 
that the N protein was synthesized as a protease sensitive 
form and that later a protease resistant form appeared. This 
explanation does not appear to explain the apparent 
conversion of a 38K polypeptide into N during pulse chase 
experiments. 
Fernie et al. (1981) found that a nucleocapsid 
associated polypeptide was expressed on the surface of 
Balb/c cells persistently infected with RS virus, although 
it does not normally appear on the surface of virus infected 
cells (Walsh & Hruska, 1983). The N protein does, however 
appear to be a target for cytotoxic T cells (Bangham et a1. I 
.1986; Pemberton ~t al., 1987) and so at least part of the 
protein may sometimes be expressed on the cell surface. No 
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monoclonal antibodies or anti-nucleocapsid sera have been 
found that neutralize RS virus. Hendricks et al. (1987) 
found that the N protein appeared to be released into the 
supernatant of infected cell cultures. The cells were 
claimed to be intact since the F polypeptide was not 
released into the supernatant but this may not be the case 
because the N protein may have been soluble whereas the F 
protein may have been membrane associated and not released 
from disrupted cells. The N protein is not readily resolved 
on the basis of charge in 2 dimensional 
gradient electrophoresis/SDS-PAGE 
non-equilibrium 
possibly due 
pH 
to 
aggregation or association with RNA (Dubovi, 1982). The N 
polypeptide has not been observed to be glycosylated 
phosphorylated or sulphated. 
The P protein 
The P protein migrates more slowly when studied by 
SDS-PAGE than would be expected from its Mr calculated from 
the predicted sequence. It has a Mr calculated from its 
mobility in SDS-PAGE of 31K to 35K depending on the strain 
compared with a ~ calculated from the sequence of 27K. It 
shows the most marked inter-strain variation in mobility on 
SDS-polyacrylamide gels of all the RS virus polypeptides 
(Cash et al., 1977). It is called the phosphoprotein of RS 
virus because it is the most extensively phosphorylated of 
the RS virus polypeptides (Cash et al., 1979b; Lambert & 
Pons, 1983). It has been observed to be an acidic protein as 
would be expected of a phosphorylated protein rich in acidic 
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residues (Dubovi, 1982). Virus fractionation studies suggest 
that the P protein is more closely associated with the 
nucleocapsid of the virus than the M protein (Peeples & 
Levine, 1979; Huang et al. I 1984). Lambert & Pons (1983) and 
Huang et al. (1984) observed that P was associated with 
nucleocapsids purified on caesium chloride gradients or by 
gel filtration respectively. Monoclonal antibodies to the P 
protein frequently co-precipitate the N protein suggesting 
that the two proteins are closely associated (Gimenez et 
al., 1984). Immunofluorescence studies with monoclonal 
antibodies directed against the P protein gave differing 
results perhaps indicating differences in conformation of 
this protein at different locations in the cell (Gimenez et 
al., 1984). Three monoclonal antibodies directed against the 
P protein gave cytoplasmic immunofluorescence whereas two 
other anti-P protein monoclonal antibodies gave only cell 
surface staining. One of the antibodies giving cytoplasmic 
staining did give fluorescence at the periphery of RS virus 
infected cells fixed at a late stage of infection. 
The H protein 
The M protein of RS virus has a mobility on 
SDS-polyacrylamide gels corresponding to a polypeptide with 
an ~ of about 26-28K. It is solublized from virions by 
non-ionic detergent (Peeples and Levine, 1979; Huang et al .• 
1984). The M protein has been identified at a peripheral 
location in acetone fixed RS virus infected cells using 
immunofluorescence with an anti-M protein monoclonal 
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antibody but it was not detected on the surface of unfixed 
cells (Routledge et al. 1987b). These results suggest that 
the M protein is a non-glycosylated matrix-like protein 
similar to that of paramyxoviruses, morbilliviruses and 
rhabdoviruses. Wunner & Pringle (1976) showed that the RS 
virus M protein behaved in a similar manner to the VSV M 
protein on gradients of metrizamide containing non-ionic 
detergent. Lambert & Pons (1983) identified the M protein in 
a preparation of nucleocapsids purified on a caesium 
chloride gradient but other groups have not found the M 
protein to be nucleocapsid associated (Wunner & Pringle, 
1976; Huang et al., 1984). A RS virus specific protein that 
was probably M (although reported as having the rather high 
~ of 33K) was observed to be basic (Dubovi, 1982). Cash et 
AI. (1979b) and Lambert & Pons (1983) did not identify any 
phosphorylated polypeptide with a mobility corresponding to 
that of the M protein. Lambert et al. (1988) did however 
identify a phosphorylated polypeptide that they believed to 
be the M protein. Gruber & Levine (1983) observed two bands 
with mobilities similar to the M protein when radiolabelled 
viral proteins were analysed under non-reducing conditions 
and suggested that this polypeptide existed as two forms 
differing in the number or position of intra-molecular 
-. 
disulphide bonds. No anti-M protein monoclonal antibodies 
have been reported to have neutralizing activity. 
The H2 protein 
The H2 protein is a second non-glycosylated membrane 
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associated protein that occurs in RS virus but apparently 
does not have any counterpart in paramyxoviruses, 
morbilliviruses or rhabdoviruses (Huang et al., 1984; 
Routledge et al., 1987b). It has been observed to be a basic 
polypeptide (Dubovi, 1982). Like the M protein it is 
solublized by treatment of virions with non-ionic detergent 
(Huang et al o , 1984). It has not been identified in 
preparations of nucleocapsids (Wunner & Pringle, 1976; 
Lambert & Pons, 1983; Huang et al., 1984). The M2 protein 
exists in three different forms when analysed by 50s-PAGE 
under reducing conditions and shows 5 different forms under 
non-reducing conditions (Routledge et al., 1987a). Six 
different forms of M2 appeared to exist under non-reducing 
conditions but two of these co-migrated. The six bands 
observed 
forms of 
under 
each 
non-reducing conditions corresponded to two 
of the bands observed under reducing 
conditions. The reason for the existence of different forms 
of the H2 protein when it was analysed under reducing 
conditions is not clear, but Routledge et al. (1987a) 
suggested that the bands were artefacts that arose during 
sample preparation. Different forms of the M2 polypeptide 
observed under non-reducing conditions were considered to be 
due to different numbers or arrangements of disulphide 
bonds. Unlike the M protein the M2 protein is expressed on 
the surface of infected cells late in infection (Routledge 
et al. 1987b). 
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The 14K (1C) polypeptide 
The 14K polypeptide was not described in many early 
reports of RS virus polypeptides probably due to it being 
insufficiently labelled in cell lysate preparations and 
absent from purified virus. Dubovi (1982) described a 15K 
acidic polypeptide that probably corresponded to this 
polypeptide. The 14K polypeptide has been identified 
primarily in in vitro translation experiments. It was first 
described clearly as one of 3 proteins translated in vitro 
from a set of closely migrating mRNA molecules excised from 
a gel (Huang & Wertz, 1983). Collins et al. (1984a) used 
hybridization selection with cDNA clones to show that the 
14K polypeptide was translated in vitro from a mRNA 
designated 1c from which it derives its other name of the 1C 
polypeptide. The same paper also clearly showed the presence 
of the 14K polypeptide in infected cell lysates and showed 
that partial digestion of the polypeptides with S. aureus V8 
protease gave similar peptides. The 14K polypeptide is 
considered to be a non-structural protein since it has not 
been identified in preparations of purified virus. Nothing 
is known of its function. 
The 11K (1B) poln»eptide 
The 11K polypeptide like the 14K polypeptide described 
above was first clearly identified by in vitro translation 
of mRNA eluted from a gel (Huang & Wertz, 1983). Cash et al . 
. (1977) observed a 10K polypeptide in infected cell lysates 
which could have corresponded to this polypeptide or the 
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9.5K polypeptide. However the 10K polypeptide was not 
identified when the cells were labelled and the samples 
harvested in the presence of 'TLCK or TPCK to inhibit 
proteases suggesting that it may have been a breakdown 
product of a larger polypeptide (Cash et al., 1979b). The 
11K polypeptide was first clearly identified in infected 
cell lysates by Collins et al. (1984a) who also showed that 
it gave a similar peptide pattern to the 11K polypeptide 
synthesized in vitro following digestion with S. aureus V8 
protease. It is translated from the mRNA designated 1B 
giving it the alternative name of the 1B polypeptide. The 
11K polypeptide is considered to be a non-structural 
polypeptide since it has not been identified in purified 
virions. The function of the 11K polypeptide is not known. 
The 
polypeptides 
translation 
identified 
The 9.5K (lA) polypeptide 
9.5K polypept"ide, like the 
was first clearly identified 
of mRNA " eluted from a gel. 
in cell lysates by Collins et 
14K and 11K 
by iTt vitro 
It has been 
al. (1984a) 
although they could not show that it was related to the 
polypeptide synthesized in vitro because it was too small to 
give more than one band in partial proteolysis experiments. 
Like the 14K and 11K polypeptides it was considered to be a 
non-structural polypeptide. However immunoprecipitation of 
RS virus infected cell lysates with an antiserum directed 
"against a synthetic peptide corresponding to the predicted 
carboxy-terminal sequence of the 9.5K protein identified 
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glycosylated forms of the 9.5K polypeptide. A discrete band 
and a lower mobility broad smear of label centred at a 
mobility corresponding to a ~ of'about 30K was observed (R. 
Olmsted, C.Caravokyri, personal communications). ~his type 
of glycosylated polypeptide is not unique to RS virus. the 
influenza B virus NB protein producing a similar broad smear 
on the gel which Williams & Lamb (1986) suggested was due 
interactions of the carbohydrate to produce aggregates of 
the NB protein alone or with host cell proteins. It is not 
clear if the glycosylated form of the 9.5K polypeptide 
occurs in virions. A weak broad smear appears to be present 
in [3H]-glucosamine labelled virus shown in the paper by 
Lambert & Pons (1983) although the authors did not consider 
this label to be associated with a viral protein. 
1.1.3 Differences between polypeptides of the two subgroups 
of RS virus 
Most of the information on RS virus described above 
refers to the A subgroup since the two most commonly used 
strains of RS virus, the A2 and Long strains both belong to 
this subgroup. The results of Cashet al. (1977, 1979b), 
Pringle.t al. (1981) and Gimenez et al. (1984) referred to 
the RSN-2 strain of the B subgroup. The G protein has been 
observed to exhibit the greatest degree of variation in 
mobility when analysed by SDS-PAGE. This mobility variation 
is strain specific and not related to the subgroup of the 
virus (Norrbyet al .• 1986; Routledge et al . , 1986) . 
Variation in the mobility of the M2 protein is similarly not 
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dependent on the subgroup of the virus (Norrby et aI'
J 
1987). The P, Fl and F2 proteins do show subgroup specific 
differences in mobility (Table 6). All of these mobility 
differences are quite small relative to differences in 
mobility between polypeptides of RS virus and PVM (Cash et 
aI., 1977). Other differences observed between the 
polypeptides of viruses of the two subgroups are the 
presence of an additional F related polypeptide with a 
mobility slightly lower than F2 in subgroup A viruses and 
the instability of glycoproteins of subgroup B viruses in 
tunicamycin treated cells. 
1.2 Bovine and caprine respiratory syncytial viruses 
Since the bovine and caprine RS viruses have not been 
distinguished in reaction patterns with monoclonal 
antibodies (Orvell et al' J 1987) and little work has been 
published on the caprine RS virus these viruses are 
described together. Less detailed work has been reported at 
the molecular level on these viruses than on human RS virus 
so they are only considered briefly. Bovine RS virus was 
isolated from calves with respiratory disease (Paccaud & 
Jacquier, 1970) and has been shown to be important in lower 
respiratory tract infection in cattle (Inaba et al., 1972; 
Rossi & Kiesel, 1974). Caprine RS virus has been isolated 
from a pygmy goat with respiratory disease (Lehmkuhl et al., 
1980) but little is known about the incidence of infection 
of goats with RS virus. 
Bovine respiratory syncytial virus shows a close 
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antigenic relationship to human respiratory syncytial virus 
(Paccaud & Jacquier, 1970; Rossi & Kiesel, 1974). The 
viruses differ in the cell types that can be infected in 
tissue culture in that bovine RS virus will not grow in 
primate cell lines unlike RS virus (Cash et al. J 1977). The 
polypeptide profile of bovine RS virus is essentially 
identical to that of human RS virus (Cash et al' J 1977). 
1.3 Pneumonia virus of mice 
Pneumonia virus of mice (PVM) was first isolated from 
3.5 to 4 week old albino swiss mice (Horsfall & Hahn, 1939, 
1940). Mice were inoculated intranasally with nasopharyngeal 
washings obtained from patients with respiratory tract 
diseases other than influenza. Lung homogenates were then 
serially passaged by the intranasal route of infection. This 
procedure resulted in the appearance of transmissible 
pulmonary consolidations after 2 to 7 passages with deaths 
occurring at the earliest after 3 passages and on average 
after 5 passages. It was found that the same result was 
obtained when lung homogenates of normal mice were used and 
the infectivity therefore appeared to be due to an 
endogenous infectious agent. The susceptibility of mice to 
infection was found to vary depending on the supplier of the 
mice. One ten thousandth of the dose required to kill the 
mice, given intranasally, was sufficient to protect mice 
subsequently challenged with a lethal dose of virus. Two 
intraperitoneal injections of the virus were found to 
protect mice against challenge with any strain of the virus 
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but not against influenza virus infection suggesting that 
there was little antigenic variation in the virus. 
Antibodies to PVM appear to be common in mice (Horsfall & 
Hahn, 1940; Jakubik & Skoda, 1974). PVM was found to be 
strictly pneumotropic, not causing any infection unless 
inoculated by the intranasal route. It was thought to be 
pathogenic only in mice. Later Horsfall & Curnen (1946) 
found that PVM would cause pneumonia in cotton rats and 
hamsters. The infection was not contagious, uninfected mice 
kept in the same cages as infected mice did not become 
infected (Horsfall & Hahn, 1940; Smith et al., 1984). 
Passage of PVM in chick embryo cultures or BHK-21 cells 
resulted in a reduction in virulence in mice (Horsfall & 
Hahn, 1940; Harter & Choppin, 1967). 
Pearson & Eaton (1940) identified an agent 
antigenically related to PVM from Syrian hamsters and Eaton 
& van Herick (1944) described a similar agent in cotton 
rats. 
1.3.1 Serological evidence for the possible exposure of many 
.,..."ls to a PVM like virus. 
Eaton & van Herick (1944) found evidence of 
neutralizing antibodies to PVM in rabbits. Horsfall & Curnen 
(1946) studied sera from a variety of animals and showed 
that neutralizing antibody against PVM could be found in 
rabbits, cotton rats, monkeys (/"acaca 7IIulatta-) , man, 
chimpanzees, hamsters guinea pigs and mice. Neutralizing 
activity was absent from the sera of chickens and mongooses. 
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Gannon & Carthew (1980) found neutralizing activity against 
PVM in mouse and rat colonies but not in guinea pig colonies 
but the nUmber of guinea pig colonies studied was small. 
Carthew et al. (1978) did obtain serological evidence of PVM 
infection in a guinea pig. Anti-PVM antibodies have also 
been detected in rats using an enzyme linked immunosorbent 
assay (ELISA. Payment & Descoteaux. 1978). Horsfall & Curnen 
(1946) observed that there was a seasonal variation in the 
neutralizing activity of sera from cotton rats, and to a 
lesser extent, hamsters and mice, a much higher incidence of 
PVM antibody being detected in sera collected from January 
to June than in those collected from September to January. 
The animals tested at each time were new animals acquired 
from breeders so the antibody levels probably reflected the 
incidence of infection at different times of year. Horsfall 
& Curnen (1946) believed that the virus was present in mice 
in a latent form but Tennant et al. (1965) could find no 
evidence of latent infections and believed that the virus 
caused a low level of acute infections. The reason for the 
increased incidence of anti-PVM neutralizing activity 
observed when cotton rats or hamsters received intranasal 
inoculations of chick embryo cell suspensions or samples 
from ·patients with primary atypical pneumonia is unknown. 
The stimulation of antibody production by irrelevant 
antigens appeared to be dependent on a pre-existing antibody 
response in the animals but the authors did not study paired 
serum samples so it was not possible to tell if this was 
definitely the case. 
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Approximately one third of human sera were found to 
have neutralizing activity against PVM (Horsfall & Hahn, 
1940). The antibody response to PVM in man has been studied 
in more detail by Pringle & Eglin (1986). More than 75 per 
cent of adult sera contained PVM neutralizing activity at a 
titre of greater than 40. The proportion of sera with 
similar levels of PVM neutralizing activity was found to 
increase with the age of children from which ~ the samples 
were taken. Seroconversion (defined as >fourfold increase in 
titre) was observed in 4 of 108 paired serum samples from 
patients with undiagnosed respiratory infections. Sera from 
patients with Paget's disease of bone tended to have higher 
titres of PVM-neutralizing antibody than sera from patients 
with other bone diseases. This is similar to the results of 
immunofluorescence studies showing an increase in the 
frequency of antigens of other paramyxoviruses (e.g. measles 
virus, simian virus 5, parainfluenza 3, Basle et ai. 1985 
and RS virus, Mills et al. 1981) in the osteoclasts of 
patients with this disease. 
1.3.2 Experiments with PVH grown in vivo 
Early studies on PVM used lung suspensions from 
infected mice as the source of virus. A large part 
of this early work concentrated on the 
haemagglutinating activity of the virus which was 
reviewed by Ginsberg (1951). PVM agglutinates murine 
and hamster erythrocytes (Mill & Dochez, 1944, 1945). The 
fluid expressed from lungs showed haemagglutination whereas 
lung suspensions from mice infected with PVM did not show 
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haemagglutinating activity unless the haemagglutinin was 
first dissociated from particulate material. Dissociation 
could be carried out with heat, high pH (Curnen & Horsfall, 
1946, 1947) or low salt conditions (Davenport & Horsfall, 
1950). The haemagglutinating activity was found to pass 
through bacteriological filters whereas the tissue 
associated form would not (Curnen & Horsfall, 1947j Curnen 
et al., 1947). The haemagglutinin-lung tissue combination 
was reversible when the ionic strength was altered and in 
contrast to orthomyxoviruses and paramyxoviruses the 
haemagglutinin would recombine with the same cells (Curnen & 
Horsfall, 1946; Volkert & Horsfall, 1947). The 
haemagglutinin was later found to combine with mammalian 
tissues in which it had not been observed to multiply 
(Davenport & Horsfall, 1950) but not with chick embryo cells 
although the virus does multiply in these cells. 
Ginsberg & Horsfall (1951a) and Horsfall & Ginsberg 
(1951) studied the multiplication of PVM in mouse lungs. 
Ninety per cent of the virus inoculated was not recoverable 
all of the infectivity having been lost within 12 hours of 
infection although haemagglutination activity could be 
demonstrated. Discrete cycles of replication occurred with 
the virus yield increasing by about 16 fold after each 
cycle. The rate of development of pneumonia was slower than 
the rate of multiplication of the virus and both these 
measurements reached limiting values. Multiplication of PVM 
. and development of pneumonia are inhibited by some bacterial 
polysaccharides (Horsfall & McCarty, 1947; Ginsberg & 
37 
Horsfall. 1951bj Nemes & Hilleman, 1962) and by prior 
infection with a large dose of mumps virus (Ginsberg & 
Horsfall. 1952). These effects are considered to be due to 
the induction of interferon, polyI:C and double stranded RNA 
having similar effects (Nemes et al., 1969a&b; Tytell et 
~l .• 1970). PVM was more susceptible to these agents than 
other viruses tested including rabies, influenza A and B, 
Rous sarcoma virus, and Marek's disease virus. 
1.3.3 Studies on PVH carried out in tissue culture 
The first tissue culture system in which PVM was grown 
was minced chicken embryo cultures (Horsfall & Hahn, 1940). 
Tennant & Ward (1962) showed that PVM would grow in suckling 
hamster kidney cells and to a lesser extent in BS-C-1 cells 
but not in a variety of cells from man or mice. The first 
cell culture system used for more detailed studies of PVM 
was baby hamster kidney (BHK) cells (Harter & Choppin, 1967; 
Compa~s et al .• 1967). This cell system was also used by 
Jakubik & Skoda (197~) who found that fibroblastic rather 
than epithelial cells gave the best yields of virus and that 
the best yields were obtained if the cultures were incubated 
at 3~C rather than 31°C and high multiplicities of 
infection of virus were used. In contrast Harter & Choppin 
(1967) found that PVM infected BHK-21 cells gave higher 
virus yields when incubated at 31°C than when incubated at 
lower temperatures. Cash .t a1. (1977) also used BHK cells 
~hen radiolabellin, PVH. Cash et a1. (1979&) found that 
satisfactory labellin, of PVM polypeptides at 31°C was 
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a 
b 
Figure 2 Haemadsorption with PVM infected BS-C-l cells 
BS-C-l cells infected 48 hours previously with PVM 
(m.o.i. of 4, a) or mock infected (b) were washed with PBS 
and exposed to murine erythrocytes in PBS (2 per cent v/v). 
The erythrocytes were washed off and the mono layers 
photographed revealing erythrocytes adsorbed to infected but 
not uninfected cells. 
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obtained using BS-C-1 cells in which more virus specific 
polypeptides could be identified. Haemadsorption has been 
demonstrated us~ng murine erythrocytes and PVM infected 
BHK-21 cells (Compans et al., 1967) or BS-C-1 cells (Figure 
2). Cash et al. (1979a) found that like RS virus but unlike 
Sendai virus and measles virus PVM multiplied in enucleated 
cells (Follett et al., 1975, 1976). Syncytium formation does 
not normally occur but has been observed using a high 
multiplicity of infection in BHK-21 cells (Figure 3). 
The first assays of the virus were carried out using 
the dilution at which the virus caused CPE in 50 per cent of 
infected cultures as the titre (TCIDso assay). Shimonaski & 
Came (1970) were able to perform a plaque assay using BHK 
cells with chymotrypsin or pancreatin but Jakubik & Skoda 
(1974) were not able to get reproducible results with this 
system. Cash et al. (1979a) assayed the virus on BS-C-1 
cells where foci of darkly staining cells similar to but 
smaller than those produced by RS virus in BS-C-1 cells were 
observed. 
Barter & Choppin (1967) found that haemagglutinating 
activity was more stable than infectivity. The replication 
of the virus was found to be insensitive to inhibitors of 
replication of DNA viruses and it was concluded that PVM was 
an RNA virus. Eosinophilic inclusion could be detected in 
the cytoplasm of infected BHK cells (Harter & Choppin, 
1967). These inclusions were stained red by acridine orange 
indicative of the presence of single stranded RNA or DNA. 
Viral antigen was found to be localized in the cytoplasm. In 
40 
a 
b 
Figure 3 Syncytium formation in PVM infected BBK-21 cells 
The figure shows PVM infected (at an m.o.i. of 10, a ) 
and mock infected (b) BEK-21 cells at 3 days post infection. 
Syncytia are apparent in the infected but not the mock 
infected cells. 
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contrast to the virus grown in mouse lungs heating was not 
required to give the maximum haemagglutination titre. In 
contrast to influenza virus PVM was found to adsorb to 
erythrocytes that had been treated with neuraminidase. 
Pelleting of the virus and ammonium sulphate precipitation 
resulted in large reductions in the amount of infectious 
virus but an increase in the amount of haemagglutinating 
activity. Two peaks of infectivity were observed on 
potassium tartrate gradients, a visible band being 
associated with the minor but not the major peak. The 
haemagglutinating activity was not associated with the 
infectivity peaks suggesting that most of the 
haemagglutinating activity was associated with 
non-infectious virus (Harter & Choppin, 1967). 
The structure and morphogenesis of PVM grown in Vero 
and BHK21 cells has been described (Berthiaume ~t a1., 1974; 
Compans ~t al., 1967). PVM existed mainly as filamentous 
form lOOnm in diameter and up to 3um in length. A bulbous 
tip was sometimes observed at one end and spherical or 
pleomorphic particles have also been observed. The 
morphology is considered to be generally similar to that of 
RS virus but there are differences in that the surface 
projections of PVM are narrower and closer together than 
those of RS virus. Compans et al. (1967) found that the 
internal nucleocapsid structure was coiled inside 
filamentous forms of virus budding from the cell surface, 
whereas Berthiaume et a1. (1974) found that the internal 
structures ran the length of the filaments. The diameter and 
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pitch of the helix in the internal components of PVM and RS 
virus were similar and different from the dimensions of 
paramyxovirus nucleocapsids (Table 1). Infected cells 
contained dense inclusions consisting of material with a 
thread-like appearance that were occasionally observed 
extracellularly probably due to disruption of infected 
cells. The dense material appeared to enter budding virions. 
Vesicles have also been observed on the surface of infected 
cells. PVM virions have been observed adsorbed to murine 
erythrocytes in electron micrographs and erythrocytes have 
been seen adsorbed to the surface of PVM infected cells but 
virus specific changes in cell morphology were not always 
evident at the points of contact. 
1.3.4 Polypeptides of PVM 
The polypeptides of PVM synthesized in infected BHK21 
and BS-C-l cells have been described (Cash et al. 1977 and 
1979a). Two glycosylated and 10 unglycosylated polypeptides 
were observed in total using samples of radiolabelled BS-C-l 
cell lysates and polyethylene glycol (PEG) precipitates of 
the supernatants of such cells. These authors identified one 
polypeptide as the nucleocapsid polypeptide and observed 
that 5 of the non-glycosylated polypeptides had similar 
mobilities to RS virus polypeptides. The polypeptides of PVM 
are considered in Sections 3 and 4 and will not be described 
in detail here. 
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Table 1 Structural features of paramyxoviruses1 
Property RS virus PVM TRT virus NDV 
Diameter of 100-350 80-200 80-200 100-400 
spherical forms/nm 
Length of <5000 <3000 1000-2000+ 
filamentous forms/run 
Diameter of 60-110 100 
filamentous forms/run 
Length of 12-15 8-12 13-14 12 
projections/run 
Spacing of 10 6 
projections/run 
Nucleocapsid 13.5-14 12-15 14 18 
diameter/run 
Nucleocapsid 6.5-7.0 6.5 7.0 5.5 
pitch/run 
1) Dimensions of the viruses of the genus Pneu.ovirus are 
compared with those of NDV, a representative of the 
genus Paraayxovirus. 
References- Berthiaume et al. (1974); Collins & Gough 
(1988); Compana et al. (1967). 
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1.4 Turkey rhinotracheitis virus 
Turkey rhinotracheitis is a disease of the upper 
respiratory tract of turkeys. that nas been desQribed in many 
countries and reviewed by Lister & Alexander 
(1986).Morbidity is high with a mortality rate varying 
between less than 1 and 30 per cent (McDougall & Cook 1986). 
In the USA and West Germany the disease was considered to be 
caused by the bacterium Alcaligenes faecalis. However in 
other countries it has not been possible to associate this 
agent with the disease. A variety of viruses h~s been 
isolated from infected turkeys (Alexander et al., 1986) 
including adenoviruses, enterovirus-like viruses,reoviruses, 
rotaviruses and several unidentified viruses. Enveloped 
viruses have been isolated in avian tracheal organ cultur~s 
in several countries including the United Kingdom (McDougall 
& Cook, 1986; Jones et al., 1986; Wyeth et al., 1986), 
France (Giraud et al. J 1986) and earlier in South Africa 
(Buys & du Preez, 1980 in Collins & Gough 1988). The 
. isolates obtained by Wilding et al. (1986) and Wyeth et al. 
(1986) were found to be antigenically similar (Baxter-Jones 
et al., 1986). Isolates of this virus appear to be the most 
likely agent causing the primary infection at least in the 
United Kingdom.The viral infection predisposes the birds to 
secondary infections resulting in the symptoms of turkey 
rhinotracheitis. This virus has now been called turkey 
rhinotracheitis virus (TRT virus). The morphol?gy and 
polypep~ides of partially purified virus have been described 
(Collins.t al .• 1986b; Collins & Gough, 1988). Further work 
45 
on the polypeptides of this virus has been described by Ling 
& Pringle (1988) and is described in this thesis. 
Collins ~t al. (192Gb) using virus concentrated from 
the medium of tracheal organ cultures believed that the 
virus they observed had a similar morphology to viruses of 
the family Paramyxovirida~. They observed ribbon like 
structures some of which appeared to consist of two strands 
coiled around each other (or one strand coiled on itself) 
with a total diameter of 20nm but were not sure if these 
structures were virus specific. Later Collins & Gough (1988) 
described several forms of virus particles: roughly 
spherical forms were usually 80-200nm in diameter but 
sometimes they were several times larger; filamentous forms 
that sometimes exceeded 2~m in length also occurred. These 
pleomorphic forms of virus are similar to those associated 
with pneumoviruses (Berthiaume et al., 1974). The dimensions 
of the surface projections and nucleocapsid structures were 
similar to those reported for pneumoviruses (Table 1). The 
flexible appearance of the nucleocapsid resembled the 
appearance of PVM nucleocapsids more closely than that of RS 
virus nucleocapsids but the distinct surface projections of 
TRT virus were more similar to those of RS virus than those 
of PVM. 
Collins et al. (1986b) 
partially purified TRT virus 
compared the polypeptides of 
grown in tracheal organ 
cultures and those of viruses representative of the 
Ortho.yxovirida~, Para.yxoviridae and the Coronaviridae. The 
polypeptides were analysed by SDS-PAGE followed by staining 
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with Coomassie blue. The polypeptide profile obtained more 
closely resembled that of bovine RS virus than that of the 
Ulster strain of NDV, the parakeet/Netherlands/.449/75 strain 
of avian paramyxovirus 3, the M41' and T avian coronaviruses 
or an orthomyxovirus, parrot/NI. The Mrs of the polypeptides 
that they reported appeared to be rather high by comparison 
with those expected for the pneumovirus polypeptides shown 
and these sizes have been revised in a later paper by the 
s~e group (Collins & Gough, 1988), The later paper 
describes similar work but the virus was grown in chick 
embryo cell cultures and the glycoproteins identified by 
staining with Schiff's reagent are described, Seven major 
virus specific polypeptides were identified with calculated 
~s of 54K. 47K; 42K. 37K. 36K> 31K and 14K when Coomassie 
blue staining was used. A 200K polypeptide was tentatively 
identified as being virus specific whereas four polypeptides 
with low ~s were probably host cell contaminants. The 
glycoproteins had MrS of 84K and 54K. The 84K polypeptide 
was more strongly labelled with Schiff's reagent although it 
was scarcely visible using Coomassie blue staining. Two 
other areas of heterogeneous staining were observed but no 
indication of their approximate mobilities was given. 
1.5 Aims of the project 
The polypeptides of RS virus have been studied in some 
detail, particularly the glycoproteins which appear to be 
the major viral antigens responsible for inducing immune 
responses in animals. The polypeptides of PVM have not been 
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described in such detail and their similarity to those or RS 
virus is not known. The study or RS virus polypeptides has 
been aided by the use of monoclonal antibodies directed 
against the viral proteins. This approach was thererore 
adopted for the study or PVM proteins. In particular the 
glycoproteins of PVM were studied to determine the extent of 
variation in the nature of the oligosaccharide-protein bonds 
and the processing of pneumovirus glycoproteins. 
TRT virus has been suggested to be a fourth virus or 
the genus Pneumovirus on the basis of similarities in 
morphology and polypeptide profile to RS virus and PVM 
(Collins et al .• 1986b; Collins & Gough. 1988). The 
polypeptides of TRT virus were characterized to compare the 
polypeptides of this virus and those of PVM and RS virus. 
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MATERIALS 
AND 
METHODS 
MATERIALS 
Suppliers names and addresses are given in Appendix 2. 
2.1 Cell Lines 
Balb/c 3T12 
BS-C-1 
BHK-21 
NS-1 
X63-Ag8.653 
., 
Flow Laboratories Inc. 
Professor C.R.Pringle, 
Department of Biological 
Sciences, University of 
Warwick, Coventry, UK 
Flow Laboratories Inc. 
Dr. E.A.Jones, Department of 
Biological Sciences, 
University of Warwick 
Flow Laboratories Inc. 
2.2 Virus strains 
Pneumonia virus of mice, strain 15 from the American 
type culture collection, and respiratory syncytial virus 
(RSS-2 strain originally isolated in Newcastle upon Tyne in 
1970) were obtained from Professor C.R.Pringle. TRT virus 
was obtained from Dr. R. Gough (Central Veterinary 
Laboratory, Weybridge) by Dr. A. Easton and plaque purified 
6 times by Professor C.R. Pringle. 
2.3 Tissue culture media 
Glasgow modification of Eagles medium with 
non-essential amino acids (GMEM) or 10 per cent Tryptose 
phosphate broth (GMEMB) and buffered with sodium hydrogen 
carbonate were provided by the virus group media preparation 
49 
laboratory. Double strength GMEM without methionine, valine, 
leucine, glutamine or sodium hydrogencarbonate, sterile 
~istilled water, PBS, neutral red, trypsin and versene were 
also provided by this laboratory. 
Aminopterin (lOOOX) 
Aminopterin 
Sodium hydroxide (O.lM) 
25mg 
10ml 
When the aminopterin had dissolved the solution was 
made up to 142ml with distilled water, filter sterilized and 
dispensed in 5ml aliquots at -20°C 
Antibiotics (1000X) 
Crystapen 
Streptomycin sulphate 
Distilled water 
Filter sterilized and stored at 4°C 
Fusion medium 
RPMI1640 
Foetal calf serum 
Sodium hydrogen carbonate solution (5%w/v) 
Antibiotics 
Glutamine (200mM) 
ESG hybridoma arowth factor 
50 
106 Units 
19 
10ml 
500ml 
50ml 
20ml 
lml 
5ml 
12.6ml 
GMEMx 
GMEM 
Foetal calf serum 
Glutamine (200mM) 
Antibiotics 
GMEMBx 
As for GHEM with GMEMB in place of GMEM. 
HAT medium (2X) 
Fusion medium 
Aminopterin (1000X) 
HT (100X) 
OR HAT medium supplement (50X) 
HT (lOOX) 
llitre 
x%w/v 
20ml 
1ml 
100ml 
O.lml 
1ml 
4ml 
Hypoxanthine 136.1mg 
Distilled water 100ml 
Heated at 70°C for 1 hour to dissolve hypoxanthine, 
allowed to cool and then added, 
Thymidine 37.Bmg 
Filter sterilized and stored in 10ml aliquots at -20°C 
Hybridoma medium 
Fusion medium 
HT (100X) 
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500ml 
5ml 
Hybridoma freezing medium 
Serum free myeloma medium 
Foetal calf serum 
Dimethyl sulphoxide 
Methionine free medium 
2X GMEM without leucine, valine, 
methionine, sodium hydrogencarbonate 
Leucine (200mM) 
Valine (200mM) 
Glutamine (200mM) 
Sodium hydrogencarbonate (5%w/v) 
Antibiotics 
Distilled water 
Myeloma medium 
RPMI1640 
Sodium hydrogencarbonate (5%w/v) 
Foetal calf serum 
Glutamine (200mM) 
Antibiotics 
Neutral red containing overlay 
62ml 
30ml 
8ml 
500ml 
10ml 
10ml 
10ml 
20ml 
1ml 
to 1 litre 
500ml 
20ml 
50ml 
20ml 
1ml 
Made up as described below for overlay medium but 10ml 
neutral red solution (O.l%w/v) was added to solution B 
before mixing 
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Overlay medium (for plaque assays) 
A Noble agar O.l%w/v 
B 2X GMEM 100ml 
Foetal calf serum 3ml 
Antibiotics O.2ml 
A heated to melt agar and put at 45°C after allowing 
to cool 
B warmed to 4SoC 
Equal volumes of A and B were mixed before use 
Polyethylene glycol for cell fusion 
Polyethylene glycol lS00 
RPM I 1640+sodiumhydrogencarbonate 
Sg 
Sml 
pH adjusted to about 8 with sodium hydrogencarbonate 
(S%w/v) 
OR used Polyethylene glycol 1500 in HEPES from BeL 
Trypsin/versene 
Trypsin solution 
Versene 
2.4 Buffers and solutions 
Acid (for washing coverslips) 
Hydrochloric acid 
Nitric acid 
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Sml 
20ml 
15ml 
5ml 
Acrylamide solution 
Acrylamide 
N,N-methylenebisacrylamide 
Distilled water 
Crystal violet 
Crystal violet 
Ethanol 
Diluted 1 in 20 in distilled water for use 
Development solution for Western blots 
A HRP colour development reagent 
Methanol 
B Tris buffered saline (TBS) 
Tris-HCl (1M, pH7.4) 
Sodium chloride (5M) 
Distilled water 
28.5g 
1. 5g 
to 100ml 
7.5g 
500ml 
60mg 
20ml 
100ml 
3.3ml 
to 1 litre 
Immediately before use 60~1 hydrogen peroxide was 
added to 100ml TBS 
Solutions A and B were mixed immediately prior to use 
ELISA substrate 
Orthophenylenediamine 
Hydrogen peroxide (100 volumes) 
Sodium citrate buffer (O.lM, pH4.5) 
54 
10mg 
41.11 
10ml 
Gel fixing solution 
Methanol 
Acetic acid 
Distilled water 
Glutaraldehyde (for fixing plaque assays) 
Glutaraldehyde solution (50%) 
PBS 
Glycosidase buffer A 
EDTA (100rnM) 
2-Mercaptoethanol 
Nonidet P-40 
SDS (10 per cent w/v) 
Sodium dihydrogen orthophosphate 
Distilled water 
500ml 
70ml 
to 1 litre 
4ml 
200ml 
20ml 
2ml 
0.5ml 
1ml 
2.83g 
to 100ml 
pH adjusted to 8.5 ·with orthophosphoric acid 
Glycosidase buffer B 
Sodium dihydrogen orthophosphate 
Distilled water 
pH adjusted to 6.0 with orthophosphoric acid 
Glycosidase buffer C 
Calcium nitrate 
di-sodium hydrogen orthophosphate 
Nonidet P-40 
Distilled water 
pH adjusted to 6.0 with phosphoric acid 
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0.283g 
100ml 
0.131g 
4.25g 
0.5ml 
to 100 ml 
Isotonic lysis buffer 
Magnesium chloride (1M) 
Nonidet P-40 
Sodium chloride (5M) 
Trizma base 
Distilled water 
pH adjusted to 7.8 with hydrochloric acid 
Lysis buffer (Western blotting) 
Tris-HCI (1M, pH7.4) 
NP40 
EDTA 
Distilled water 
O.3ml 
1.3ml 
8ml 
O.222g 
to 200ml 
2ml 
1ml 
7.4mg 
to 200ml 
PMSF (100mM in ethanol) was added at 1:100 just before 
use 
MNH buffer 
Magnesium sulphate (MgS04 .7H2 0) 
Sodium chloride 
BEPES 
246.4g 
8.77g 
11. 92g 
Distilled water to 1 litre 
The pH was adjusted to 7.5 with 30%w/v sodium 
hydroxide 
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NEPHGE sample buffer 
Ampholines (pH3.5-10) 
Ampholines (pH5-7) 
2-mercaptoethanol 
Nonidet P-40 (20 per cent v/v) 
Urea (12M) 
Overlay buffer 
Ampholines (pH3.5-10) 
Ampholines (pHS-7) 
Distilled water 
Urea (12M) 
Paraformaldehyde 
PBS 
Magnesium chloride(lM) 
Calcium chloride (1M) 
Paraformaldehyde 
SJJl 
20lJl 
2SlJl 
SOJJl 
400lJI 
2.5JJl 
lOJJI 
112lJI 
375JJI 
200ml 
O.10ml 
O.18ml 
8g 
The suspension was heated on a magnetic stirrer until 
most of the solid had dissolved, filtered and stored 
in 5ml aliquots at -20°C 
Phenol/Chloroform 
Phenol (distilled, melted at 60°C) 
Chloroform 
100ml 
100ml 
The mixture was equilibrated by shaking with several 
changes (equal in volume to the phenolic phase) of 
phenol equilibration buffer. 
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Phenol equilibration buffer 
EDTA (100mM) 
Sodium chloride (5M) 
Trizma base 
Distilled water 
pH adjusted to 7.8 with hydrochloric acid 
Phenol extraction buffer 
EDTA (lOOmM) 
Sodium chloride 
SDS (10 per cent w/v) 
Trizma base 
Urea 
Distilled water 
pH adjusted to 7.8 with hydrochloric acid 
Phosphate buffered saline (PBS) 
Potassium chloride 
Sodium chloride 
Potassium dihydrogen orthophosphate 
di-Sodium hydrogen orthophosphate 
Pistilled water 
2ml 
eml 
0.222g 
to 200ml 
2ml 
14g 
20ml 
0.222g 
112g 
to 200ml 
0.2g 
8.18g 
0.2g 
1.15g 
1 litre 
Phosphate buffered saline + bovine serum albumin (PBSBx) 
PBS as above + x%w/v bovine serum albumin 
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Phosphate buffered saline + phenylmethylsulphonylfluoride 
(PBSP) 
PBS as above 
phenylmethylsulphonylfluoride 
ethanol 
containing 
solution 
Phosphate buffered saline + Tween 20 (PBST) 
PBS as above containing O.l%v/v Tween20 
Polyethylene glycol (PEG) for precipitating virus 
1%v/v 
{,lOOmM) in 
PEG6000 36g 
Distilled water to 100ml 
Ponceau S 
Ponceau S 
Acetic acid 
Distilled water 
Radioactive ink 
19 
2ml 
200ml 
Ink 1ml 
Culture medium containing [ 35 S]-methionine luei 
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RIP buffer 
Triton X-100 
Sodium chloride 
Potassium chloride 
Magnesium chloride (MgC1 2 .6H2 0) 
Tris-HCI (1M, pH7.4) 
Distilled water 
2ml 
1.758g 
8.95g 
O.02g 
2ml 
to 200ml 
PMSF (lOOmM in ethanol) was added to give a final 
concentration of lmM immediately before use 
RIP wash buffer 
Lithium chloride 
Tris-HCl (1M, pHS.9) 
Distilled water 
The pH was adjusted to 
hydrochloric acid 
Running buffer 
Trizma 
Glycine 
Sodium dodecyl sulphate 
Distilled water 
60 
8.5 with 
21g 
100ml 
to 1 litre 
concentrated 
6g 
4g 
19 
1 litre 
Sample buffer 
Glycerol 
Tris-HCl (1M, pH6.7) 
2-Mercaptoethanol 
Bromophenol blue 
Sodium dodecyl sulphate 
Distilled water 
Stacking gel buffer 
Tris HCI (1M, pH6.7) 
Sodium dodecyl sulphate (10%w/v) 
Distilled water 
Thin layer chromatography buffer 
Acetic acid 
Butan-1-ol 
Distilled water 
Pyridine 
Thin layer electrophoresis buffer 
Acetic acid 
Distilled water 
Formic acid 
Thin layer electrophoresis tracking dye 
Acid fuchsin 
Orange G 
Thin layer electrophoresis buffer 
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3ml 
1.5ml 
1.5ml 
1ml 
O.6g 
3ml 
37.5ml 
3ml 
to 300ml 
10ml 
65ml 
40ml 
50ml 
450ml 
2400ml 
150ml 
O.lg 
O.2g 
10ml 
Transfer buffer for Western blotting 
Trizma base 
Glycine 
Methanol 
Distilled water 
Tris buffers (1M) 
Trizma base 
Distilled water 
3.03g 
36g 
200ml 
800ml 
121.1C 
to 900ml 
The pH was adjusted to the required value with 
concentrated hydrochloric acid and the volume made up 
to 1 litre with distilled water 
2.5 Methods 
2.5.1 Growth of BS-C-1, BBK-21 and Balb/c 3T12 cells 
BS-C-1 and BHK-21 cells were grown in 1.5 litre roller 
bottles using GMEM5 and GMEMB5 media respectively. Cells 
were passaged at 4 day intervals at a ratio of 1:4. The 
cells were rinsed twice with versene and then with 
trypsin/versene solution, a small amount of which was left 
in the. bottles. The cells were incubated at 37°C until all 
the cells became detached and they were then resuspended in 
the appropriate medium. Balb/c aT13 cells were passaged in a 
similar manner in 1 litre flat bottles. 
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2.5.2 Growth of virus stocks 
Cloned virus (5xl05 -4xlOs/ml) was used to infect 
confluent monolayers of BS-C-1 cells in 25cm2 flasks 
(O.4ml/flask) or 1.5 litre roller bottles (1-2ml/bottle). 
The cells were incubated for 2 hours at 33°C and GMEM1 
added, (5ml/25cm2 flask or 15ml per roller bottle). The 
infected cells were incubated until CPE was extensive (3-4 
days for RSS-2, 4-6 days for PVM) , and then the cells were 
scraped into suspension and the suspension stored in 5ml 
aliquots at -70°C. 
2.5.3 Plaque assay and plaque purification of the virus 
Serial dilutions of virus were made in GMEM1 (10 fold 
for assays and 2 fold for plaque purification) and samples 
(O.lml) added in duplicate to monolayers of BS-C-1 cells in 
12 well (for assays) or 6 well (for plaque purification) 
tissue culture clusters. The cells were incubated for 1 hour 
at 37°C and overlay medium added (3ml/well or 7ml/well for 
12 and 6 well clusters respectively). When this had set the 
plates were incubated at 37°C in a carbon dioxide gassed 
incubator for 5-6 days (for RSS-2) or 7-8 days (for PVM). 
The cells were fixed for 4 hours for assays with 
glutaraldehyde, the agar was then removed and the cells 
stained with crystal violet for 2-3 minutes. Excess stain 
was then washed off and foci of darkly stained cells counted 
with a low power microscope. When virus was to be isolated 
from widely separated foci a neutral red containing overlay 
was added instead of fixing the cells and the cells 
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incubated overnight in the dark. Foci were removed using a 
pasteur pipette inserted through the agar. A white 
background aided the visualisation of foci. The material in 
the pipette was resuspended in GMEM1 (O.lml) and added to 
monolayers of BS-C-1 cells in 25cm2 flasks. The monolayers 
were incubated at 33°C for 2 hours and GMEM1 then added 
(5ml/flask). The virus was harvested as described above up 
to 15 days after infection. 
2.5.4 Neutralization assay 
Serial 2 fold dilutions of serum or ascites were made 
and an equal volume of diluted virus added to each giving 
100 infectious units in 0.2ml of the mixture. The mixtures 
were incubated overnight at 4°C and then added to 
monolayers. The assay was completed as described for the 
plaque assay. The numbers of foci obtained were plotted 
against the serum dilutions and the dilution giving 50% 
reduction of the number of foci defined as the 
neutralization titre. 
2.5.5 Baemagglutination (HA) assay and haemagglutination 
inhibition (HI) assay. 
Serial 2 fold dilutions of virus samples were made in 
PBS in 96 round bottomed well plates. Mice were killed by 
cervical dislocation and blood removed from the thoracic 
cavity after cutting the vena cavae. The blood cells were 
washed with PBS and the cells resuspended to give 5XI08 cells 
per 10~l. 10~1 of this suspension was added to each well and 
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the cells suspended by tapping the sides of the plates. The 
plates were left at room temperature for 2 hours and the HA 
titre determined as the highest virus dilution at which the 
cells did not form a pellet. 
In the HI assay virus was diluted to an HA titre of 8 
and equal volumes of this added to serum dilutions in 96 
well plates. Murine erythrocytes were added as described for 
the HA assay and after 2 hours at room temperature the HI 
titre was determined as the highest serum dilution that 
inhibited haemagglutination. 
2.5.6 Preparation of immunogen 
1) Balb/c 3T12 cells were infected with PVM (5ml per 1 litre 
flat bottle at >10 6 infectious units per ml) and 
incubated at 31°C for 15 days after which time CPE became 
apparent. The cells were scraped into suspension and 
pelleted for 30 minutes at 4°C and 3000rpm using a 4x380 
rotor of an MSE 6L centrifuge. The pellet was washed 3 
times in PBS. resuspended at 2.5X107 cells per ml in PBS 
and stored at -70°C. 
2) PVM was grown in 1.5 litre roller bottle cultures of 
BS-C-l cells as described above. The cells were scraped 
into suspension and pelleted as described for Balb/c 
cells above. The supernatant was put on ice and made 6% 
with respect to polyethylene glycol 6000. The supernatant 
was left at 4°C overnight and the precipitate pelleted as 
described for the cells above. The surface of the pellet 
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was rinsed with GMEMO and it was then resuspended at 1 
roller bottle of virus in 0.2ml of GMEMO. This was mixed 
with an equal volume of Freund's complete, (for the first 
injection) or incomplete (for subsequent injections), 
adjuvant for intraperitoneal inoculations. 
3) PVM was prepared as a PEG precipitate as described above 
and then diluted in MNH to 30ml which was layered over 
2ml sucrose in MNH (1.246gcm- 3 ) and 5ml sucrose in MNH 
(1.114gcm- s ) and centrifuged for 1 hour at 24000rpm in a 
Beckman 
of the 
SW27 rotor. The lower interface, containing most 
viral infectivity and haemagglutinin,was 
homogenized (30 strokes of a Iml Dounce homogenizer), 
cleared for 1 minute at 10,OOOg and used as antigen for 
intravenous inoculations. 
2.5.7 Enzyme-linked immunosorbent assay 
BS-C-l cells in 60 well HLA plates (lOul at 5XI05 ceils 
per ml), were infected with lOul per well PVM or mock 
infected with GMEM1. The plates were incubated for 4 days at 
330C. washed with PBS and fixed for 30 minutes with 0.25% 
glutaraldehyde in PBS. The plates were then washed twice 
with PBS and non-specific binding sites blocked by 
incubation for 30 minutes with PBSB!. The plates were washed 
in PBS and stored at -20°C in PBS. Before use the plates 
were allowed to thaw and the PBS flicked off. The antibody 
was added to infected and uninfected and uninfected cells 
(lOul per well serum or ascites diluted in PBSBO.l or 
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undiluted hybridoma supernatant) 
for 3 hours at 37°C. The wells were 
and the plates incubated 
emptied and washed 3 
times with PBST. Biotinylated rabbit anti-mouse 
immunoglobulin diluted 1:1000 in PBSBO.1 was the added and 
the plates incubated for 2 hours at 37°C. The wells were 
emptied and washed as before. Streptavidin diluted 1:500 in 
PBST was added and the plates incubated for 20 minutes at 
37°C. The plates were washed again and biotinylated 
horseradish peroxidase diluted 1:2000 in PBSBO.l was added 
followed by a further 20 minute incubation at 37°C. The 
plates were then washed 6 times with PBST and ELISA 
substrate added. The assay was read by eye a positive result 
being indicated by more colour development in the wells with 
infected as opposed to uninfected cells. 
2.5.8 Immunization of mice 
When Balb/c cells infected with PVM were used, 2 or 3 
intraperitoneal (i.p) injections of 107 cells in 0.4 ml 
GMEMO were given at 1-2 week intervals. When PEG 
precipitates were used, 3 injections of 0.4 ml of the 
antigen adjuvant mixtures were given at 1-2 week intervals, 
followed after 3 weeks by 2 intravenous injections of 
partially purified virus (50~l per mouse), 7 and 4 days 
prior to fusion of the spleen cells. 
2.5.9 Fusion of spleen cells with NS-l or AgS.653 myeloma 
cells. 
Spleen cells were removed from mice receiving a final 
67 
boost of antigen 4 days previously and rinsed in ethanol. 
The fusions were carried out essentially as described by 
Galfre et al. (1977). The spleen was placed in a Petri dish 
containing 10ml serum free myeloma medium, one end cut and 
the cells teased out with sterile curved forceps. The outer 
coat of the spleen was then discarded and the cells 
suspended in the medium. Large clumps were allowed to settle 
and the suspension added to 15 ml myeloma medium containing 
107 myeloma cells. The cells were pelleted for 5 minutes at 
position 3 on the MSE minor bench centrifuge in conical 
bottomed bottles. The supernatant was completely removed and 
the cells resuspended over a 1 minute period in 1ml of 
polyethylene glycol made up as described above or obtained 
from BCL. Serum free medium (lml) was then added at a 
similar rate followed by 10ml of this medium over a period 
of 5 minutes. A further 10ml of this medium was then added 
and the cells pelleted for 5 minutes as described above. The 
cells were resuspended in about 50ml of fusion medium and 
distributed into 96 well tissue culture plates at O.lml per 
well. The cells were incubated for 24 hours at 37°C and 
double strength HAT medium added (O.lml per well). The cells 
were then left undisturbed at 37°C for a further 9 days. 
Supernatants of wells containing colonies were screened for 
anti-PVM antibody by ELISA 10-20 days after fusion. 
2.5.10 Propagation, cloning and freezing of hybridoma cells 
Cells from wells giving positive reactions in ELISA 
tests were transferred to 24 well clusters containing 106 
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normal mouse spleen cells per well. When the cells showed 
good growth the medium was removed and placed in 1.5ml 
polypropylene tubes at -20°C. The cells were resuspended in 
cold hybridoma freezing medium (O.lml per well) and placed 
in 2ml cryogenic storage vials on ice. The vials were placed 
in a vacuum flask or thick walled polystyrene box at -700C 
overnight and then placed in liquid nitrogen. The cells were 
thawed by adding 1.5ml warm hybridoma medium from 12 well 
clusters of spleen feeder cells (108 per well) and the 
medium replaced in the wells with the feeder cells. 
The cells were cloned by limiting dilution. The cells 
were diluted to give expected cell numbers per well of 50, 5 
and 1 cell per well for the first cloning and 10, 1 and 0.2 
cells per well for subsequent cloning steps. The plates were 
incubated in humidified boxes at 37°C and the supernatants 
of wells containing single colonies screened for antibody 
production by ELISA 8-20 days later. Some of the cells were 
recloned immediately whilst the rest were grown up in 24 
well clusters with spleen feeder cells. When large colonies 
were obtained in 24 well clusters the cells were transferred 
to 5ml hybridoma medium in 25cm2 flasks. Cells growing in 
flasks were either frozen (O.5ml hybridoma freezing medium 
per flask) or, after the cells had been cloned 3 times, 
passased at 2-3 day intervals (by dilution 1 in 10 in fresh 
hybridoma medium). Cells were grown up to 200ml for freezing 
(5 vials, 1ml per vial) or for inoculation into mice. 
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2.5.11 Production of ascites 
Mice were inoculated i.p. with 0.4 ml per mouse 
2,6,10,14-tetramethylpentadecane 1 to 4 weeks prior to 
inoculation with 107 hybridoma cells in serum free myeloma 
medium. Ascitic fluid was withdrawn 2 or 3 times before 
killing the mice by cervical dislocation. The ascites was 
clarified for 10 minutes at the maximum speed on the MSE 
minor bench centrifuge and stored at -20°C or -70°C. 
2.5.12 Labelling of virus infected cells 
BS-C-1 cells in 6 well tissue culture clusters (108 
cells per well) were infected at a multiplicity of infection 
(m.o.i) of 1 to 4 and the inoculum replaced after incubating 
for 2 hours at 33°C by GMEM1, (3ml per well). The cells were 
then incubated at 33°C for 2 days and the medium replaced 
with 2ml per well methionine free medium. The cells were 
incubated for from 1 to 6 hours in this medium before 
replacing it with 0.5 ml per well of methionine free medium 
containing 50-1000~Ci per ml 35S-methionine. When 
Sa-glucosamine was used, serum free medium was used in place 
of methionine free medium and 3a glucosamine used at 100uC1 
per mI. 
The cells were scraped into the medium after 18-24 
hours ~d pelleted for 20 seconds at 10,000g. The 
supernat~t was made 6 per cent with respect to polyethylene 
glycol 6000 ~d ImH with respect to PMSF and put at 4°C for 
from 2 hours to overnight. The precipitate was collected by 
pelleting for 5 minutes at 10,000g. The cells were washed 
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twice in PBSP and lysed in RIP buffer for 30 minutes on ice. 
Debris was removed by centrifugation for 5 minutes at 
10,OOOg and the supernatants transferred to new tubes. 
2.5.13 Pulse chase experiments 
BS-C-l cells in a 6 well tissue culture clusters were 
infected as described above (2.5.12) for other labelling 
experiments. 2 or 3 days after infection when CPE was 
extensive the medium was removed and for experiments with 
[35 S]-methionine the cells were incubated with methionine 
free medium (3ml per well) for 6 hours prior to labelling. 
1-[3S]-glucosamine hydrochloride was diluted with an equal 
volume of double strength GHEM and this solution diluted 
with GMEMO to give a radioactive concentration of 500~Ci per 
ml. L-[ 35 S]-methionine was diluted in methionine free medium 
to give a radioactive concentration of 500~Ci per mI. Pulse 
labelling was performed for 10 or 20 minutes at 33°C using 
0.2 ml label solution per well. Pulse samples were harvested 
as described above for other samples except that the cells 
were only washed once in PBSP. Cells that were to be left 
for a chase period were washed 3 times with GMEM5 after 
labelling and then incubated at 33°C for the indicated chase 
periods· with GMEMS (O.Sml per well). When [ 35 S]-methionine 
was used as the label, 200 times the usual concentration of 
methionine was used in the medium used for washing the 
cells. The samples were harvested in the same way as the 
pulse samples. 
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2.5.14 Preparation of Immuno-Precipitin for 
immunoprecipitation. 
Immuno-Precipitin (formalin fixed Staphylococcus 
.ur.us, BRL) was pelleted 10 minutes at 4000g at ,4°C. the 
bacteria were resuspended in PBS containing 10 per cent 
2-mercaptoethanol and 3 per cent SDS and incubated in a 
boiling water bath for 30 minutes. This procedure was 
repeated and the bacteria resuspended 
stored at 4°C. This procedure was 
in RIP buffer and 
recommended by the 
manufacturer to reduce non-specific binding. 
2.5.15 Radioimmunoprecipitation 
PEG precipitate (1 well equivalent resuspended in 
100~1 RIP buffer) and cell lysates were put on ice for 30 
minutes with 50~1 Immuno-Precipitin and 10~1 of ascites or 
serum not containing anti-viral antibody. The bacteria were 
pelleted for 5 minutes at 10,OOOg. Ascites or serum (3-30~1 
was added to each supernatant and put at 4°C for from 3 
hours to overnight. Immuno-Precipitin in RIP buffer was 
added to each tube (50-300ul) and pelleted at 10,OOOg for 1 
minute after incubation for 30 minutes on ice. The bacteria 
were washed 3 times in immunoprecipitation washing buffer 
using 1ml volumes and pelleting for 30 seconds at 10,000g, 
before resuspending in 40~1 boiling buffer and either 
storing at -20°C or boiling for 3 minutes and loading onto 
gels. 
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Table 2 Co.aposition of polyacrylaBide gel solutions 
(gradient gels) 
Reagent 
6% gel 
Acrylamide-Bis 4.8ml 
Tris-HCl(lM, pHS.9) 9.0ml 
Tris-HCl(lH,pH6.7) 
Distilled water 9.81ml 
Glycerol 
SDS (10%) 0.24ml 
Ammonium per sulphate O.15ml 
(10%w/v) 
TEMED O.Olml 
Amount used in 
15~ gel 
12 ml 
9.0ml 
O.36ml 
2.4ml 
O.24ml 
O.075ml 
O.Olml 
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Stacking 
gel 
5ml 
3.75ml 
20.7ml 
O.3ml 
O.25ml 
O.012ml 
2.6.16 Polyacrylamide gel electrophoresis (SDS-PAGE) 
The discontinuous buffer system of Laemmli (1970) was 
used. 6-15 per cent gradient resolving gels were used as 
described by Marsden et al. (1976). The composition of the 
stacking gel and resolving gel solutions are indicated in 
Table 2. In some experiments 15 per cent single 
concentration gels were used, the composition of the gel 
solutions used for these gels are shown in Table 3. The gels 
were electrophoresed using 250x200mm plates with 1.5 mm 
spacers in a vertical slab gel apparatus at a constant 
current of 12mA per gel until the dye front reached the 
bottom of the gel. 
2.6.11 Two dimensional NEPBGE/SDS-PAGE 
BS-C-1 cells were grown in 96 well tissue culture 
plates (2.5X105 cells per ml, 0.1 ml per well) and infected 
24 hours later with PVM, RS virus or TRT virus (200 ul per 
well at titres of 4Xl0 6 , 8X10s and 2XIOs per ml 
respectively). After a 2 hour adsorption period the cells 
were incubated at 33°C for 48 hours (for PVM and RS virus 
infected cells), or 72 hours (for TRT virus infected and 
uninfected cells) with GMEM1. The cells were incubated in 
methionine free medium containing actinomycin D (2.5ug per 
ml) for six hours before labelling with [ 35 S]-methionine 
(lmCi per ml, 50ul per well) overnight. The supernatant~ 
were removed clarified for 1 minute at lO,OOOg and 
precipitated overnight at 4°C with 6 per cent (final 
concentration) PEG6000. The precipitate was resuspended in 
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Table 3 Composition of polyacrylamide gel solutions 
(15 per cent gel) 
Reagent 
Acrylamide-Bis (2) 
Tris-BCl (1M, pB8.9) 
Tris-BCI (1M, pBS.7) 
Distilled water 
SDS (10 per cent w/v) 
Ammonium persulphate 
(10 per cent w/v) 
TEMED 
Volume used 
Stacking gel 
2.5ml 
3.75ml 
8.45ml 
0.15ml 
0.15ml 
O.OOSml 
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for:-
Resolving gel 
35ml 
28ml 
5.Sml 
0.7ml 
0.7ml 
0.02ml 
50~l NEPHGE sample buffer. The cells were solubilized in 
NEPHGE sample buffer. Two dimensional NEPHGE/SDS-PAGE was 
carried out as described by O'Farrell et al. (1977).The 
samples were clarified at 10,OOOg 
loading onto the first dimension 
for 5 minutes before 
NEPHGE gels. The 
composition of the NEPHGE gel mixture is shown in Table 4. 
The samples were overlayed with NEPHGE overlay buffer (20ul 
per tube) and the tubes filled with phosphoric acid (O.OlM). 
The gels were electrophoresed in a rod gel apparatus with 
phosphoric acid (O.OlM) in the upper reservoir and sodium 
hydroxide (O.02M) in the lower reservoir. The gels were 
electrophoresed at 400V for 6 hours with the cathode at the 
bottom. The gels were extruded by forcing water between the 
gel and the tube with a syringe and blowing the gel out with 
a pipette filler. Before the gel had completely emerged from 
the tube the acid end was marked with a piece of fine wire. 
The second dimension gel was a 6-15 per cent gradient 
gel with a 5 per cent stacking gel. A comb was not used in 
the stacking gel a small piece of spacer being used to form 
a well for marker polypeptides and the gel overlayed with 
water. The gel surface was washed with melted agarose (1 per 
cent w/v in stacking gel buffer) and the first dimension gel 
sealed in with the agarose. The gels were electrophoresed at 
12 rnA overnight and processed for autoradiography (cell 
lysate samples) or fluorography (all other samples). 
2.5.18 Western blotting - preparation of samples 
1.5 litre roller bottles of BS-C-l cells were infected 
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Table 4 Composition of polyacrylamide gel solutions 
(NEPBGE gels) 
Reagent 
Acrylamide-Bis 
Urea 
Distilled water 
Ampholines (pH3.5-10) 
Nonidet-P40 
(20 per cent v/v) 
Ammonium per sulphate 
(10 per cent w/v) 
TEMED 
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Quantity 
1.33ml 
5g 
2.95ml 
O.5ml 
1ml 
O.02ml 
O.014ml 
at an m.o.i. of 0.1 to 0.25 and the virus allowed to adsorb 
for 2 hours at 37°C. GMEM1 (15m! per bottle) was added and 
the incubation continued until CPE was extensive. The cells 
were then scraped into suspension and pelleted at 4000g at 
4°C for 10 minutes. The supernatant was made 6 per cent w/v 
with respect to PEG 6000 and lmM with respect to PMSF and 
incubated for 2 hours at 4°C before pelleting for 30 minutes 
at 4000g and 4°C. The precipitate was suspended in PBSP at 1 
roller bottle per 0.2 ml and stored at -20°C. The cells were 
washed twice with PBSP and lysed in lysis buffer at 1 roller 
bottle per ml for 10 minutes on ice before storage at -20°C. 
Samples (10~1 per well) were diluted to 40~1 per well with 
boiling buffer. 
2.5.19 Western blotting- transfer of protein to 
nitrocellulose, staining and immunological detection of 
antigen 
Gels were equilibrated with transfer buffer for 30 
minutes and then placed on paper (Whatman 3MM) on a fibre 
pad resting on half of a gel holder of the trans-blotTH 
apparatus (Bio-rad). The assembly was completed with 
nitrocellulose, paper and another fibre pad (all soaked in 
transfer buffer) according to the manufacturers 
instructions. The gel holder was inserted in the tank 
containing transfer buffer with the nitrocellulose towards 
the anode. Transfer was performed for 3 hours at a constant 
voltage of 70V. The gel assemblies were removed from the 
tank, opened, and the nitrocellulose sheets stained for 5 
minutes with Ponceau Sand destained for 3 minutes with 
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distilled water. The positions of marker bands was indicated 
using a pencil and the sheet cut into strips. The 
nitrocellulose was then destained by four 10 minute washes 
in distilled water, any residual stain being removed during 
the blocking step. Blocking of non-specific binding was 
carried out using PBSB3 overnight at 4°C. Blots were washed 
(5 times for 5 minutes each for this and all subsequent 
steps unless otherwise indicated) and antibody added (1 in 
250 dilution in PBSBl of serum or ascites or undiluted 
tissue culture supernatant). The blots were incubate at room 
temperature for from 1 to 3 hours and then washed. 
Biotinylated second antibody (directed against the first 
antibody) diluted 1 in 500 in PBSB1 was incubated with the 
blot for 1-3 hours and the blot washed. Biotinylated 
horseradish peroxidase-streptavidin complex (1 in 400 in 
PBSB1) was then incubated with the blot for 30 minutes at 
room temperature. The blot was then washed 3 times for 5 
minutes each with PBST and twice briefly with PBS before 
adding the development solution. When bands became apparent 
the blot was quickly washed with water and allowed to dry. 
2.5.20 Expert.ents with tunicamycin and monensin 
·In the experiments with tunicamycin or monensin these 
inhibitors were added to all media at concentrations of 
2.5ug per ml and O.SuM respectively or as indicated. 
2.5.21 Immunofluorescence 
Glass coverslips were washed once with acid, 3 times 
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with ethanol and then 
flamed and placed in 6 
well). Alternatively 12 
stored in ethanol. Coverslips were 
well clusters (2 coverslips per 
well tissue culture slides (Flow 
Laboratories Inc.), were washed once with detergent followed 
by rinsing in distilled water and sterilization by heat 
treatment (160°C for 4 hours). BS-C-1 cells were grown 
overnight on the coverslips or slides, (4XIO s cells per well 
for the coverslips or 5XIO s cells in a 9cm diameter Petri 
dish for the slides). The cells were infected at a m.o.i. of 
0.2 or mock infected with an equal volume of GMEMl and 24 
hours later washed 3 times with PBS at 37°C followed either 
by fixation with cold (-20°C) acetone for 10 minutes or 
incubation on ice for 30 minutes with antibody. The 
antibodies were used as 1 in 100 dilutions of ascites or 
serum in PBSBO.l or undiluted tissue culture supernatant. 
Fixed cells were allowed to dry and stored dry at -20°C. 
Antibody was added to fixed cells at 37°C for 1 hour. The 
cells were then washed 3 times in cold PBS for unfixed cells 
or PBS at ambient temperature for fixed cells and 
fluorescein isothiocyanate conjugated rabbit anti-mouse 
immunoglobulin antibody diluted 1 in 60 in PBSBO.l added. 
The incubation was carried out for 30 minutes on ice for 
unfixed cells and for 1 hour at 37°C for fixed cells. The 
cells were then washed 3 times in PBS (at 4°C when unfixed 
cells were used). Fixed cells were mounted using 80 per cent 
glycerol and 20 per cent saline and viewed with a Nikon 
Optiphot microscope with an incident ultraviolet light 
source at 1250X magnification. Photography was carried out 
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using exposures of 60-200 seconds with Ektachrome 160 colour 
reversal film. Unfixed cells were fixed for 15 minutes with 
paraformaldehyde, washed in PBS, mounted and examined as 
described above. 
2.6.22 Partial proteolysis of viral proteins 
Two methods were used that gave similar results, the 
first method (from McCrae & Joklik, 1978) possibly giving 
less streaking on the gels. Bands were excised from dried 
gels using an autoradiogram as a template and placed in 
O.5ml polypropylene tubes. The gel slices were ground up in 
stacking gel buffer (140~1 per tube) and left to swell for 
10 minutes. Undigested samples were then placed on ice. 10~1 
of protease at either 1.5mg per ml or 150~g per ml was added 
to each tube containing samples to be digested and the tubes 
incubated at 37°C for 30 minutes. The tube tops were then 
punctured with a l~rge bore needle and 2 holes made near the 
bottoms of the tubes with 25g needles after cleaning them 
with industrial methylated spirit. The tubes were placed in 
1.5 ml polypropylene tubes without lids and centrifuged at 
2000g at 4°C for 5 minutes. Boiling buffer was added to the 
liquid collected in the larger tubes and the samples 
transferred to new tubes before boiling for 3 minutes and 
loading onto gels. 
An alternative procedure was that of Cleveland et al. 
(1977). The gel slices were rehydrated in stacking gel 
buffer and placed in wells of a second gel. The slices were 
overlayed with 20~1 per slot of 20 per cent v/v glycerol in 
81 
stacking gel buffer. This was then overlayed with 10ul of 
stacking gel buffer containing an appropriate protease 
concentration, 10 per cent glycerol and 0.15mg bromophenol 
blue per mI. The gel was electrophoresed at 40 rnA until the 
dye was about two thirds of the way down a 5 em stacking gel 
an the power was then turned off for 40 minutes to allow 
digestion to occur. The gel was then electrophoresed 
overnight at 12 mAo 
2.5.23 Fluorography and autoradiography 
Gels were fixed with 2 changes of fixer the gels being 
left in the second change overnight. Fluorography was 
carried out using AmplifyTH for 30 minutes. Gels were dried 
under vacuum for 1.5 hours using a Bio-rad gel drier. Gels 
were exposed to pre-flashed X-ray film at -70°C. When 
autoradiography was used to detect bands for partial 
proteolysis the gels were dried down immediately after 
electrophoresis and the film was not pre-flashed. 
Calculation of ~s was carried out by comparison of the 
mobilities of the polypeptides with those of radiolabelled 
molecular weight markers. A sonic digitizer was used to 
record the mobilities and the Mrs of the polypeptides were 
calculated using a third degree log curve using the Beckman 
Microgenie Software. 
2.5.24 Two dimensional tryptic peptide maps of PVH 
polypeptides 
PVM infected BS-C-l cells were labelled from 48 hours 
to 72 hours after infection in the presence or absence of 
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tunicamycin (2.5ug per ml). 
[ 3S S]-methionine (500uCi per 
The 
ml) 
radiolabels used were 
and [4.5-3 H]-leucine 
(750uCi per ml). The polypeptides were immunoprecipitated 
with murine anti-PVH serum and separated by SDS-PAGE using a 
6-15 per cent resolving gel as described in Sections 2.5.15 
and 2.5.16. Radioactive ink spots were used to mark the 
dried gel so that the fluorograph could be aligned with the 
gel. Tryptic peptide mapping was carried out as described by 
Elder et al. (1977). The bands to be digested were cut out 
of the gel using the fluorograph as a template and washed 4 
times for 30 minutes with 25 per cent propan-2-o1 and left 
overnight in 10 per cent methanol. The gel slices were 
lyophilized and incubated for 24 hours at 37°C in ammonium 
hydrogen carbonate (O.05H) containing trypsin (50ug per ml). 
The liquid was removed from the tubes. lyophilized and 
reconstituted in 50ul per sample of thin layer 
electrophoresis buffer. Samples and TLC tracking dye (4ul of 
each) were loaded 40mm from opposite ends and 40mm from one 
edge of a 200X200mm· cellulose thin layer chromatography 
plate. The plate was placed on a glass plate on a horizontal 
gel tank. The chambers of the tank were filled to just touch 
the glass plate with thin layer electrophoresis buffer and 
the p+ate was sprayed with this buffer. A strip of dialysis 
membrane soaked in the same buffer was placed along the two 
ends of the plate and wicks of 3 thicknesses of 3MM paper 
were placed on top of the membrane and allowed to dip into 
the buffer in the reservoirs. The tanks were covered with 
cling film and the samples run at lOOOV at 4°C until the 
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leading dye reached the point of application of the sample. 
The sample migrated towards the cathode. The plates were 
allowed to dry at room temperature overnight. The second 
dimension was carried out using thin layer chromatography 
the edge of the plate parallel to the direction of the first 
dimension and nearest to the spots was placed in TLC buffer 
in a glass tank lined with 3MM paper soaked in this buffer. 
When the leading dye was about 10mm from the end of the 
plate the chromatographs were removed and allowed to dry at 
room temperature (in a fume hood) overnight. The 
chromatographs were sprayed with diphenyloxazole (PPO, 22 
per cent w/v in diethyl ether) in a fume hood. The coating 
was ·checked by visualization under an ultraviolet lamp. The 
plates were then exposed to pre-flashed X-ray film at -70°C. 
2.5.25 Digestion of glycoproteins with glycopeptidase F and 
endo-«-N-acetylgalactosaminidase. 
PVM infected cells incubated in the presence or 
absence of tunicamycin (2.5~g per ml) were labelled from 48 
to 72 hours post infection. The labelling was carried out in 
the presence or absence of tunicamycin with either 
[ 35 S]-methionine or [3H]-glucosamine each at 100~ Ci per mI. 
RS virus infected cells were labelled with [3H]-glucosamine 
in the absence of tunicamycin in a similar way. The samples 
were immunoprecipitated as described in Section 2.5.12 and 
2.5.15 using 50~l of monoclonal antibody 1S/l/CS, 40~1 of 
murine anti-PVM or, for RS virus infected cells, 30~1 of 
bovine anti-RS virus serum with samples from lXl0 6 cells. 
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Table 5 Composition of glycosidase digestion mixtures 
Reagent Volume (ul) used in each digestion 
U1 N M 0 N+O 
Glycopeptidase Fa 20 4 
Mixed enzymes 3 1 1 1 
Neuraminidase 4 1 1 1 
Endo-«-N-acetyl- 1 1 
galactosaminidase 
Distilled water 8 
Buffer AS 12 
Buffer B 18 17 
Buffer C 13 
1) U- control, N- digestion to remove N-linked sugars, M-
digestion with mixed exoglycosidases, 0- digestion to 
remove O-linked sugars, N+O- digestion to remove N- and 
0- linked sugars. The volumes of solutions refer to 20ul 
reaction volumes, where total volumes of 10ul were used 
the volumes indicated were halved. 
2) 100ul diluted to 233ul with glycosidase buffer A. 
3) Mixed glycosidases from Turbo cornutus at 0.1 mg per ml. 
4) Neuraminidase at 1 unit per ml. 
5) The buffers are the glycosidase buffers A, Band C. 
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The polypeptides were separated by SDS-PAGE and the bands 
located and excised using fluorographs of the gels as 
templates. Four bands of each polypeptide were eluted 
electrophoretically through stacking gels in 10XO.5cm gel 
tubes with dialysis tubing at the bottom. The dialysis 
tubing was attached to the gel tubes with grommets and the 
other end tied off. The gel slices were rehydrated in sample 
buffer and overlayed in the gel tubes with 200~1 of this 
buffer. The gels were run until the bromophenol blue entered 
the dialysis tubing. The dialysis membrane was tied off at 
the top and the samples dialysed against 5 changes of 
ammonium hydrogencarbonate (O.lH). The samples were divided 
into 5 aliquots and lyophilized. 
Samples that were digested with glycopeptidase F were 
incubated for 17 hours at 37°C after resuspension in 20~1 
(for [ 3s S]-methionine labelled samples) or 10~1 (for 
[3H]-glucosamine labelled samples) of glycopeptidase F 
(diluted to 60U per ml in glycosidase buffer A). Undigested 
samples were incubated under similar conditions with buffer 
A only (Table 5). 
Digestion with Endo-«-N-acetylgalactosaminidase was 
performed in the presence of exoglycosidases since this 
enzyme. only cleaves unsubstituted disaccharides from 
polypeptide chains. Therefore a sample digested with these 
enzymes alone had to be included as a control. The 
composition of the mixtures used is shown in Table 5. The 
incubations were carried out 
buffer (20~1) was added to 
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rt 3~C 
all the 
overnight. Sample 
digestions and the 
samples heated to 100°C for 2 minutes prior to analysis by 
SDS-PAGE with 6-15 per cent gradient resolving gels and 
fluorography of the dried gels. 
2.5.26 Preparation of cellular RNA 
BS-C-l cells were infected with PVM (m.o.i. of 1), RS 
virus (m.o.i of 2) or TRT virus (m.o.i of 0.5) or mock 
infected and the inoculum replaced with GMEM1 after 2 hours 
adsorption at 37°C. The cells were incubated at 37°C for 24 
hours and the medium replaced with similar medium containing 
actinomycin D (2.5pg per ml). The cells were scraped into 
suspension and pelleted at 4000g for 5 minutes at 4°C, 48 
(PVM and RS virus infected cells) or 72 hours (TRT virus and 
mock infected cells) after infection. The RNA extraction was 
carried out using a method based on that of Kumar & Lindberg 
(1972), (Dr. A. Easton, personal communication). All the 
glqssware was treated at 200°C for 2 hours and the solutions 
were autoclaved. The cells were lysed by resuspension and 
incubation for 10 minutes on ice using isotonic lysis 
buffer. The cell debris was pelleted for 5 minutes at 4000g 
and 4°C. The cell lysate (5ml containing 4X106 cells) was 
added to a mixture of 5ml equilibrated phenol/chloroform and 
5ml of phenol extraction buffer. The mixture was shaken and 
the upper (aqueous) phase removed and re-extracted twice 
with phenol/chloroform. The final aqueous phase was 
precipitated overnight with 2.5 volumes of ethanol at -20°C. 
The precipitate was resuspended in 100pi of DEPC treated 
water and diluted to lmg per ml. The concentration of RNA 
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was calculated on the basis that an absorbance of 20 units 
at a wavelength of 260nm was equivalent to that due to an 
RNA solution at a concentration of lmg per mI. 
2.5.27 in vitro translation of cytoplasmic RNA 
RNA extracted from infected or uninfected cells 
extracted as described in Section 2.5.26 was translated in 
vitro using commercially prepared rabbit reticulocyte lysate 
(Amersham International). [ 35 S]-methionine (250~Ci) was 
freeze dried resuspended in the reticulocyte lysate (100ul) 
and divided into 8~1 aliquots. RNA (luI and DEPC-treated 
water (l~l) were added to each tube and the mixtures were 
incubated at 30°C for 90 minutes. For samples to be analysed 
directly 30~l of sample buffer or NEPHGE sample buffer were 
added to each tube. When samples were immunoprecipitated 50 
of RIP buffer were added to each tube and 
immunoprecipitation performed as described in Section 
2.5.15. 
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:3 RESULTS 
3.1 POLYPEPTIDES OF PVM 
3.1.1 Introduction 
The polypeptides of RS virus, the type member of the 
genus Pneumovirus, were described in Section' 1. The 
description of PVM polypeptides have been limited to 
preliminary observations without the aid of specific 
antibodies to confirm their virus specificity. 
The aims of the experiments described in this section 
were to establish common and specific features of the 
polypeptides of the pneumoviruses, to verify and extend the 
observations of Cash et al. (1979) on PVM polypeptides. RS 
virus was used as a control in most of the experiments since 
it is the established prototype of the genus. Polyethylene 
glycol precipitates of cell supernatants were used 
extensively in the work described in this and subsequent 
sections to identify proteins detected in clarified cell 
supernatants. This procedure described in Section 2.5.12 was 
a convenient way of concentrating polypeptides present in 
cell supernatants for analysis by SDS-PAGE either directly 
or following immunoprecipitation. These polypeptides could 
have represented virion polypeptides, secreted protein or 
protein released from disrupted cells. This approach was 
used 'since virus purification was difficult and 
unsatisfactory. The results presented in this section 
describe the properties of the PVM polypeptides in terms of 
estimated relative molecular masses and relative charges. 
Polyclonal antisera were used to establish the viral 
specificity of the polypeptides and to examine antigenic 
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cross reactions between PVM and RS virus. 
3.1.2 Polypeptides of PVH synthesized in vivo 
The polypeptides observed in [ 35 S]-methionine 
labelled PVM infected cell lysates and the polyethylene 
glycol precipitates of the supernatants of these cultures 
are shown in Figure 4. PVM infected BS-C-1 cells were 
labelled from 48 hours to 96 hours post infection in the 
presence of actinomycin D as described in the figure legend. 
Actinomycin D was used to inhibit cellular mRNA synthesis 
and hence reduce the incorporation of labelled amino acid 
into cellular protein. Figure 4b is an overexposure of the 
gel to reveal the weakly labelled polypeptides with high 
mobilities and Figure 4a is a shorter exposure of the same 
gel. The 39K, 25K, 23K, 20K, 19K, 18K, 16K, 12K and 9K 
polypeptides were designated according to their relative 
molecular masses (Mr , XIO- s e .. g. the 39K polypeptide had a 
calculated Mr of 39,000). The t\s were obtained by comparing 
the mobilities of the polypeptides with those of protein 
molecular weight standards using a digitizer and Microgenie 
software (Section 2.5.23). The Gl, G2 and Fl polypeptides 
are virus specific glycoproteins (see Section 3.3). The F1, 
Nand M designations were given to PVM polypeptides which on 
completion of studies described in this thesis were 
have similar properties to RS virus 
corresponding names. No non-structural 
be identified. The Gl, G2, Fl, 25K, 16K 
polypeptides were only identified in the PEG 
considered to 
polypeptides with 
polypeptides could 
and 9K 
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Figure 4. Polypeptides of PVM synthesized in vivo 
PEG precipitates of supernatants of PVM, or mock 
infected (MI) cells labelled with [ 35 S)-methionine and 
lysates of these cells were analysed by SDS-PAGE. The 
samples were prepared as described in Section 2.5.12. Cell 
lysate from the equivalent of 5Xl05 BS-C-l cells or PEG 
precipitate equivalent to supernatant from 2X106 BS-C-1 
cells was used in each gel well. A multiplicity of infection 
of 1 was used and the labelling carried out at 15uCi 
[ 35 SJ-methionine per ml for a 48 hour labelling period in 
the presence of actinomycin D (2.5pg per ml). Two prints of 
a fluorograph of PVM polypeptides analysed on a 15 per cent 
resolving gel are shown to enable bands of different 
intensities to be identified. The polypeptides are indicated 
by circles to the right of the tracks. 
PEG Polyethylene glycol precipitate of cell supernatant. 
PVM Samples from PVM infected cultures 
HI Samples from mock infected cultures 
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G1 
G2 
F1 
39Kti 
M 
25K 
23K 0 0 
20K 0 0 
19K 0 
18K 0 
16K 0 
12K 0 0 
9K 0 
precipitated supernatant sample. 
It was possible that the cell type or the labelling 
conditions could affect the presumptive PVM polypeptides 
observed. Figure 5 shows PVM induced polypeptides 
synthesized in infected BS-C-l and BHK-21 cells. The cells 
were infected and labelled under the same conditions as 
described above for the samples shown in Figure 4 except 
that where indicated a 1 hour pulse labelling period, 
beginning 48 hours after infection, was used rather than a 
48 hour continuous labelling regime. A single virus specific 
band (N, 39K or both) was resolved in the 40K region in 
infected BS-C-l cells on this gel whereas two virus specific 
bands (N and 39K) were resolved in the infected BHK-21 cells 
in this region. Two virus specific bands were sometimes 
resolved in this region in infected BS-C-1 cells but never 
as clearly as in BHK-21 cells. The pattern of polypeptides 
with low MrS differed between the two cell types and also 
between different preparations of PVM infected BS-C-l cell 
lysates. A 20K polypeptide was observed only when a 1 hour 
labelling period was used whereas a 18K polypeptide was 
observed only when a 48 hour labelling period was used. The 
variability in the pattern of polypeptides with low MrS 
observed in cell lysates in Figure 5 is difficult to explain 
since the same virus stock was used at the same m.o.i. for 
each labelling period. In subsequent experiments (Section 
3.3) no difference in the polypeptides immunoprecipitated 
from lysates of cells labelled for either 10 minutes or 24 
hours (except for the absence of the 12K polypeptide after a 
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Figure 5. PVH polypeptides synthesized in PVH infected 
BS-C-l and BBK-21 cells 
Cells were infected and labelled in a similar manner 
to that described in the legend to figure 4. Where 1 hour 
labelling periods were used these were carried out 72 hours 
after infection using 50~Ci per ml of [ 35 S]-methionine in 
the presence of actinomycin D (2.5ug per mI. The fluorograph 
shows PVM polypeptides observed in cell lysates when 
labelled under different conditions and analysed on a 6-15 
per cent gradient gel. The polypeptides are indicated by 
circles to the right of the tracks. 
Top line of figure heading indicates cell type infected. 
Middle line indicates duration of labelling. 
Bottom row indicates whether cells were infected with PVM 
(PVM) or mock infected (MI). 
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10 minute pulse) was observed and although no protease 
inhibitors were used in the experiment shown in Figure 5 
this again was subsequently shown to have no effect on virus 
specific polypeptides with low Mrs (Section 3.3.11). The 
differences may have been due to different amounts of 
protein being loaded onto the gel. This result suggests that 
care needs to be taken when looking at virus induced 
polypeptides in total cell lysates. In contrast the pattern 
of polypeptides observed in experiments where 
immunoprecipitation was used (described in Section 3.1.3) to 
identify virus specific polypeptides was consistent although 
the possibility that not all virus specific polypeptides 
were recognized by the antiserum used has to be considered. 
The failure to detect the Gl, G2, and Fl polypeptides 
in the PVM infected cell lysates was probably due to poor 
labelling of these polypeptides and the high background of 
cellular polypeptides since in later experiments, (see 
Section 3.1.5), these polypeptides were detected by 
immunoprecipitation. 
3.1.3. Analysis of PVH polypeptides using two dimensional 
polyacrylamide gel electrophoresis 
Polyethylene glycol precipitates of the supernatants 
of radiolabelled virus infected cells were analysed by two 
dimensional polyacrylamide gel electrophoresis (Figure 6). 
The first dimension used non-equilibrium pH gradient 
electrophoresis to separate the polypeptides on the basis of 
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charge (O'Farrell et a1. 1977) whereas the second dimension 
was SDS-PAGE to separate the polypeptides primarily on the 
basis of size. The acidic end is on the right. Diagrams are 
shown adjacent to the fluorographs of the PVM and RS virus 
samples to aid the identification of virus specific spots. 
The pattern of spots obtained on analysis of the PEG 
precipitate of the supernatant of RS virus infected cells 
showed the N, P and 15K polypeptides to be relativelY8cidic 
whereas the M and M2 polypeptides were relatively ba~ic 
(Figure 6a). Several polypeptides with the same mobility as 
the M protein in the second dimension but which were 
slightly more acidic could also be seen. A possible 
explanation of what these spots may represent is considered 
in Section 4. Two virus specific polypeptides (labelled N 
and M) could be identified in the PEG precipitates of 
proteins in the supernatants of PVM infected cells by 
comparing the pattern of spots observed in Figure 6b with 
that observed with PEG precipitates of the supernatants of 
uninfected cells, (Figure 6c). The M polypeptide co-migrated 
with a host cell protein but the spot showed a higher 
intensity relative to the other spots when compared with the 
pattern obtained with supernatants of uninfected cells. The 
M polypeptide was observed to be basic. The N polypeptide 
was observed to be acidic but to have streaked in the 
direction of the separation carried out on the basis of 
charge. This may have been due to charge heterogeneity or, 
more likely a combination of aggregation as indicated by the 
large amount of label at the acid end (where the sample was 
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Figure 6. Analysis of PVH and RS virus polypeptides in PEG 
precipitates of infected cell supernatants on two 
dimensional gels. 
Pneumovirus infected or mock infected cells (5X104) 
were labelled from 48 to 72 hours post-infection with 
[35 S ]-methionine at lmCi per ml in the presence of 
actinomycin D (2.5ug per ml). PEG precipitates ot the 
supernatants of these cells were analysed by non-equilibrium 
pH gradient electrophoresis followed by SDS-PAGE as 
described in Section 2.5.17. NEPHGE was carried out in the 
horizontal direction with the acid end on the right. 
Diagrams are shown adjacent to the fluorographs of PVH and 
RS virus polypeptides to aid the interpretation of the data. 
a) Fluorograph of PEG precipitate of RS virus infected cell 
supernatant analysed by NEPHGE/SDS-PAGE 
b) Fluorograph of PEG precipitate 'of PVH infected cell 
supernatant analysed by NEPHGE/SDS-PAGE 
c) Fluorograph of'PEG precipitate of mock infected cell 
supernatant analysed by NEPBGE/SDS-PAGE 
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loaded) and association with nucleocapsid structures. 
Figure·7 shows lysates of [35 S]-methionine labelled 
BS-C-1 cells infected with RS virus (a), PVM (b), or 
uninfected (c), separated on two dimensional gels. The 
positions of virus specific polypeptides superimposed on the 
polypeptide pattern of uninfected cells are shown adjacent 
to each fluorograph. It can be seen that each virus had 
acidic polypeptides with ~s in the regions of 40K, 35K and 
16K and a more basic polypeptide of about 30K. RS virus 
infected cell lysates revealed four spots in addition to the 
four spots shared with other members of the Pneumovirus 
genus (Figure 7a). A diffuse region of label in the 45K 
region probably corresponded 
protein. The M2 polypeptide 
polypeptides (wi th ~ s of 
to the F1 part of the fusion 
and two higher mobility 
20K and 17K on this gel) were 
highly basic. The 20K polypeptide can be seen more clearly 
on the longer exposure of this gel shown in Figure 63. 
There were several PVM specific spots on the 
autoradiograph of PVM polypeptides analysed on a two 
dimensional gel (Figure 7b). Two basic spots in the 45K to 
50K region probably represented two forms (FO and Fl) of the 
major polypeptide expressed on the surface of infected cells 
which is described in Section 3.3.13. An additional spot 
below the nucleocapsid streak corresponded to the 39K 
polypeptide and two acidic spots occurred in the region of 
the 25K band which was usually observed as a broad smear on 
single dimension gels (Figure 4). Three acidic polypeptides 
corresponding to the 20K, 19K and 18K polypeptides observed 
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Figure 7. Analysis of PVM and RS virus polypeptides in 
infected cell lysates on two dimensional gels. 
BS-C-l cells were infected and labelled as described 
in the legend to Figure 6. The cells were lysed and analysed 
by non-equilibrium pH gradient electrophoresis followed by 
SDS-PAGE as described in section 2.5.17. NEPHGE was carried 
out in the horizontal direction with the acidic end to the 
right. Diagrams of the virus specific polypeptides overlaid 
on the mock infected cell polypeptides are shown adjacent to 
each autoradiograph. 
a) Autoradiograph of gel of RS virus infected cell lysate. 
b) Autoradiograph of gel of PVM infected cell lysate. 
c) Autoradiograph of gel of mock infected cell lysate. 
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single concentration gels were observed. Two slightly acidic 
spots were observed with mobilities corresponding to a 16K 
polypeptide. 
PVM and RS virus had five polypeptides with similar 
mobilities and charges (Fl, N, P/35K, M and 15K/16K). Since 
these were the strongest spots observed on two dimensional 
gels of the polypeptides from PVM or RS virus infected cells 
they were probably the most abundant methionin6 containing 
polypeptides. The Fl polypeptides were basic, and produced 
rather diffuse spots streaked in the direction of the charge 
separation. The N polypeptides did not resolve well in the 
first dimension of any of the gels described above. This 
could have been due to association of the polypeptides with 
RNA. The P and 35K polypeptides were observed to be acidic. 
In the case of RS virus the P protein is known to be 
phosphorylated (Cash et al. 1919b). Phosphate groups are not 
responsible for the acidic nature of the PVM 35K polypeptide 
since it does not appear to be phosphorylated. The M 
polypeptides of RS virus and PVM were observed to be basic 
suggesting that these polypeptides may be homologous. 
Although both viruses had polypeptides migrating slightly 
faster than the M polypeptide the 25K polypeptide of PVM was 
observed to be acidic suggesting that it had different 
properties from the corresponding polypeptide (M2) observed 
in one dimensional separations of RS virus polypeptides 
which is highly basic (Dubovi 1982, Figure 7b). The 15K 
polypeptide of RS virus {possibly representing the 14K 
non-structural protein or one of the 16K polypeptides 
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synthesized in vitro) and the two 16K polypeptides of PVM 
were acidic. 
3.1.4 Immunoprecipitation of [ 3s S]-methionine labelled PVH 
and RS virus polypeptides 
Immunoprecipitation of RS virus and PVM polypeptides 
was performed to confirm the virus specificity of the 
polypeptides described in the preceding sections. The 
anti-PVM serum used was a murine anti-PVM serum obtained 
during the production of monoclonal antibodies to this 
virus. The mice had been immunized with PVM infected Balb/c 
antibodies 
polypeptides 
and 
to 
of 
so the antiserum was expected to contain 
non-structural as well as structural 
the virus. Since Balb/c mice were used 
little antibody to host cell polypeptides would be expected 
to be produced and this would not necessarily react with 
BS-C-l cell proteins. In some of the later experiments 
described in Section 3.3 this serum was adsorbed using ten 
per cent w/v acetone fixed BS-C-l cells and this removed 
most antibody to host cell proteins. The anti-RS virus serum 
was obtained from Dr. E.J. Stott (AFRC, Compton) and had 
been raised in gnotobiotic calves. 
The polypeptides precipitated from radiolabelled cell 
lysates and PEG precipitates of the supernatants of 
radiolabelled cells using the antisera described above and 
formalin fixed S.aur~us are shown in Figure 8. The samples 
from PVM infected and mock infected cells were 
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Figure 8. PVH and RS virus polypeptides immunoprecipitated 
by ha.ologous antisera 
Cell lysates and polyethylene glycol precipitates of 
the supernatants from lX10 8 PVM and RS virus infected BS-C-l 
cells labelled from 48 to 72 hours post infection (50~Ci 
( 35 S]-methionine per ml) were immunoprecipitated with the 
homologous 
SDS-PAGE. 
antisera described 
The fluorograph 
in the text and analysed by 
shows the polypeptides 
immunoprecipitated analysed on a 6-15 per cent gradient gel. 
PEG PEG precipitate of infected cells 
immunoprecipitated with homologous antisera. 
MI Mock infected cell samples that were 
immunoprecipitated with the anti-PVM serum. 
PVH polypeptide desianations shown on the left and 
RS virus polypeptide designations on the right. 
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immunoprecipitated using the anti-PVM serum whereas the 
anti-RS virus serum was used to precipitate polypeptides 
from the samples from RS virus infected cells. The F1, N. P. 
H, H2, F2 and 14K polypeptides of RS virus were readily 
identified whereas the identity of the 22K polypeptide was 
less clear. The 22K polypeptide may represent a different 
form of H2 since several forms of this polypeptide with 
different mobilities have been described (Routledge et aI. 
1987a). The 22K and F2 polypeptides were observed in the PEG 
precipitate track on overexposure of the gel unlike the 14K 
polypeptide suggesting that they were structural 
polypeptides. The L polypeptides of both RS and PVM were not 
observed on the gel shown in Figure 8 but were observed on 
other gels (e.g. Figure 39). 
The major PVM specific polypeptides shown in Figure 8 
were reproducibly precipitated by the anti-PVM antiserum. 
Gl was usually a more intense band than G2 in cell lysates 
whilst the reverse was observed to be the case in the PEG 
precipitate. The N polypeptide and a 39K polypeptide with a 
slightly faster mobility than the N polypeptide could not 
always be resolved from each other. The 35K polypeptide 
could only be identified when immunoprecipitation was used 
and appeared to be absent from the supernatant sample. The M 
polypeptide was always observed but the 25K polypeptide was 
not. The reason for this was not clear since the antiserum 
did immunoprecipitate bands corresponding to such a 
polypeptide from PVM polypeptides synthesized in vitro 
(Figure 11). Cash, 1979 identified at least 2 bands in this 
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region on under exposure of a gel. The 20K, 19K and 12K 
polypeptides were reproducibly immunoprecipitated by the 
anti-PVM serum and were identified in immunoprecipitates of 
PEG samples if the fluorographs were exposed for a 
sufficient period of time (e.g. Figure 12). The 18K 
polypeptide was not always observed and in some cases a 16K 
polypeptide was observed (Figure 12). 
The polypeptides designated G1, G2, N, 39K, M and 25K 
are probably equivalent to polypeptides II (~ of 79,000, 
79K), III (63K), IV (42K), V (40K), VII (28K) and VIII (26K) 
previously described by Cash et ai. (1979a), since they 
showed similar relative mobilities. However, there were 
several differences from the pattern described by Cash et 
al. (1979a) which included the polypeptide designated F1, 
the absence of the 200K and 35K polypeptides when 
imrnunoprecipitation was not used and a larger number of 
polypeptides with low Mrs which could be virus specific 
(Table 7). The absence of polypeptides of about 200K and 35K 
in Figures 4 and 5 was probably due to poor label 
incorporation and/or high background incorporation into 
cellular polypeptides, because polypeptides with calculated 
Mrs of 200K and 35K were observed when the samples were 
imrnunoprecipitated. The 20K and 19K polypeptides were 
probably genuine virus specific polypeptides since they were 
imrnunoprecipitated by anti-PVM serum, and are probably 
equivalent to polypeptide IX (17K) described by Cash et al. 
(1979a). This suggestion was made on the basis that the 
polypeptide designated IX by these authors had a similar 
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mobility to the 20K and 19K polypeptides that were observed 
during the course of this project and were not always well 
resolved. The 23K, 18K and 16K polypeptides were usually 
weak bands and their virus specificity appears. uncertain 
although their intensity may simply reflect the labelling 
conditions. The 18K polypeptide had a similar relative 
mobility to polypeptide X, (16K), described by Cash et al. 
(1979a). The 12K band had a similar relative mobility to 
polypeptide XI, (13.5K), identified by Cash et al. (1979a). 
No band equivalent to polypeptide XII, a 12K non-structural 
polypeptide described by Cash et al. (1979a), was ever 
observed. The 9K polypeptide observed in Figure 4 was not 
often observed and its significance is not clear, a possible 
explanation of what this band may represent is discussed 
later (3.3.15). When immunoprecipitation was used 
polypeptide G2 as well as polypeptide G1 could be observed 
in PVM infected cell lysates in contrast to the results of 
Cash et al. (1979a) who only observed G1 in infected cell 
lysates. The reason for this was probably that G2 was not 
well labelled and could not be detected above the background 
of labelled cellular polypeptides by Cash et al. (1979a), 
whereas the use of immunoprecipitation enabled the 
polype~~ide to be precipitated from a larger number of cells 
than could be lysed and run on a single gel track. 
Immunoprecipitation also reduced the background of labelled 
cellular polypeptides that were observed. The 25K 
polypeptide, (polypeptide VIII of Cash et al. 1979a), was 
not observed in experiments involving immunoprecipitation 
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which could have been due to low levels of antibody against 
this polypeptide, although as mentioned above the antiserum 
precipitated this polypeptide from among the products of in 
vitro translation reactions, or the polypeptide may not have 
been present in the samples at sufficient level to detect. 
The 35K polypeptide was 
described by Cash et aI. 
observed to be non-structural as 
(1979a). The 18K polypeptide 
(polypeptide X) was observed in the PEG precipitate after 
immunoprecipitation in contrast to the results of these 
authors who did not use immunoprecipitation. This 
discrepancy was probably due to the greater sensitivity that 
could be achieved using immunoprecipitation enabling 
polypeptides of low abundance to be detected. 
3_1_5. rmaunoprecipitation of [3B]-glucosamine labelled PVH 
and RS virus polypeptides 
Figure 9 shows the [3H]-glucosamine labelled 
polypeptides that were immunoprecipitated by the anti-PVM 
and anti-RS virus antibodies. The anti-RS virus serum 
immunoprecipitated the G, F1 and F2 polypeptides along with 
26K and 25K polypeptides from both cell lysates and PEG 
precipitates of (3H]-glucosamine labelled, RS virus infected 
BS-C-.1 cells. The F2 polypeptide could be resolved into two 
bands in the PEG precipitate sample. The G protein was 
identified in immunoprecipitates of [3H]-glucosamine 
labelled but not of [ 35 S]-methionine or [3H]-leucine 
labelled RS virus cell lysates or PEG precipitates. This has 
been observed by others and is considered to be due to low 
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Figure 9. [3B]-glucosamdne labelled PVH and RS virus 
polypeptides i .. unoprecipitated with hoaolo.ous antisera 
PVH and RS virus infected cells were infected. 
labelled and immunoprecipitated as described in the le,end 
to Figure 8 except that [3H]-,lucosamine was used to label 
the cells instead of [ 35 S]-methionine. The fluoro,raph shows 
the labelled polypeptides immunoprecipitated analysed on a 
6-15 per cent ,radient ,el. The labellin, of the fiaure is 
the same as described for Figure 8. 
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abundance~ low methionine content and high glucosamine 
content of this polypeptide. 
The anti-PVM serum immunoprecipitated Gl, G2 a 42K 
polypeptide and possibly also 44K and 27K bands from PVM 
infected. cell lysates and PEG precipitates of the same 
cultures. The nature of the 44K and 42K polypeptides is 
considered further in Section 3.3. The 27K band was not 
M 
usually observed and probably represented a co-precipitating 
host cell polypeptide or was due to a small fraction of the 
3H becoming transferred from carbohydrate to amino acids. 
The bands observed above G1 in the figure were not virus 
specific (see Figure 29). 
The glycosylated 26K and 25K RS virus specific 
polypeptides identified by immunoprecipitation were probably 
related to the F protein since at least one polypeptide with 
a similar mobility to these polypeptides was 
immunoprecipitated by an anti-F but not by an anti-G 
monoclonal antibody (Figure 47). The band labelled F2 was 
considered to be the F2 protein since it was the most 
heavily labelled of the F related polypeptides and the F2 
subunit of the RS fusion protein has 4 of the 5 potential 
glycosylation sites (Collins et al •• 1984b; Baybutt & 
Pringle, 1987). The two bands observed in the region of the 
gel where F2 occurred in the immunoprecipitate of the PEG 
precipitated supernatant may have been due to variations in 
the extent of glycosylation of the F2 polypeptide. The other 
F related polypeptides could be fragments of Fl. 
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3.1.S. PVH polypeptides identified on Western blots 
The polypeptides of PVM that could be identified on 
Western blots of PVM infected cell lysates and PEG 
precipitates of the supernatants of PVM infected cells using 
the murine anti-PVM serum are shown in Figure· 10. The 
pattern of polypeptides observed differed from that seen in 
immunoprecipitates and varied between samples (compare 
Figure lOa and c). Possible explanations for this are 
considered below. Polypeptides N, 39K, 35K, M and 18K were 
usually observed whereas the occurrence of the 25K, 23K and 
20K polypeptides was more variable. Figure lOb shows the 
absence of a reaction when blots were incubated with 
pre-immune mouse serum instead of anti-PVM serum. 
The variation in the patter~ of polypeptides observed 
could have been due to different amounts of sample being 
loaded on the gel, different transfer efficiencies or the 
use of different preparations of anti-PVM serum. The 
presence of a 35K polypeptide in PEG precipitates could have 
been due to the relatively high level of PEG precipitate 
loaded on the gels (obtained from 5 times the number of 
cells used to prepare the cell lysate in the adjacent 
tracks). The band may be due to low levels of 35K 
polypeptide, possibly contamination from disrupted cells, or 
another.protein of similar mobility on the gel that cross 
reacts with the anti-PVM serum. Failure to detect G2 could 
have been due to the presence of cellular proteins with 
which the antiserum cross reacted in this region of the gel. 
Failure to detect Gi, G2, Fl, 12K and sometimes other 
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Figure 10. PVH polypeptides identified on Western blots 
Polypeptides of PVH or mock infected cell lysate 
(equivalent to 5X10 5 cells) and PEG precipitates of 
supernatants from 2X10 8 PVH infected or mock infected BS-C-1 
cells were separated by SDS-PAGE and transferred to 
nitrocellulose as described in Section 2.5.18. The 
nitrocellulose was stained to show the positions of the 
tracks and markers. destained. blocked and the polypeptides 
recognized by the antisera visualised as described in 
Section 2.5.19. 
a) Blot reacted with anti-PVM serum. 
The designations of the PVH specific polypeptides are 
indicated on the left. 
PEG PEG precipitates 
PVM PVM infected cell samples 
HI Hock infected cell samples 
b) Blot reacted with pre-immune mouse serum. 
c) Blot reacted with anti-PVH serum. 
(b) and (0) are labelled in the same way as (a) 
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polypeptides may have been due to low abundance of the 
polypeptide, failure of the polypeptide to transfer from the 
gel to the nitrocellulose or inability of the antibodies 
present in the serum to recognize some of the polypeptides 
when denatured. It is also possible that some of the 
polypeptides identified in immunoprecipitation experiments 
were only detected due to co-precipitation with other 
polypeptides and that the serum did not actually contain 
antibodies directed against them. Immunoprecipitation 
appeared to give more consistent results and since this was 
necessary for some experiments, for example pulse chase 
experiments, this was the method used for identifying virus 
specific polypeptides in most of the experiments described 
in this thesis. 
3.1.1 PVH and RS virus polypeptides synthesized in vitro 
The polypeptides synthesized in vitro using RNA from 
PVM and RS virus infected and mock infected cells were 
analysed by SDS-PAGE without prior immunoprecipitation 
(Figure 11). Polypeptides corresponding to the N, 39K, 35K, 
H, 20K, 19K, 16K and 12K polypeptides observed in vivo were 
observed among the in vitro translation products obtained 
using RNA from PVM infected cells. A 48K polypeptide 
synthesized in vitro may correspond to an F related 
polypeptide, (FO and F1 both occur in this region of the gel 
and neither was extensively glycosylated, Figure 38). Three 
bands observed below H in Figure 12 (labelled 25K) probably 
correspond to the 25K polypeptide described in Section 3.1.2 
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and the 24K polypeptide described in Section 3.1.9. There 
was a weak 23K polypeptide band the significance of which 
was unclear since there was a greater degree of 
incorporation of label into many polypeptides in this track 
compared with the mock infected RNA track. The relationship 
of the 17K polypeptide to PVM polypeptides labelled i rl v i ~/O 
is not known. Fewer polypeptides could be identified amongst 
the in vitro translation products of RNA from RS virus 
infected cells. N, P, H, some bands possibly corresponding 
to different forms of H2 and a 16K polypeptide could be 
clearly identified with possibly a faint 22K polypeptide 
similar to the 23K polypeptide observed with PVM and a 12K 
polypeptide. 
Most of the unglycosylated PVM and RS polypeptides 
identified in vivo could therefore be identified amongst the 
HI ~/i tro translation products obta.ined using RNA from virus 
infected cells. The L polypeptide of PVM or RS was not 
detected amongst the in vitro translation products probably 
due to their large size. A polypeptide that could correspond 
to the PVM L protein immunoprecipi tated f rom the i rl vi t r () 
translation products obtained using RNA from PVM infected 
cells is, however, described below (Section 3.1.8). The PVM 
glycoproteins were not identified amongst the in vitro 
translation products of RNA from PVM infected cells as would 
be expected, but the 48K polypeptide probably represented an 
unglycosylated form of one of them since it was a relatively 
large polypeptide that was not observed iTi ~/i VO. The 14K 
polypeptide of RS virus and the two glycoproteins were not 
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identified among the in vitro translation products of RNA 
from RS virus infected cells. If the 14K polypeptide was 
poorly labelled failure to detect it could have been due to 
it being obscured by the globin band (the broad smear near 
the bottom of the gel due to translation of residual globin 
mRNA in the reticulocyte lysate). The absence of any 
detectable glycoprotein precursors could have been due to 
the low abundance of these messages and, in the case of the 
G glycoprotein, the low methionine content of the 
polypeptide. The identity of the 16K and 12K polypeptides 
observed amongst the in vitro translation products was not 
clear. The 12K polypeptide may have represented the 11K non 
structural polypeptide but the mobility of the 16K 
polypeptide appeared to be too low for it to represent the 
14K polypeptide. Aberrant mobility did not appear to be a 
likely explanation for this band since a 14K polypeptide was 
observed in vivo . 
3.1.8. Immunoprecipitates of PVH and RS virus polypeptides 
synthesized in vitro 
The polypeptides 
immunoprecipitated by the antisera 
3.1.4 . _are shown in Figure 
synthesized in vitro and 
described in Section 
12. The polypeptides 
immunoprecipitated from infected cells and PEG precipitates 
of supernatants of such cells labelled in vivo are also 
shown in Figure 12 for comparison. Two exposures of the gel 
are shown so that all the polypeptides observed can be seen. 
The polypeptide patterns observed in this figure are similar 
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Figure 12. PVH and RS virus polypeptide •• ynthe.ized in 
vitro and t.munoprecipitated 
PVM and RS virus polypeptides synthesized in vitro as 
described in the preceding ficure were immunoprecipitated 
and analysed by SDS-PAGE usin, a 6-15 per cent ,radient 
resolving ,el. The polypeptides immunoprecipitated from 
samples labelled in vivo were run on the same ,el for 
comparison and the ,el was fluoro,raphed. Two exposures of 
the fluorocraph are shown to enable bands of different 
intensities to be identified. The antisera used were murine 
anti-PVM serum (anti-PVM) and bovine anti-RS serum 
(anti-RS) . 
PEG Polypeptides immunoprecipitated from PEG precipitates of 
cell supernatants 
PVH Samples derived from PVH infected cells or RNA from 
such cells translated in vitro 
as Samples derived from RS virus infected cells or RNA from 
such cells translated in vitro 
HI Samples derived from mock infected cells or RNA from 
such cells translated in vitro 
The PVH specific polypeptides are labelled on the left 
the as virus specific polypeptides on the rilht. 
polypeptide. are indicated by circles and the 
polypeptides by r's on the rilht of each track. 
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and 
The 
RS 
a in-vitro translation 
CELL LYSATE PEG anti-PVM anti-RS 
PVMRS MI PVMRSMI PVM RS MI PVM RS MI 
L a 
- 97-4 
G1 
- 68 
G2 
FO 
48K 
F1 F1 - 43 
N/39K N 
35K P 
M M 
-25-7 25K rM2 r 
23K r22K 
20K 
-18-4 19K 
r16K 
16K r14K -14 -3 
12K a 
b in-vitro translation 
CELL LYSATE PEG anti-PVM anti-RS 
PVM RS MI PVM RS MI PVM RS MI PVM RS MI 
L 0 o 
- 97-4 
G1 0 0 
- 68 
G2 a FO 
A8K 0 
F1 r F1 - 43 
N/39K r rN 
35K 
r rP 
M 0 rM 
25K r -25 -7 rM2 r 
23K r 0 r22K 
20K 0 a 
19K 
0 
-18 -4 
r16K 
16K 0 r14K -14-3 0 0 
12K o o 
to those observed in the previous figure but the 
polypeptides with lower ~s are reduced in intensity or 
absent presumably due to there being lower levels of 
antibody directed against these smaller polypeptides than 
against the larger ones. The immunoprecipitate of PVM 
polypeptides labelled in vitro revealed a polypeptide with a 
high Hr migrating at a similar position to polypeptide L 
labelled in vivo. Some of the PVM polypeptides labelled in 
vitro were observed in the track immunoprecipitated with 
anti-RS serum. This may have represented non-specific 
binding since the intensity of the bands was very low 
compared with that of the polypeptides immunoprecipitated 
with the homologous antiserum or may have been due to the 
viral polypeptides sharing common epitopes. Since pre-immune 
serum was not used in this experiment it is not possible 
todistinguish between these possibilities. The 48K, N, 35K, 
H, 25K, 20K and two bands in the region of the 16K 
polypeptide were immunoprecipitated from the in vitro 
translation products of RNA from PVM infected cells. The 19K 
polypeptide of PVM and the 12K polypeptides of PVH and RS 
virus were absent in contrast to the situation when 
immunoprecipitation was not used (Figure 11). This suggested 
that the 19K and the 12K polypeptides that were observed in 
immunoprecipitates of PVM polypeptides labelled in vivo may 
have been precipitated due to association with other 
polypeptides rather than because they were recognized by 
antibody. This is in agreement with the results obtained in 
Western blotting experiments where the 19K and 12K 
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polypeptides were not recognized by antibody (Figure 10). An 
alternative explanation would be that the antibody 
recognizes epitopes absent on the polypeptides synthesized 
in vitro and on denatured polypeptides. 
3.1.9 Analysis of PVM and RS virus polypeptides synthesized 
in vitro on two d~ensional gels 
The polypeptides synthesized in vitro were analysed on 
two dimensional gels without prior immunoprecipitation 
(Figure 13). The RS virus polypeptides synthesized in vitro 
(Figure 13a) included the N, P, M and M2 polypeptides 
identified amongst the RS virus polypeptides synthesized in 
RS virus infected cells (Figure 7). A 20K polypeptide 
observed amongst the polypeptides synthesized in vitro was 
more acidic than the polypeptide of similar mobility 
identified amongst RS virus polypeptides synthesized in 
vivo, suggesting that these polypeptides were different. The 
basic 16K polypeptide occurred in a similar position to a 
17K polypeptide synthesized in vivo and these polypeptides 
were probably therefore equivalent. The other two 
polypeptides with mobilities corresponding to polypeptides 
with ~s of about 16K were more acidic than the 16K 
polypeptide observed amongst the polypeptides synthesized in 
vivo. 
The N, 39K, 35K, H, 25K and 19K polypeptides of PVM 
present in Figure 13b occurred in similar locations on the 
gel to 
(Figure 
polypeptides 
7). A 24K 
synthesized in PVH infected cells 
basic polypeptide that had not been 
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Figure 13. ADalysis ot PVH aDd RS virus polypeptide. 
synthesized in vit,o on two dimensional .els. 
Polypeptide. synthesized in vitro as described in the 
le.end to Fieure 11 were analysed by NEPHGi/SDS-PAGE as 
described in Section 2.5.17. NEPHGE was carried out in the 
horizontal direction with the acidic end to the ri,ht. 
a) Fluoro,raph of PVH polypeptides synthesized in vit,o 
analysed by NEPRGE/SDS-PAGi 
b) Fluoro,raph of RS polypeptide. synthe.ized.ln vitro 
analysed by NEPHGE/SDS-PAGI 
c) Fluoro,raph of mock infected cell polypeptides 
synthesized .In vitro analysed by NIPHGI/SDS-PAGI 
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BASIC -NEPHGE ACIDIC 
a b 
- 97·4 
- 97 '4 
- 68 - 68 
- 43 - 43 
M 
- 25 ·7 - 25 '7 25K-24K-
-18 '4 - 18 ·4 
19K-
- 14 '3 - 14·3 
16K- SDS-
PAGE 
c 
- 97·4 
- 68 
- 43 
- 25·7 
-18 ·4 
- 14 ,3 
observed among the PVM polypeptides synthesized in infected 
cells was present. The 19K spot was somewhat diffuse and may 
have represented the 20K and 19K polypeptides that were not 
well resolved. The 18K polypeptide was not observed. Two 
acidic 16K polypeptides were observed similar to those 
observed in vivo (Figure 7). 
The N polypeptides of PVM and RS virus synthesized in 
vit~o showed streaking in the first dimension as had been 
observed for this polypeptide synthesized in vivo This was 
probably due to aggregation, (a large amount of label 
remained at the origin) and perhaps association with viral 
RNA. The matrix polypeptide of RS virus had several more 
acidic spots associated with it as was observed for this 
polypeptide synthesized in vivo and which was probably due 
to minor forms with different arrangements of disulphide 
bonds as described in Section 3.1.3. The basic 24K 
polypeptide of PVM has similar a similar electrophoretic 
mobility and charge properties to the M2 polypeptide of RS 
virus. The acidic 25K polypeptide of PVM observed both in 
vitro and in vivo did not have a counterpart amongst RS 
virus polypeptides. The25K polypeptide may be related to 
the 39K polypeptide (Section 3.4.7). The nature of the 16K 
polypeptide of PVM is not clear. The nature of the 20K and 
16K polypeptides observed amongst the products of in vitro 
translation of RNA from RS virus infected cells was not 
clear since they did not correspond to the polypeptides 
observed by others, (e.g. Collins et al. 1984a). The central 
16K polypeptide may have corresponded to the 14K polypeptide 
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Figure 14. Absence of cross reaction of anti-RS virus serum 
with PVH polypeptides 
PVM (P), RS virus (R) and mock infected (M) cells were 
labelled and the cell lysates and PEG precipitates of the 
supernatants were immunoprecipitated with anti-RS virus 
serum and analysed by GDG-PAGE using a 6-15 per cent 
gradient gel. A fluorograph of the gel is shown. RS virus 
specific polypeptides are labelled on the right. 
~. 
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anti - R S serum 
Cell 
Cell lysate PEG lysate PEG 
P M P M R R 
Fl 
N 
M 
M2 
22K 
F2 
14K 
observed amongst the polypeptides synthesized in vivo, the 
others possibly representing breakdown products of larger 
polypeptides or polypeptides prematurely terminated during 
synthesis. 
3.1.10 Cross-immunoprecipitation between PVM and RS virus 
polypeptides 
Gimenez et aI. (1984) observed a cross reaction on a 
Western blot of a murine anti-RS virus serum with the 
nucleocapsid protein of PVM. It was of interest to know if a 
similar cross reaction could be obtained using the murine 
anti-PVM serum produced during the present study. Since the 
Western blotting system was less well developed than the 
immunoprecipitation studies the latter system was used for 
examining the cross reaction of the antisera with 
heterologous virus. Western blotting was unsuitable 
primarily because the antibody system for detecting RS virus 
antigen did not give clear results so it was not possible to 
determine whether a negative reaction of anti-PVM serum with 
RS virus antigens was due to absence of cross-reacting 
antibody or insufficient antigen on the blot. 
The results obtained in cross-immunoprecipitation 
studies -are shown in Figures 14 and 15. It was found that 
the bovine anti-RS virus serum did not immunoprecipitate any 
PVM polypeptides, (Figure 14). In contrast the murine 
anti-PVM serum but not pre-immune mouse serum did 
immunoprecipitate the nucleocapsid protein of RS virus, 
(Figure 15). This provides evidence that PVM and RS virus 
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Figure 1~. Cross-reaction of anti-PVH serum with the as 
virus nucleocapsid protein. 
The figure shows the fluorograph of a gel of PVM (P), 
RS virus (R) and mock infected (H) cell samples prepared as 
described in the legend to Figure 8 immunoprecipitated with 
anti-PVM or mouse pre-immune mouse ~erum. PVH specific 
polypeptides are labelled on the left. 
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.. 
N/3 
3 
12K 
I anti-PVM serum 
Cell lysate PEG 
P R M P R 
I pre-immune mouse serum I 
Cell lysate PEG 
P R M P J/;" 
nucleocapsid polypeptides are related. 
3.1.11 Summary 
The results presented in this chapter show the 
pneumovirus polypeptides identified in infected cell 
lysates, polyethylene glycol precipitates of infected cell 
supernatants and in in vitro translation experiments usin~ 
unfractionated RNA from infected cells. The RS virus 
polypeptides that have been described by others are the L, 
G, FO (cleaved to give F1 and F2 polypeptides), N, P, H, H2. 
14K, 11K and 9.5K polypeptides. The major RS virus 
polypeptides observed during the course of this project were 
G, F1, N, P, H, H2 (probably two forms of differing 
mobility), 26K and 25K glycosylated polypeptide, F2, a 16K 
polypeptide (observed only in vitro and consi5tin~ of three 
polypeptides of different charge), and the 14K polypeptide. 
The L polypeptide of RS virus was not detected in any of the 
experiments described in this section probably due to this 
being the least abundant polypeptide for the reasons 
described in the Introduction (Section 1.1.1). Four major 
glucosamine labelled polypeptides were observed 
corresponding to G, Fl, a 25K polypeptide and F2. The G 
protein was only observed using [3H]-glucosamine labelling 
probably due to its low methionine content although since 
the use of [3H]-leucine label failed to reveal this 
polypeptide its abundance in the system used during this 
project was probably quite low. The 26K and/or 25K 
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polypeptides probably represented a fragment of F1 since a 
polypeptide of similar mobility was immunoprecipitated by a 
F specific monoclonal antibody. The F1, N, P, H, H2 and 14K 
polypeptides were identified in [35S]-me~hionine labelled 
cell lysates or PEG precipitates of supernatants from 
infected cells using immunoprecipitation or two dimensional 
gels. The 11K and 9.5K polypeptides were not observed the 
reason for tnis not being clear since the mRNA coding for 
these polypeptides would be expected to be relatively 
abundant since they occur towards the 3' end of the viral 
genome which is the first part transcribed. A 16K 
polypeptide observed in ~/itro which appeared to consist of 3 
spots of differing charge may have included these 
polypeptides if they showed aberrant mobility. The 
experiments involving immunoprecipitation could have failed 
to identify these polypeptides due to them not being 
recognized by the antiserum. 
The PVH polypeptides identified were L, G1, G2, Fl, 
44K. 42K, N, 39K, 35K, H, 25K, 24K, 23K, 20K, 19K, 18K, 16K, 
and 12K. The viral specificity of all of these apart from 
the 23K polypeptide was confirmed by immunoprecipitation 
using murine anti-PVM serum. The Gl, G2, 44K and 42K 
polypeptides were glycosylated. The unglycosylated 
polypeptides except the L protein, which was detected when 
immunoprecipitation was used, were observed in in vitro 
translation experiments using RNA obtained from PVH infected 
cells. 
The data on RS virus polypeptides is compared with the 
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published data of Collins et al. (1984a) and Norrbyet al. 
(1986) in Table 6 and summarised in Table B. The PVM 
polypeptides identified are compared with those observed by 
Cash et al. (1979) in Table 7 and the results summarised in 
Table 9. 
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Table 6 Coaparison of RS virus polypeptides with published 
observations 
Published results 
RS virus H.: (X10- 3 ) 
protein Subtype A Subtype 
L 200 200 
G1 84 84 
F02 10 10 
F1 48 46-41 
N 42 42 
P 35 32 
H 26 26 
H2 24 24 
23K 23 
F2 18-20 18.5-20 
14K 14 
11K 11 
9.5K 9.5 
B 
Present results 
RS virus 
protein 
L 
G 
F1 
N 
P 
M 
GP26 
GP25 
M2 
22K 
F2 
16K 
14K 
190, 
86.5 
44.83 
39.4 
33.13 
26.2 
25.6 
24.1 
24.5 + 23.4 
22.44 
19.4 
16.0 
13.6 
1 Strain dependent but subtype independent variations in 
mobility have been reported 
2 Fa was not observed although the dimer Fl,2 was observed 
in experiments described in Section 3.3. 
3 This is a subtype A strain but the calculated ~s differ 
from those published due to the use of different marker 
proteins. 
4 This polypeptide was probably a Fl fragment showing 
inter-strain variability. 
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Table 1 Comparison of PVM polypeptides observed with the 
published data 
Published results 
PVM Mr (Xl0- 3 ) 
protein 
I 
II 
III 
IV 
V 
VI 
VII 
VIIl 3 
IX 
X 
XI 
XII 
200 
79 
63 
42 
40 
35 
28 
26 
17 
16 
13.5 
12 
Present results 
PVM 
protein 
L 
G1 
G2 
48K1 
F12 
44K 
42K 
N 
39K 
35K 
M 
25K 
24K 
23K 
20K 
19K 
18K 
16K 
12K 
191 
76.4 
62.0 
48.0 
45.1 
43.5 
42.3 
40.3 
39.0 
35.4 
27.3 
25.1 
23.9 
22.9 
20.2 
19.3 
18.1 
15.8 
12.0 
1 Only observed amongst polypeptides synthesized in vitro. 
2 Only observed amongst polypeptides synthesized in vivo. 
3 Two polypeptides were sometimes observed in this region of 
the gel. 
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Table 8 Polypeptides of RS virus 
RS virus Mr (X10- 3 ) Polypeptide Acidic Identified 
protein identified or basic by immuno-
in vivo in vitro precipitation 
L 190 + 
-+-
G 86.5 + + 
FO 62.9 + basic + 
F1 44.8 + basic + 
N 39.4 + + acidic -+-
P 33.1 + + acidic -+-
M 26.2 + + basic -+-
GP26 25.6 + + 
GP25 24.7 + + 
M2 23.4+24.5 + + basic + 
F2 19.4 + + 
16K 16.0 + bothl -+-
14K 13.6 + + 
1 Three spots were observed corresponding to this band on 
two dimensional gels, one of which was basic, one slightly 
acidic and one acidic. 
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Table 9 Polypeptides of PVM 
PVM 1\ (X10- 3 ) Polypeptide Acidic Identified 
protein identified or basic by immuno-
in vivo in vitro precipitation 
L 191 + + + 
Gl 76.4 + ,+ 
G2 62.0 + + 
48K 48.0 + basic + 
F1 45.1 + basic + 
44K 43.5 + + 
42K 42.5 + + 
N 40.3 + + acidic + 
39K 39.0 + + acidic + 
35K 35.4 + + acidic + 
M 27.3 + + basic + 
25K 25.1 + + acidic + 
24K 23.9 + + basic + 
23K 22.9 + 
20K 20.2 + + acidic + 
19K 19.3 + + acidic + 
18K 18.1 + + acidic + 
17K 17.0 + + 
16K 15.8 + + acidic1 + 
12K 12.0 + + +2 
1 Two __ spots were observed on two dimensional gels 
corresponding to two slightly acidic polypeptides differing 
in charge. 
2 This polypeptide was not immunoprecipitated when it was 
labelled in vitro . 
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3.2 Characterization of PVH-speciiic mODocloDal antibodies 
3.2.1 Introduction 
To study single PVM polypeptides antibodies reacting 
specifically with single viral polypeptides of the virus 
were required. This would enable precursor-product 
relationships between polypeptides to be established and 
enable polypeptides with similar or identical mobilities to 
be studied independently. Ideally polyclonal antibodies 
raised against purified viral polypeptides would be used. 
However. due to the cell associated nature of most of the 
infectivity the virus could not be readily purified. In 
addition the simplest way of obtaining purified polypeptides 
for immunization purposes, excising bands from gels, was not 
suitable since several viral polypeptides had similar 
mobilities. The Nand 39K polypeptides and the 20K and 19K 
polypeptides for example would be difficult to separate 
satis·factorily. These problems could be overcome by 
producing monoclonal ~tibodies. This approach enables 
highly specific antibodies to be obtained despite immunizing 
animals with crude antigen preparations. In addition. once 
cell lines were established. qualitatively identical 
antibody preparations could be reproducibly obtained. There 
were some disadvantages in that the antibodies would only 
recognize single epitopes, so that a monoclonal antibody 
recognizing a protein involved in neutralization of the 
virus by polyclonal sera for example, might fail to 
neutralize the virus. The ability of the antibodies to 
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recognize denatured polypeptides would also vary. In 
addition some properties of antibodies are subclass specific 
so that not all monoclonal antibodies would bind to S.aureU5 
protein A for example. 
Hybridoma cell lines secreting PVH-specific antibodies 
were produced and screened as described in Materials and 
Methods. Several immunization protocols were used, in Fusion 
Experiment No.23 two intraperitoneal injections of a PEG 
precipitate of the supernatant of PVH-infected Balb/c a T12 
cells followed by an intravenous injection of PVM purified 
from the supernatant of infected BS-C-l cells was used. In 
Fusion Experiments Nos. 20 and 22 two intraperitoneal 
injections of PVM-infected BS-C-l cells followed by one 
intravenous injection of the same material, sonicated and 
pelleted at 10,OOOg for 30 minutes to remove cell debris. 
were used. In Fusion Experiments Nos. 24, 25 and 26 two 
intraperitoneal injections of a PEG precipitate from 
PVM-infected Balb/c cells followed by two intravenous 
inoculations of the same material was used. In Fusion 
Experiments Nos. 4, 6 and 7 two intraperitoneal injections 
of PVH-infected Balb/c cells were used.In the Fusion 
Experiments not mentioned above three intraperitoneal 
injections of PVH infected Balb/c cells were used. The sera 
of the mice showed an anti-PVM ELISA titre of at least 5000 
in each case before the final boost which was given 4 days 
before removal of the spleens and fusion of the ceils with 
myeloma cells. The. pooled hyperimmune sera of these mice had 
a neutralization titre of 45,000 and recognized most of the 
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virus specific polypeptides in immunoprecipitation 
experiments as previously described (3.1.4). Pre-immune sera 
from these mice showed neutralization titres of less than 
100 and failed 
polypeptides. The 
to immunoprecipitate 
numbers of hybridoma 
virus specific 
cell lines, the 
numbers of these producing PVM-specific antibodies and the 
characterization of these antibodies are described in this 
Section. 
3.2.2 Bybridoma cell lines obtained 
A total of 26 Fusion Experiments were performed, 22 
using mice immunized with PVM infected Balb/c cells and 4 
using mice immunized with partially purified virus, as 
described above. The numbers of clones grown up and the 
numbers of these producing PVM-specific antibody are shown 
in Table 10. Fusion Experiments in which no hybrids grew up 
are not included for clarity. The reason for the low·numbers 
of hybrids obtained in most experiments is not clear. There 
are three possible explanations for this, firstly there may 
have been deficiencies in technique, secondly the reagents 
used in the process may have varied with respect to fusion 
efficiency and thirdly the state of the cells may have been 
important. The final three Fusion Experiments were performed 
on the same day with no noticeable variation in technique 
but the results varied considerably. In Fusion Experiment 
No.26 Ag8.aS3 cells were used rather than NS-l cells. 
although these cells had also been used in earlier Fusions 
Experiments (numbers 11 and 19) where no improved efficiency 
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Table 10 Details of fusions performed 
Number and Ant.igen Myeloma Number of Number of 
dat.e of used cells colonies clones 
fusion for used obtained producing 
final PVM-specific 
boost. ant.ibodies 
1, 14/ 6/85 a NS-1 19 2 
2, 15/ 6/85 a NS-1 5 1 
3, 19/ 6/85 a NS-1 21 3 
4, 8/ 7/85 a NS-l 3 0 
5, . 9/ 7/85 a NS-l 1 0 
8, 23/ 7/85 a NS-l 17 2 
9, 6/ 8/85 a NS-l 44 0 
11, 13/ 8/85 a Ag8.653 13 2 
12, 16/ 8/85 a NS-1 6 0 
13, 19/ 8/85 a NS-l 2 0 
14, 23/ 8/85 a NS-l 1 0 
17, 28/ 9/85 a NS-l 15 3 
19, 3/10/85 a Ag8.653 41 6 
24, 29/11/85 b NS-1 35 23 
25, 29/11/85 b NS-l 11 2 
26, 29/11/85 b Ag8.653 371 182 
1. a PVM-infected Balb/c cells inoculated intraperitoneally. 
b Partially purified PVM from BS-C-1 cells inoculated by 
the intravenous route. 
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was observed. In Fusion Experiments Nos. 25 and 26 
commercially produced polyethylene glycol solution was used, 
and this again did not produce consistent results. Changing 
to a different batch of medium and obtaining another vial of 
NS-1 cells (from a laboratory where fusions were 
successfully performed), similarly did not affect the 
results. The reason for the unsatisfactory results of most 
fusions was not therefore determined. The only satisfactory 
result was obtained using commercial polyethylene glycol 
solution and Ag8.653 as opposed to NS-l cells. 
The Fusion Experiments from which hybridoma cell lines 
were finally obtained are indicated in Table 11. The number 
of clones grown up indicates the number of cell lines that 
were successfully transferred from 96 well plates to 12 well 
tissue culture clusters. The number of clones characterized 
indicates the number of cell lines that were cloned 3 times, 
grown up in mice to produce ascites fluid and the antibodies 
characterized by the tests described below. After the 
initial screening the results of the ELISA assays during the 
screening of cloned cells for antibody production frequently 
failed to give clear positive results. A possible 
explanation for this is given in the following section. This 
meant that recloned cells could not be selected on the basis 
of antibody production and probably accounts for the large 
proportion of cell lines that did not give virus specific 
antibody reactions in the tests described. 
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Table 11 Numbers of viable bybridoma cells producing 
PVH-specific antibody 
Fusion 
number 
19 
24 
26 
Number of 
clones 
grown up 
6 
21 
38 
134 
Number of 
clones 
characterized 
2 
4 
19 
3.2.3 Immunofluorescence using monoclonal antibodies 
Some variability was observed in the results of ELISA 
assays, perhaps due to variation in the fixation of the 
cells allowing different degrees of access of the 
monoclonal antibodies to intracellular antigens. Indirect 
immunofluorescence using acetone fixed cells was used to 
establish the viral specificity of the antibodies more 
conclusively. Screening was carried out against PVM 
infected, RS virus infected or uninfected BS-C-l cells. Six 
monoclonal antibodies gave positive results by this method 
of screening. The results are shown in Table 12 and 
representative photographs of the appearances of the 
fluorescently labelled cells are presented in Figure 16. The 
absence of fluorescence observed with monoclonal antibody 
26/1/A4, (Figure 16. 7 and 8), was typical of the results 
observed with monoclonal antibodies listed as giving 
negative reactions in Table 12. The PVM-specific antibodies 
recognized antigens expressed internally in infected cells. 
These antigens were present in localized regions of the cell 
either in a perinuclear location or associated with the 
virus-specific filamentous 
processes. These processes, first described by Faulkner et 
.1. (1976) have also been detected by Pringle and Parry 
(1980) using scanning electron microscopy to detect 
Staphylococcus .ur.us bound to virus specific antibody bound 
to viral antigen on the cell surface. These filaments are a 
distinctive feature of Pneu.ovirus infected cells not being 
observed in cells infected with other viruses, Parry et al. 
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Table 12 Results of L.aUDofluoresceDce teats 
Immunofluorescence observed with:-
PVM infected:-
fixed unfixed 
cells cells 
+ + 
+ 
uninfected:-
fixed unfixed 
cells cells 
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Antibodies showin, this 
pattern of fluorescence 
19/1/C9 
26/1/A1 
26/1/A2 
26/1/D7 
26/1/E11 
26/4/C41 
19/2/E11 
24/3/A7 
24/3/H8 
24/5/Al 
26/1/Al 
26/l/A4 
26/1/B4 
26/l/BlO 
26/l/Bll 
26/1/C4 
26/1/C7 
26/1/D7 
26/1/E3 
28/1/B8 
28/3/F10 
Immunofluorescence observed with:-
PVM infected:- uninfected:-
fixed unfixed fixed unfixed 
cells cells cells cells 
... 
Antibodies showing this 
pattern of fluorescence 
26/3/35 
26/2/E1 
26/4/B3 
26/4/B7 
24/1/Al 
26/5/E2 
1 This antibody also reacted with fixed RS virus infected 
cell~ 
I"igure 18 I_unofluoreacence reactioD of IIODooloDal 
antibodies with acetone tized, PVH or AS virua infected 
BS-C-l cella 
PVM and RS virus infec~ed BS-C-1 cell. ,rown on ,1 ••• 
coverslips or multiwell slid •• a. deacribed in Materi.la and 
Methods were fixed 24 hours after infection wi~h ace~one and 
incubated successively with monoclonal antibody and 
fluorescein conjugated anti-llouae ilDlDuno,lobulin. as 
described in Materials and Hethods (Section 2.5.21). The 
slides were examined at a lIaanification of 1000X as 
described in Section 2.5.21. 
Odd numbered ficures show stainin, with PVH infected 
cells and even numbered flaures show stainin, with RS virus 
infected cells. Number 23 and 24 show atainin, of 
antibodies 26/4/C4 and 26/5/E2 with uninfected BS-C-l cells. 
The antibodies used are indicated below. 
1,2 anti-PVH serum 
3,4 43.1 B8 (anti-RS virus F protein mAb) 
5,8 111.2a (anti-RS virus G protein mAb) 
7,8 26/1/A4 
9,10 19/1/C9 
11.12 28/1/Al 
. 
13,14 28/1/A2 
15,16 26/1/D7 
11,18 28/1/111 
19,20 26/4/C4 
21,22 26/51E2 
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Figure 17 Immunofluorescence reaction of monoclonal 
antibodies with unfixed PVH and RS virus infected BS-C-1 
cells 
Immunofluorescence was carried out essentially as 
described in the legend to Figure 16 except that the cells 
were not fixed. Odd numbered figures show the reaction with 
PVM infected cells and even numbered figures show the 
reaction with RS virus infected cells. 
1,2 anti-PVM serum 
3,4 i9/1/C9 
5,6 43.1 H8 (anti-RS virus F protein mAb) 
7,8 111.2a (anti-RS virus G protein mAb) 
9 26/1/Al 
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(1979). 
Monoclonal antibody 26/4/C4 was observed to 
cross-react with RS virus infected cells (Figure 16, 19 and 
20) but the other antibodies did not show evidence of 
cross-reaction. This reaction did not appear to be due to 
reaction with a cellular protein because it did not give a 
positive reaction with uninfected cells (Figure 16, 23). 
Antibody 26/5/E2 gave a positive reaction with mock infected 
cells (Figure 16, 24) as well as with PVM and RS virus 
infected cells (Figure 16, 21 and 22) and therefore appeared 
to recognize a cellular antigen, or to react with a viral 
and a cellular antigen as has been described by Srinvasappa 
et al (1986). The pattern of fluorescence given by this 
antibody with PVM infected cells was different from that 
obtained with RS virus or mock infected cells. This suggests 
that if the antibody recognizes a cellular protein its 
distribution is altered in infected cells. 
The monoclonal antibodies were also screened against 
unfixed cells and the results of some of these studies are 
shown in Figure 17. It was found that only antibody i9/1/C9 
showed a positive reaction with unfixed cells suggesting 
that this antibody and not the other antibodies reacted with 
an antigen expressed on the surface of infected cells 
(Figure 17, 3). Cell surface fluorescence was also observed 
when RS virus infected cells were stained with anti-F and 
anti-G monoclonal antibodies, (Figure 17, 6 and 8). Figure 
17, 9 shows the absence of fluorescence observed using 
monoclonal antibody 26/1/Al as a representative negative 
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result. 
3.2.4 Immunoprecipitation with monoclonal antibodies 
Immunoprecipitation of radiolabelled lysates and of 
PEG precipitates of the supernatants of PVM, RS virus and 
mock infected cells was performed to identify the 
polypeptides recognized by the monoclonal antibodies. It was 
found that 3 of the 25 monoclonal antibodies tested 
precipitated [35 S]-methionine labelled polypeptides, the 
results being shown in Figure 18. Antibody 19/1/C9 
precipitated both polypeptide Gl and polypeptide G2, (Figure 
18, a) antibody 26/1!Ell reacted with the M polypeptide of 
PVM. (Figure 18, b), antibody 26/4/C4 precipitated the N or 
39K polypeptide, (Figure 18, c). Figure 18, e shows the 
negative result that was obtained with antibody 26/1/A1 
which is representative of the negative results obtained 
with all the other antibodies. In another experiment a 
different result was obtained with antibody 26/4/C4 (Figure 
18, d). This antibody was found to precipitate the L 
polypeptide in addition to the N or 39K polypeptide from PVM 
infected cells and also to precipitate polypeptides L, Nand 
P from RS virus infected cells. The results obtained in 
Western blots described below showed that the antibody 
recognized the N or 39K polypeptide in PVM-infected cells 
and P in RS virus infected cells. The co-precipitation of 
the RS virus N protein by monoclonal antibodies specific for 
the P protein has been observed previously (Gimenez et al. 
(1984). The co-precipitation of the L and N or 39K 
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Figure 18 IlIIIIlunoprecipitation with anti-PVH .anoclonal 
antibodies 
Cell lysates and PEG precipitates of the supernatants 
(PEG) of [ 35 S]-methionine labelled cells infected with PVM, 
RS virus (BS) or uninfected (MI) were immunoprecipitated 
with monoclonal antibodies and analysed by SDS-PAGE usinl 
6-15 per cent resolving gels. The antibodies used are 
indicated below. 
a) I9/l/C9 
b) 26/l/Ell 
c) 26/4/C4 
d) 26/4/C4 performed after observing the cross 
reaction with RS virus shown in Figure 16. 
e) 26/1/Al 
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polypeptides and also the co-precipitation of the 3 RS virus 
proteins was probably due to the association of these 
polypeptides in nucleocapsid structures. The association of 
a polypeptide with a high Mr with nucleocapsid structures 
has been observed for the rhabdovirus, vesicular stomatitis 
virus (Bishop & Roy, 1972; Emerson & Wagner, 1972; Szilagyi 
& Uryayev, 1973), measles virus (Stallcup et aJ' J 1979; 
Robbins et al. 1981), the paramyxoviruses Newcastle disease 
virus (Hamaguchi et aI., 1983; Colonno & Stone 1976) and SV5 
(Buetti & Choppin, 1977) as well as for RS virus (Peeples & 
Levine, 1979) and PVM (Cash et al., 1979a). It was 
subsequently established that the monoclonal antibody 
26/4/C4 reacted with the 39K polypeptide (Section 3.4.6). 
The cross reaction between the two glycoproteins 
observed using monoclonal antibody 
possible relationship between these 
this is discussed later (Section 3.3). 
19/1/C9 indicates a 
two polypeptides and 
Other polypeptides 
were irregularly immunoprecipitated by this antibody (e.g. 
the N protein in Figure 18, a) and were considered to be 
precipitated non-specifically. 
Only certain subclasses of antibodies bind to 
staphylococcus aureus protein A so some of the antibodies 
might have failed to immunoprecipitate antigens due 
to failure 
problem 
overnight 
to 
formalin 
at 4°C 
bind 
in 
protein A. To overcome this 
fixed s. aureus was 
a 1 in 10 dilution 
anti-mouse immunoglobulin and used 
incubated 
of rabbit 
to adsorb 
antibody-antigen complexes from antibody-radiolabelled 
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sample mixtures for 3 hours on ice. This procedure did not 
result in the identification of the antigenic specificity of 
any further antibodies. 
3.2.5 Western blotting with anti-PVM monoclonal antibodies 
Western blots of cell lysates and PEG precipitates of 
the supernatants of uninfected, PVM and RS virus infected 
cells were probed with each of the monoclonal antibodies. 
Radioimmunoprecipitation enables antibodies to be 
characterized that do not recognize denatured proteins. 
Western blots provide a less ambiguous means of identifying 
the specificity of the antibodies since the problem of 
co-precipitation observed with radioimmunoprecipitation does 
not occur. Two of the antibodies recognized the PVM N or 39K 
proteins, 26/1/A2 and 26/4/C4 (Figure 19, b and c). Figure 
19. a shows the absence of a reaction with antibody 26/1/Al 
which is representative of the the results obtained with 
antibodies giving a negative result. The failure of 26/1/A2 
to recognize the N or 39K protein in cell lysates may have 
been due to the relatively low abundance of viral proteins 
in cell lysates on the blot compared with that in the PEG 
precipitate sample. It can be seen that the cross reaction 
of 26/4/C4 with RS virus was due to a cross reaction with 
the RS virus phosphoprotein. 
3.2.6 Neutralization and haemagglutination inhibition 
The supernatants of the two surviving clones from 
Fusion Experiment No.19 and those of all the colonies 
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Figure 19 Reaction of monoclonal antibodies in Western 
blots. 
Polypeptides from cell lysates and PEG precipitate 
samples were separated by SDS-PAGE and transferred to 
nitrocellulose. The blots were cut into strips and reacted 
with antibodies as described in Section 2.5.19. The 
antibodies used in each case are indicated below. 
a) 26/1/Al 
b) 26/1/A2 
c) 26/4/C4 
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producing PVM-specific antibody obtained in Fusions 
Experiments Nos.24, 25 and 26 were screened for neutralizing 
and haemagglutination inhibiting activity. Qnly antibody 
i9/1/C9 showed haemagglutination inhibiting activity,. 
Ascitic fluid containing antibody from this cell line had 
haemagglutination inhibition titres of 20,480 compared to 
titres of less than 20 for all other ascitic fluids tested. 
Neutralizing activity was observed in the supernatants 
of 20 clones from Fusion Experiment No.24 and 2 clones from 
Fusion Experiment No.26. None of these clones could be 
examined further however since they either failed to recover 
from storage in liquid nitrogen or their supernatants no 
longer possessed neutralizing activity after recovery of the 
cells. 
3.2.7 Summary 
The results presented in this section show that of 6 
monoclonal antibodies shown to be PVM-specific by 
immunofluorescence, the polypeptides recognized by 4 of them 
could be identified. The 19 monoclonal antibodies that gave 
negative or variable reactions in immunofluorescence 
experiments did not react in immunoprecipitation, Western 
blots, neutralization or haemagglutination inhibition 
assays. One of the monoclonal antibodies. 26/4/C4, 
recognised the 39K protein, one, 26/1/A2, recognized the N 
or 39K protein, one. 26/1/E11 recognized the matrix protein 
and one, 19/1/C9, recognized a virus glycoprotein. The 
latter monoclonal antibody inhibited haemagglutination of 
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murine erythrocytes by PVM to high titre implying that the 
polypeptide that it recognizes may be the haemagglutinin of 
the virus. PVM is unique amongst the pneumoviruses in 
possessing haemagglutination activity. None of the surviving 
hybridoma produced antibodies neutralized infectivity of the 
virus in BS-C-1 cells. Neutralizing activity was associated 
with the antibody produced by 20 clones that did not survive 
storage in liquid nitrogen. With the exception of antibody 
26/4/C4 none of the monoclonal antibodies cross-reacted with 
RS virus antigens. This anti-39K protein antibody 
immunoprecipitated the nucleocapsid protein and the 
phosphoprotein of RS virus. A summary of the properties of 
the PVM specific monoclonal antibodies is shown in Table 13. 
These antibodies provided specific reagents for studying 
processing of individual viral polypeptides in PVM infected 
cells. 
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Table 13 Reactions of PVH specific monoclonal antibodies1 
Antibody 
19/1/C9 
26/1/A1 
26/1/A2 
26/l/D7 
26/1/1:11 
26/4/C4 
II' with 
fixed. unfixed 
cells cells 
.. .. 
.. 
.. 
.. 
.. 
.. 
RIpZ HI neutralizatioD 
titre titre 
Gl+G2 
If 
20,480 
<20 
N or 39K <20 
_8 
<20 
39K,L 39K,(P) <20 
(P,N,L) 
<10 
<10 
<10 
_8 
<10 
<10 
1 AbbraviatioDs used are as follows, IF-immUDofluoresceDce, 
RIP-radiot.aunoprecipitation,- indicates DO reaction 
WB -Western blotting, - iDdicates DO reactioD 
HI -haeaagglutiDation inhibition with 4 SA units of PVH and 
aurine erythrocytes 
2 RS virus polypeptides which cross react are shown iD 
brackets 
3 Supernatants gave negative results, no ascites was 
available 
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3.3 GLYCOPROTiINS OF PNEUMONIA VIRUS OF MICE 
3.3.1 Introduction 
The envelope glycoprotein~ of RS virus have been 
extensively studied both as proteins (Fernie et al. 1985; 
Gruber & Levine 1983, 1985a & b; Hendricks et aI. 1981; 
.-
Lambert & Pons 1984; Routledge et aI. 1986; Samson et aI. 
1986; Tsutsumi et aI. 1987; Walsh & Hruska 1983; Walsh et 
, 
aI. 1984a, 1985, 1986) and as antigens (Bangham et aI. 
1986; Elango et al. 1986; Johnson et al. 1981b; Olmsted et 
al. 1986; Pemberton et al. 1981; Stott et aI. 1986; Walsh et 
al . . 1984b, 1981a&b; Ward et aI. 1983; Wertz et aI. 1981). As 
was discussed in Section 1.1.2 these studies showed that the 
G glycoprotein has a peptide backbone with a ~of 36,000 
which is processed in two stages, first a rapid stage 
probably due at least in part to N-linked glycosylation 
giving a polypeptide with a Mr of 45,000 followed by a 
slower step leading to the mature glycoprotein with a ~ of 
84,000-90,000. In addition two different glycosylated bands 
with t\s of 45,000 and 50,000 related to G have been 
observed the significance of which is not clear (Routledge 
et al. 1986). The F glycoprotein has been shown to be 
involved in fusion of infected cells to form syncytia and is 
synthesized as a 70K polypeptide which is then cleaved to 
give disulphide bonded polypeptides of about SOK and 20K. 
The glycoproteins of PVM are significantly different 
from those of RS virus (Cash et al. 1979a and Section 
3.1.5). The main aim of the experiments .described in this 
section was to study the PVM glycoproteins and their 
89 0 G 1 :; ·1 
synthesis in more detail. RS virus was used in parallel with 
PVM in most of the experiments to serve as a control for the 
techniques employed. The RS virus 'G protein could not be 
satisfactorily radiolabelled with [35S]-m~thionine, 
4,5-[3H]-leucine or [14C]-protein hydrolysate, so PVM 
glycoproteins could only be compared with the RS virus F 
glycoprotein in experiments using these radiolabelled amino 
acids. The experiments described in this section describe 
the glycoproteins of PVM, their relationship to each other 
and the nature of the linkages between the carbohydrate and 
protein. 
3.3.2 Partial proteolysis of glycoproteins Gl and G2 
Since the glycoproteins Gl and G2 were both 
immunoprecipitated by monoclonal antibody 19/1/C9 it was 
necessary to establish whether this was due to the two 
polypeptides being related, or if they were simply 
co-precipitated due to an association between them. In an 
attempt to resolve this question the Gl and G2 bands were 
excised from gels of PVM polypeptides, immunoprecipitated 
with either polyclonal anti-PVM serum or with monoclonal 
antibody 19/1/C9, and subjected to partial digestion with 
proteases. The two glycoprotein bands were found to be 
highly resistant to digestion with the enzymes used, 
(Staphylococcus aureus V8 protease, chymotrypsin, trypSin 
and endoprotease Lys-C). No digestion was observed with the 
"latter two enzymes when digestion was carried out according 
to the method of Cleveland et al. (1977) for 30 minutes 
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Figure 20 Partial proteolysis of PVH glycoproteins using 
S.aureus va protease 
The Gl and G2 polypeptides of PVM along with a 
polypeptide observed in tunicamycin ~reated, PVM infected 
cells were partially digested with S.aureus va protease 
prior to analysis by SDS-PAGE using a 6-15 per cent gradient 
gel as described in Section 2.5.22. The polypeptide bands 
were excised from gels of immunoprecipitates of 
[ 35 S]-methionine labelled PVM infected cells (labelled cell 
lysate in the figure) and PEG precipitates of the 
supernatants of such cells (labelled PEG) and digested with 
the concentration of S.aureus va protease indicated for 30 
minutes. The Glt polypeptide was immunoprecipitated from 
lysates of tunicarnycin treated, PVM infected cells labelled 
with [ 35 S]-methionine. The figure shows a fluorograph of the 
gel on which the digests were run. The circles indicate 
peptides common to Gl and G2. 
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Cell lysate PEG 
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Cell lysate PEG Cell lysate PEG 
Gl Glt Gl G2 Gl Glt Gl G2 
using each enzyme at lOOug per mI. Results of digestion with 
va protease at concentrations of 10 and 100ug per ml of the 
Gl and G2 glycoproteins isolated by immunoprecipitation with 
the monoclonal antibody are shown in Figure 20. One major 
band (0) was observed in al~ the samples which showed only 
slight mobility differences. These differences were not 
significant since they were no greater between Gl and G2 
than between Gl from the cell lysate track and Gl from the 
PEG precipitate. The significance of the other bands 
observed in the Gl tracks is not clear since this 
polypeptide was more heavily labelled than the others. The 
difference in labelling intensity could effect the number of 
bands visible or there may be contaminating labelled 
polypeptides in the Gl band. Digests of Gl and G2 derived 
from the PEG precipitate sample shared two bands (x and y) 
which had similar mobilities. In order to establish whether 
the single strong band obtained was the same in each case 
the 'band was excised and redigested with chymotrypsin. No 
digestion of this band occurred so no definite conclusions 
could be drawn from these results. 
The Glt band digested on these gels represented a band 
immunoprecipitated from cell lysates of PVM infected cells 
incubated in the presence of the N-linked glycosylation 
inhibitor tunicamycin. Glt had a similar mobility to G2, 
which was not well labelled in cell lysates in this 
experiment, and Gl was absent when cells were labelled in 
'the presence of tunicamycin. This suggested that Glt was a 
form of Gl lacking N-linked sugars. The single band obtained 
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on digestion of G1t had a higher mobility than the band from 
the glycoproteins suggesting that it may have been an 
equivalent band without N-linked sugars. Further studies on 
the products immunoprecipitated from tunicamycin treated 
cells with antibody 19/1/C9 are presented later in this 
" 
section. 
Figure 21 shows the results obtained on digestion of 
G1 and G2 with 100 or 1000ug per ml of chymotrypsin. The 
bands in Figure 21 were excised from a gel of samples 
immunoprecipitated with anti-PVM serum. Identical results 
were obtained when a similar digestion was carried out using 
bands excised from a gel of samples immunoprecipitated with 
monoclonal antibody 19/1/C9. The pattern of polypeptides 
observed was similar regardless of the source of the bands. 
Three digestion products were observed from G1 and three 
from G2. Two of the digestion products of G2 had similar 
mobilities to two products obtained on digestion of G1 
(indicated by circles in the figure). The band obtained on 
digestion of G1 absent from digests of G2 (indicated in the 
figure by a circle adjacent to the digests of G1 but not 
G2) was of a similar size to G2 and therefore could not be 
compared with its digestion products. The band obtained on 
digestion of G2 but not Gl (labelled x in the figure) was 
relatively weak. A similar band was obtained on digestion of 
the G1t polypeptide (which had a similar mobility to G2) 
observed when infected cells were labelled in the presence 
of tunicamycin. This band may therefore represent a 
breakdown product of a contaminating host cell protein in 
152 
\ 
Figure 21 Digestion of Gl and G2 polypeptides of PVH with 
Chymotrypsin 
The G1 and G2 polypeptides of PVM were' digested with 
chymotrypsin and the peptides resolved by SDS-PAGE using 15 
per cen~ resolving gels. The 
excised from gels of 
G related. polypeptides were 
[3s S]-methionine labelled PVM 
polypeptides immunoprecipitated from PEG precipitates of the 
supernatants of infected cells. The immunoprecipitation was 
carried out with the anti-PVM serum. The excised gel slices 
were inserted into the wells of the gel on which the 
peptides were to be resolved. The polypeptides were digested 
with chymotrypsin at the concentration indicated, (0, 100 or 
1000 ug per ml), during migration through the stacking gel 
as described in materials and methods (Section 2.5.22). 
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this region of the gel. This band could also indicate that 
G2 and the Glt polypeptide shared a peptide of similar 
mobility. Since the two major digestiGn products of Gl and 
G2 obtained using chymotrypsin and the single ~ajor band 
obtained when V8 protease was ,used had similar mobilities 
regardless of which glycoprotein was digested the data are 
consistent with the two glycoproteins being related. 
3.3.3 Tryptic peptide maps of Gl and G2 
To try and establish the relationship between Gl and 
G2 more clearly the glycoproteins, excised from gels of 
[35 SJ-methionine and [4,5-3 H]-leucine labelled PVM 
polypeptides immunoprecipitated with anti-PVM mouse serum 
were digested with trypsin (50ug per ml for 23 hours) and 
analysed by 2-dimensional thin layer 
electrophoresis/chromatography followed by fluorography. 
Comparison of the peptide patterns obtained on digestion of 
Gl (Figure 22a), G2 (Figure 22b) and when the two digests 
were run together on"the same TLC sheet (Figure 22c) show 
that the two polypeptides share many peptides (indicated by 
small 
fact 
circles) 
related. 
providing strong evidence that they are in 
Several unlabelled spots could not be 
identified as being present in both Gl and G2 digests due to 
insufficient label incorporation or insufficient resolution 
of the peptides. The large spot at the bottom of 
fluorographs a and c probably corresponded to glycopeptides 
which do not run in the second dimension (Montelaro et al. 
1984; Salinovich, et al. 1986). The large circle at the 
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Figure 22 Tryptic peptide map5 of Gl and G2 
The Gl and G2 polypeptides were digested with trypsin 
and the peptides separated by two dimensional thin layer 
electrophoresis/thin layer chromatography as described in 
Section 2.5.24. The bands were excised from a gel of PVM 
polypeptides labelled with [ 35 S]-methionine (500~Ci per ml) 
and 4,5-[3H]-leucine, (750~Ci per ml) and immunoprecipitated 
with anti-PVM serum. Spots common to all the fluorographs 
are indicated by small circles and the point of application 
of the samples indicated by large circles. 
(a) Fluorograph of the tryptic peptide map of Gl. 
(b) Fluorograph of the tryptic peptide map of G2. 
(c) Fluorograph of the tryptic peptide map obtained on 
running digests of Gl and G2 together 
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Thin-layer electrophoresis 
bottom left of each fluorograph indicates the point at which 
the sample was applied. The co-migration of spots in the 
mixed digest shown in part c indicates that the peptides 
were actually similar. The higher intensity of the ~pots in 
part a was due to a longer ~xposure of this fluorograph. A 
longer exposure of a peptide map similar to part b is not 
shown due to poor resolution of the peptides by 
electrophoresis. 
3.3.4 Pulse chase studies of G1 and G2 
In order to establish whether G1 and G2 represented 
different stages in the processing of a single glycoprotein 
pulse chase studies were performed. A 10 minute pulse label 
of [35 S]-methionine followed by various lengths of time in 
the presence of unlabelled methionine was used to follow the 
fate of methionine incorporated into polypeptides that could 
be immunoprecipitated by monoclonal antibody 19/1/C9. The 
result is shown in Figure 23. After the pulse period and 
after a pulse followed by a 20 minute chase period no 
PVM-specific polypeptides could be observed except possibly 
a 44K polypeptide and the N/39K polypeptide. After a 60 
minute chase period Gl but not G2 could be detected in the 
cell lysate. G2 first became apparent after a 360 minute 
chase period when both polypeptides could also be observed 
to be present in culture supernatants. The amount of G2 
relative to Gl that could be detected had increased after a 
22 hour chase period. The higher mobility bands were not 
reproducibly observed and were considered to represent 
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Figure 23 Characterization of G related polypeptides in 
pulse chase experiments 
The polypeptides immunoprecipitated by the monoclonal 
antibody lS/l/CS from PVM or mock infected cells labelled 
for 10 minutes with [35 S]-methionine (400uCi per ml) or 
labelled in the same way and then chased for various times 
with unlabelled methionine are shown in this tigure. The 
experiment was carried out as described in Section 2.5.13. 
The length of the chase period is indicated above each track 
in minutes except for the 22 hour (22h) samples (P indicates 
a pulse label only). Polypeptides immunoprecipitated from 
cell lysates are shown on the left (labelled cell lysate). 
Polypeptides immunoprecipitated from the PEG precipitates of 
supernatants of these cells are shown on the right (labelled 
PEG). Polypeptides immunoprecipitated from mock infected 
cell samples are indicated by HI above the track, all other 
tracks being polypeptides immunoprecipitated from PVM 
infected cell samples. The polypeptides immunoprecipitated 
from PVM infected cell samples are' labelled on the left. 
Unlabelled bands were not considered to be virus specific 
due to the presence of similar polypeptides in the tracks of 
mock infected samples or irregular occurrence on gels. The 
positions of the· molecular weight markers run in the centre 
track are indicated by their ~s (X10- 3 ). 
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non-specifically precipitated polypeptides. 
The apparent absence of a G related polypeptide 
following a short pulse or a pulse'label followed by a short 
chase could have been due to insufficient lab~lling. If 
label incorporation increased during the chase periods 
sufficient label to observe immunoprecipitated glycoprotein 
might only be observed after longer chase periods. 
Alternatively the glycoprotein may have a precursor that is 
unstable or not recognized by the antibody. The former 
possibility appears unlikely since there was no overall 
increase in the background level of label incorporation. The 
44K polypeptide probably represented a polypeptide 
non-specifically precipitated by the monoclonal antibody 
since several bands of high intensity were commonly observed 
in this region of the gel. Processing of G1 to give G2 was 
the most likely explanation for the decrease in intensity of 
the G1 band and increase in intensity of the G2 band after 
longer chase periods. 
3.3.5 G related glycoproteins synthesized in the presence of 
an inhibitor of N-linked glycosylation 
The two glycoproteins of RS virus show different 
patterns of glycosylation. The glycosylation of the RS F 
polypeptide appears to be entirely due to N-linked 
oligosaccharides which are not attached to the polypeptide 
chain in the presence of tunicamycin (Fernie et al. 1985; 
Gruber & Levine 1985a). The G polypeptide however, which is 
more highly glycosylated, shows only a slight increase in 
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Figure 24 Effect of different tunicamycin concentrations on 
incorporation of [ 35 S]-methionine into PVH infected cell 
polypeptides and on the virus yield from such cells. 
PVM infected cells were incubated in the presence of 
various concentrations of tunicamycin (indicated in ug per 
ml). Some of the cells were scraped into suspension and 
assayed for infectivity 96 hours after infection. Similar 
infected cells were incubated from 48 to 72 hours post 
infection with [35 S]-methionine (50uCi per ml) in the 
presence of the same concentrations of tunicamycin. The 
cells were harvested, lysed and pre-cleared in the same way 
as when immunoprecipitation was to be performed (Section 
2.5.15). Samples of the clarified lysate were then placed on 
filter paper discs and precipitated with 10 per cent TeA 
(three washes, the second one in boiling TeA solution). The 
discs were washed in ethanol:ether (1:1) and dried before 
measuring the radioactivity by scintillation counting. The 
figure shows a graph of infectivity (blue triangles) and 
label incorporation (red squares) against the tunicamycin 
concentration used. The infectivity and label incorporation 
values are expressed as a percentage of the values obtained 
when no inhibitor was used. 
159 
.' 
~~r-------------------------------~~-------------, ~ 
N 
o 
~ 
o 
~ 
~ 
ru 
~ 
z 
~ 
u 
r 
~ 
< u 
~ 
z 
~ 
~ 
~ 
mobility when synthesized in the presence of tunicamycin 
indicating that most of the carbohydrate of the mature G 
protein is not N-linked. This inhibitor was therefore used 
to study the type of linkage of carbohydrate to peptide that 
occurred in the PVM glycoproteins. 
Figure 24 shows the effect of various concentrations 
of tunicamycin on [35 S]-methionine incorporation and virus 
yield from PVM infected cells. The concentrations of 
tunicamycin selected for use in further experiments was 
2.5~g per mI. which caused a significant reduction in virus 
yield (>99 per cent) whilst still allowing a reasonable 
level of label incorporation (>50 per cent of the control 
level). Figure 25 shows the effect of tunicamycin and 
monensin treatment (the effect of monensin is considered in 
the following section) of PVM infected cells on 
[ 35 S]-methionine labelled polypeptides immunoprecipitated 
with the monoclonal antibody 19/1/C9. 
One band (G1t), could be identified in 
immunoprecipitates of lysates of tunicamycin treated PVH 
infected cells carried out using monoclonal antibody 
19/1/C9. Two bands (G1t and G2t) were observed when PEG 
precipitates of the supernatants of tunicamycin treated PVM 
infected cells were immunoprecipitated. Since G1 was the 
predominant band immunoprecipitated from the cell lysate, 
whilst G1 and G2 had similar intensities when PEG 
precipitates 
that Glt 
were immunoprecipitated, it 
represented Gl without 
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Figure 25 Effect of tunicamycin and monensin treatment of 
PVM infected cells on the synthesis of G related 
polypeptides 
PVM and mock infected cells were infected and labelled 
with [ 35 S]-methionine (50~Ci per ml), in the presence or 
absence of tunicamycin or monensin. The polypeptides were 
immunoprecipitated with monoclonal antibody 19/1/e9. The 
samples immunoprecipitated were either cell lysates 
(labelled cell lysate) or polyethylene glycol precipitates 
of the supernatants of the labelled cells (labelled PEG in 
the figure). The figure shows a fluorograph of the 
immunoprecipitated polypeptides analysed by SDS-PAGE using a 
6-15 per cent gradient gel. 
PVM- Samples from PVM infected cells. 
MI- Samples from mock infected cells. 
T- Samples from cells treated with tunicamycin 
(2.5~i per ml). 
M- Samples from cells treated with monensin (O.8~M). 
c- Samples from untreated cells. 
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oligosaccharides and G2t represented G2 without its N-linked 
oligosaccharides. 
3.3.6 G related glycoproteins synthesized in the presence of 
the ionophore, monensin 
The monovalent ionophore monensin inhibits the passage 
of membrane and secretory proteins through the Golgi 
apparatus and this prevents the relatively late event of 
O-linked glycosylation (Johnson & Spear, 1983). This reagent 
has been used to inhibit glycosylation of the G protein of 
RS virus and results in a much greater increase in mobility 
than the use of tunicamycin (Fernie et al. 1985; Gruber & 
Levine 1985a). Such data have been used to suggest that most 
of the carbohydrate of G is O-linked. 
Figure 26 shows the effect of different monensin 
concentrations on virus yield and [ 35 S)-methionine 
incorporation in PVM infected BS-C-1 cells. A concentration 
of O.8uM was found to give a satisfactory combination of 
inhibition of virus yield and level of polypeptide 
synthesis. In the fluorograph shown in Figure 25 monensin 
treatment of infected cells was observed to cause a small 
increase of mobility in the RS Fl polypeptide as has been 
reported by Gruber & Levine (1985a), this may be due to 
inhibition of the later stages of N-linked carbohydrate 
processing. The RS G polypeptide could not be labelled with 
amino acids under the conditions used in this project so it 
was not possible to determine the effect of monensin on this 
polypeptide. 
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Figure 26 The effect of different monensin concentrations on 
[ 35 S]-methionine incorporation into PVH infected cells and 
the yield of virus from such cells. 
PVM infected cells were incubated in the presence of 
various concentrations of monensin (indicated in uH per ml). 
Some of the cells were scraped into suspension and assayed 
for infectivity 96 hours after infection. Similar infected 
cells were incubated from 48 to 72 hours post infection with 
[ 35 S]-methionine (50uCl per ml) in the presence of the same 
concentrations of monensin. The cells were harvested, lysed 
and pre-cleared in the same way as when immunoprecipitation 
was to be performed (Section 2.5.15). Samples of the 
clarified lysate were then precipitated with TCA as 
described in the legend to Figure 24. The figure shows a 
graph of infectivity (blue triangles) and label 
incorporation (red squares) against the tunicamycin 
concentration used. The infectivity and label incorporation 
values are expressed as a percentage of the values obtained 
when no inhibitor was used. 
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Figure 27 The effect of treatment of PVH infected cells with 
different monensin concentrations on the polypeptides 
immunoprecipitated by monoclonal antibody 19/1/C9. 
PVM and mock infected cells were incubated for 48 
hours and labelled for 24 hours with [ 35 S]-methionine (50~Ci 
per ml) in the presence of various concentrations of 
monensin (added immediately after the adsorpti?n period). 
of two gels of 
such labelled cells. 
The figure shows fluorographs 
immunoprecipitates of samples from 
Monoclonal antibody i9/l/C9 was used to immuno~recipitate 
labelled cell lysates (labelled cell lysate in the figure) 
or PEG precipitates of the supernatants of cells (labelled 
PEG in the figure). The monensin concentration used during 
incubation 
(0.2, 0.4, 
of the infected cells and labelling is indicated 
0.6, 0.8 or 1.0 ~M). The PVM polypeptides 
immunoprecipitated by the monoclonal antibody are indicated 
on the left. 
P- Immunoprecipitates of samples from PVM infected 
cells. 
M- Immunoprecipitates of samples from mock infected 
cells. 
164 
Cell Iy,a'e 
[ M one.""U 0 2 0 4 0 '6 08 
IvM P M P M P M P M 
GI 
G2 
N 
PEG 
10 o 2 0 4 0 '6 0 ,8 1 0 
P M P MPM PMPMPM 
N 
\ 
Figure 28 Absence of an effect of monensin on synthesis of 
the 39K polypeptide of PVM 
PVM and mock infected cells (PVM and MI) were 
incubated for 48 hours in the presence of tunicamycin 
(2.5~g per ml, T) monensin (O.8~MJ M) or were untreated 
(C) and were then labelled with [ 35 S]-methionine (50~Ci per 
ml) for 24 hours in the presence of the same inhibitors. The 
cells were lysed and immunoprecipitated with monoclonal 
antibody 26/4/C4. The figure shows a fluorograph of these 
immunoprecipitates analysed by SDS-PAGE using a 6-15 per 
cent gel. 
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No G related polypeptides could be observed in the 
samples from monensin treated PVM infected cells, the use of 
differing concentrations of monensin revealed either the 
usual pattern of polypeptides or no specifically 
precipitated polypeptides (Figure 27). The polypeptide 
precipitated in the cell lysate sample in this figure was 
found to be N (by partial digestion with chymotrypsin) 
rather than a G related polypeptide. The absence of any 
bands related to Gl or G2 in the samples from monensin 
treated PVM infected cells could have been due to the 
overall level of protein synthesis being reduced so that the 
poorly labelled G polypeptides could no longer be observed. 
Alternatively the failure to detect G related polypeptides 
in monensin treated cells could have been due to the 
presence of a form of G that was unstable or not recognized 
by the antibody. The reduction in label incorporation 
observed for the glycoprotein bands when infected cells were 
labelled in the presence of monensin was not observed for 
the 39K band when the' samples were immunoprecipitated with 
the anti-39K monoclonal antibody 26/4/C4 (Figure 28). This 
observation argues against the failure to detect the G 
polypeptide in monensin treated PVM infected cells being due 
to a reduction in the overall level of polypeptide 
synthesis. 
3.3.7 Effect of tunicamycin on [3B]-glucosamine labelled 
PVM and RS virus polypeptides. 
Figure 29 and 30 show the effect of tunicamycin and 
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monensin on PVM and RS virus glycoproteins labelled with 
[3H]-glucosamine, immunoprecipitated from the cell lysates 
and PEG precipitates respectively.' The effect of monensin is 
considered in the next section. The PVM samples were 
immunoprecipitated with anti-PVM serum whilst the as virus 
samples were immunoprecipitated with anti-F (43.1) and 
anti-G (lll.2a) monoclonal antibodies. 
The F1 and F2 polypeptides of as virus were present 
only at low levels in the supernatant and FO was totally 
absent. A small amount of G was immunoprecipitated by the 
anti-F monoclonal antibody from the supernatant of RS virus 
infected cells (Figure 30). No sugar labelled polypeptides 
related to F could be detected in samples from tunicamycin 
treated, as virus infected cells as was expected for a 
glycoprotein with only N-linked oligosaccharides. The G 
glycoprotein of RS virus showed only a slight increase in 
mobility when precipitated from cells incubated in the 
presence of tunicamycin. The G related bands in the 45K 
region of the gel were absent when samples were prepared 
from tunicamycin treated cells suggesting that this 
polypeptide had only N-linkages as would be expected of the 
precursor of G. 
The 42K polypeptide in samples from PVM infected cells 
differed from the G related p45 polypeptide of RS and the RS 
F1 polypeptide in being relatively unaffected by the 
presence of tunicamycin during labelling. The 42K 
polypeptide in PVM infected cell lysates is more readily 
apparent in a longer exposure of the gel shown in Figure 29, 
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Figure 29 The effect of tunicamycin and monensin on 
[3B]-glucosamine labelled PVM and RS virus polypeptides 
occurring in the lysates of infected cells. 
PVM, RS virus or mock infected cells were incubated 
for 48 hours at 33°C and then labelled for 24 hours using 
[3H]-glucosamine hydrochloride (100~Ci per ml). Tunicamycin 
and monensin were used at 2.5ug per ml and O.8uM. 
respectively. The PVM and mock infected cell lysates were 
immunoprecipitated with the anti-PVM serum whilst the RS 
virus cell lysates were immunoprecipitated successively with 
the anti-F monoclonal antibody (43.1) and the anti-G 
monoclonal antibody (111.2a). The figure shows a fluorograph 
of the immunoprecipitates analysed on a 6-15 per cent 
gradient gel. PVM sp.oific polypeptides are labelled on the 
left and RS virus specific polypeptides on the right. 
PVM- Samples immunoprecipitated from PVM infected cell 
lysates. 
MI- Samples immunoprecipitated from mock infected 
cell,lysates. 
RS-Samples immunoprecipitated from RS virus infected 
cell lysates. 
anti-PVM, 43.1 and 111.2a indicate the antibodies used 
for the immunoprecipitations. 
T- Cells were incubated and labelled in the presence 
of tunicamycin 
M- Cells were incubated and labelled in the presence 
of monensin 
C- ~ells were incubated and labelled in the absence 
of any inhibitors. 
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Figure 30 [3S]-glucosamine labelled virus polypeptides in 
the PEG precipitates of tunicamycin and monensin treated 
cells 
Polyethylene glycol pr~cipitates of the supernatants 
of the [3H]-glucosamine labelled cells described in the 
legend to Figure 29 were studied by immunoprecipitation. The 
figure shows a fluorograph of the labelled polypeptides 
immunoprecipitated with the antibodies indicated and 
analysed by SDS-PAGE on a 6-15 per cent gel. PVM specific 
polypeptides are labelled on the left and RS virus specific 
polypeptides on the right. 
PVM- Polypeptides immunoprecipitated from the PEG 
precipitate of the supernatant of PVM infected 
cells 
MI- Polypeptides immunoprecipitated from the PEG 
precipitate of the supernatant of mock infected 
cells. 
RS- Polypeptides immunoprecipitated from the PEG 
precipitate of the supernatant of RS virus 
infected cells 
anti-PVM, 43.1 and 111.2a indicates the antibody used 
for the immunoprecipitation 
T- The cells were incubated and labelled in the 
presence of tunicamycin (2.5~g per ml). 
M- The cells were incubated and labelled in the 
presence of monensin, (O.8~M). 
c- The cells were incubated and labelled in the 
·absence of any inhibitor 
169 
PVM MI RS 
onti-PVM onti-PVM 43.1 111.20 
TMC TMC T MC TMC 
p45.Fl 
31K 
7 
F2 
T Y 
(Figure 55). The insensitivity of glycosylation of the 42K 
polypeptide to tunicamycin suggests that this polypeptide 
has non-N-linked oligosaccharide.. However it is possible 
that the band observed in tunicamycin treated cel+s was G2t 
which would run in a sim~lar position to the 42K 
polypeptide. Glt and G2t (the latter polypeptide was only 
apparent in PEG precipitate samples, ~igure 30) were heavily 
glycosylated indicating that Gl and G2 had a high proportion 
of oligosaccharides that were not N-linked. 
3.3.8. The effect of monensin on [3B]-glucosamine labelled 
PVM and RS virus polypeptides 
Monensin caused a slight increase in mobility of the F 
related polypeptides of RS virus (Figures 29 and 30), 
probably due to inhibition of the later stages of the 
processing of N-linked oligosaccharides. A diffuse region 
was observed below the G band which may have been due to G 
partially devoid of O-linked oligosaccharides. The p45 
polypeptide band was increased in intensity relative to G as 
might be expected if this was the precursor to G since this 
would be the form without O-linked oligosaccharides whose 
addition was blocked by monensin. The presence of bands in 
the s~pernatants is unexpected since monensin would have 
been expected to block transport of glycoproteins to the 
cell surface and hence their export to the supernatant. The 
absence of a clear cut effect of monensin on the 
-glycosylation of this polypeptide suggested that the 
monensin concentration may not have been sufficiently high 
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Figure 31 Increase in the mobility of G1 and G2 in monensin 
treated cells 
PVM infected cells were incubated in the presence or 
absence of monensin (O.8uM) for 48 hour~ after allowins the 
virus to adsorb. The cells were then labelled for 24 hours 
with [3H]-glucosamine and the PVM specific polypeptides 
immunoprecipitated from the cell lysates with anti PVH 
serum. The figure shows 
immunoprecipitates analysed 
gradient gel. 
a fluorolraph of the 
by SDS-PAGE on a 6-15 per cent 
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to block transport and the subsequent O-linked 
glycosylation. 
Polypeptide G2 was slightly reduced in intensity 
relative to Gl in the samples from monensin treated cells. 
This could indicate that the effect of monensin was only 
partial in these experiments and that production of G2 
occurs at a location in the cell distal to the site of 
action of monensin. In some gels even a suboptimal monensin 
concentration (O.luM) did appear to cause a small increase 
in mobility consistent with inhibition of the final stages 
of modification of N-linked oligosaccharides (Figure 31). 
3.3.9 Partial proteolysis of Glt and G2t 
In order to confirm the suggested relationships 
between Glt and G2t and Gl and G2 the appropriate bands were 
excised from gels and subjected to partial proteolysis with 
chymotrypsin. The results of these digestions are shown in 
Figure 32. In all the comparisons involving G2t only samples ~ 
from PEG precipitates were used since this polypeptide was 
not adequately labelled in immunoprecipitates from cell 
lysates. Two of five bands observed on digestion of G1t and 
G2t had similar mobilities, (Figure 32, the bands being 
indicated by circles). The three differences observed, 
(indicated by crosses), were due to extra bands obtained on 
digestion of the larger polypeptide Glt which could have 
arisen due to sequences or carbohydrate chains present only 
in this polypeptide or due to digestion of contaminating 
polypeptides. One of these bands obtained on digestion of 
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Figure 32 Partial digests of Glt and G2t with chymotrypsin 
PVM infected cells were incubated in the presence of 
tunicamycin (2.Sug per ml) and then labelled 'for 24 hours 
with [ 35 S]-methionine (SOOuei per ml) in the presence of 
using. the monoclonal tunicamycin. Immunoprecipitates 
antibody 19/1/C9 of PEG precipitates of the supernatants of 
these cultures were run on a 6-15 per cent gradie~t gel. The 
bands were excised and inserted into the wells of another 
gel (15 per cent resolving gel with Scm stacking gel). The 
proteolysis was carried out in the stacking gel as described 
in Section 2.5.22. The figure shows a fluorograph of the 
gel, 0, 100 and 1000 indicating the chymotrypsin 
concentration used in ug per mI. Circles indicate peptides 
common to both Glt and G2t whilst crosses indicate peptides 
unique to Glt. 
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Figure 33 Partial digestion of Gl and Glt polypeptides with 
Chymotrypsin 
Gi, G2 and Glt were excised from a gel of PVM 
polypeptides labelled in the presence or absence of 
\ 
tunicamycin as described in the legend to Figure 32 and 
immunoprecipitated from cell lysates with anti-PVM serum. 
The gel slices Were inserted into the wells of a second gel 
and digested during migration through the stacking gel as 
described in Section 2.5.22. The concentration of 
chymotrypsin used (0, 100 or 1000~g per ml) is indicated 
above each track. Circles indicate bands common to Glt. G2 
and for 3 of the 4 bands Gi. Crosses indicate unique bands. 
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polypeptide Glt had a similar mobility to G2t and so could 
not be compared with the digestion products of G2t. In 
Figure 20 it was observed that Va'protease digestion gave a 
band of greater mobility on digestion of Glt than those 
obtained on digestion of Gl a~d G2. This could have been due 
to the absence of N-linked sugars on the band obtained on 
digestion of Glt.· 
A similar comparison of Glt with Gl and G2 was carried 
out using chymotrypsin to digest the polypeptides (Figure 
33). These polypeptides had four bands in common but there 
were several differences (notably the two polypeptides 
marked x in the figure). This could have been due to 
peptides without N-linked sugars being produced from Glt. 
There was therefore some evidence that Glt and G2t were 
related to each other and to Gl and G2 but this was not 
conclusive. The precipitation of these bands by the 
monoclonal antibody made it appear likely that these bands 
were related. 
3.3.10 Tryptic peptide maps of Glt and G2t 
Since the results'of partial proteolysis did not give 
clear cut results with regard to the relationship between 
G1t, G2t, G1 and G2, tryptic peptide mapping was carried 
out. The results are shown in Figure 34. Included in this 
figure are the maps shown previously in Figure 21 of Gl and 
G2 for comparison with those of Glt, G2t, Glt+G2t, Glt+Gl, 
and G2t+G2. It can be seen that all these maps share spots 
in common (indicated by small circles). This indicated that 
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Figure 34 Tryptic peptide maps of Glt and G2t 
G1, G2, Glt and G2t were excised from gels of PVM 
polypeptides labelled with [35 S]-methionine (500~Ci per ml) 
and 4,5-[3H]-leucine, (750uCi per ml) an~ immunoprecipitated 
with anti-PVM serum. The polypeptides were digested with 
trypsin as described in Section 2.5.24 and the peptides 
analysed by two dimensional thin layer electrophoresis/thin 
layer chromatography. Spots common to all the fluorographs 
are indicated by small circles. Large circles indicate the 
points of appli.cation of the samples. 
(a) Fluorograph of a tryptic peptide map of Gl. 
(b) Fluorograph of a tryptic peptide map of G2. 
(c) Fluorograph of a tryptic peptide map of Glt. 
(d) Fluorograph of a tryptic peptide map of G2t. 
(e) Fluorograph of a tryptic peptide map of mixed Glt 
and G2t peptides. 
(f) Fluorograph of a tryptic peptide map of mixed G1 
and G1t peptides. 
(g) Fluorograph of a tryptic peptide map of mixed G2 
and G2t peptides. 
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these polypeptides were in fact related. Other spots not 
indicated by circles could not be identified on some 
fluorographs due ~o insufficient label incorporation into 
the peptides or insufficient resolution of the spots. The 
large circles at the bottom left hand corner indicate the 
point of application of the sample. Material at the bottom 
of the fluorographs probably represents glycopeptides. 
3.3.11 Effect of protease inhibitors on glycoprotein 
processing 
The results of the pulse chase experiment described in 
Section 3.3.4 suggested that G2 was derived from Gl by a 
post-translational event. Proteolytic cleavage would provide 
a mechanism by which Gl could be modified to give G2. 
Phenylmethylsulphonyl fluoride was routinely used in the 
buffers used during the preparation of samples but it could 
be that the change had occurred during the labelling period 
when no inhibitor was present or that the protease involved 
was not inhibited by this inhibitor. If the proteolytic 
cleavage occurred intracellularly the protease inhibitors 
would probably not be effective so this possibility could 
not be excluded. Since G2 became relatively abundant in the 
supernatant it was possible that at least part of the 
processing continued after release of virus or protein from 
the cells and that the G2 polypeptide occurring in the cell 
lysates could have been due to proteolytic cleavage during 
the immunoprecipitation procedure. 
To study these possibilities samples were prepared 
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Figure 35 Effect of «2-macroglobulin on PVH polypeptides 
identified by immunoprecipitation 
PVM infected BS-C-l cells were labelled with 
[
35 S]-methionine (50~Ci per ml) for 24 hours in the presence 
or absence of «a-macroglobulin. Cell lysates and PEG 
precipitates of the supernatants were then 
immunoprecipitated with anti-PVM serum in the presence or 
absence of «a-macroglobulin. The figure shows a fluorograph 
of the immunoprecipitates analysed by SDS-PAGE using a 6-15 
per cent gradient gel. The PVM specific polypeptides are 
indicated on the left, x indicating a polypeptide only 
observed when the protease inhibitor was not used. 
Cell 
PEG 
+ 
lysate Samples immunoprecipitated from cell 
lysates. 
Samples immunoprecipitated from PEG 
precipitates of cell supernatants. 
Samples prepared with «2-macroglobulin 
present throughout labelling and 
immunoprecipitation 
Samples prepared without any protease 
inhibitors being present. 
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without any protease inhibitors and with «2-macroglobulin 
present throughout the labelling and immunoprecipitation 
steps. This protease inhibitor has been shown to inhibit all 
endoproteases tested (Barrett & Starkey, 1973). The result 
is shown in Figure 35. It was observed that the only 
apparent difference between the two sets of samples was the 
presence of a band just below L when no protease inhibitor 
was used which was absent when the protease inhibitor was 
used. This suggested that only the L polypeptide was 
affected by proteases during these experiments. It would 
appear therefore that the conversion of G1 to G2 was 
unlikely to have been due to extracellular proteolytic 
activity or proteolytic activity during sample preparation. 
The possibility that an «2-macroglobulin insensitive 
protease existed or that the concentration used (lOugml-lwas 
not sufficient to inhibit the proteases present cannot be 
excluded. 
3.3.12 Relationship of G1t and G2t in pulse chase 
experiments. 
The most likely relationship of Glt and G2t to Gl and 
G2 would be that Glt represented G1 without its N-linked 
polypeptides and G2t represented G2 without its N-linked 
polypeptides as suggested earlier (Section 3.3.5). If this 
was the case it could be predicted by comparison with the 
relationship between Gl and G2 that G2t would be derived 
from Glt in pulse chase experiments. The result of such an 
experiment is shown in Figure 36. As predicted Glt appeared 
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Figure 36 G related polypeptides observed during a pulse 
chase experiment performed in the presence of tunicamycin. 
PVM or mock infected cells were pulse labelled for 10 
minutes with [35 S]-methionine (400uCi pe+ ml) 48 hours after 
·infection and were then incubated in the absence of labelled 
methionine for various times as described in Section 2.5.13. 
Cell lysates and PEG precipitates of cell supernatants were 
immunoprecipitated with the monoclonal antibody lS/l/eS. The 
figure shows a fluorograph of these samples analysed by 
SDS-PAGE on a 6-15 per cent gradient gel. Samples 
immunoprecipitated from cell lysates are labelled cell 
lysate and those immunoprecipitated from PEG precipitates of 
cell supernatants are labelled PEG. Samples 
immunoprecipitated from mock infected cell samples are 
indicated by MI above the track, all the other tracks show 
immunoprecipitates of PVM infected cells. The length of the 
chase periods is indicated in minutes except for the 22 hour 
(22h) chase period. P indicates that the samples were 
harvested immediately following the 
(Xl0- 3 ) are indicated adjacent to 
standards. PVM specific polypeptides 
pulse period. MrS 
the molecular weight 
are indicated by 
circles to the right of the tracks and labelled on the left. 
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first, (as in the pulse chase experiment with untreated PVM 
infected cells no precursor was observed), after a chase 
period of about 60 minutes, followed by G2t which was not 
clearly visible until after a 22 hour chase period. 
Increasing amounts of the N/39K polypeptide with increasing 
chase periods was probably due to an association of the N 
polypeptide with other virus polypeptides that occurred 
under the conditions used for the immunoprecipitation as is 
discussed later (Section 3.4.4). 
3.3.13 Demonstration of a 42K glycoprotein related to G 
Two glycosylated polypeptides with Mr's of 44K and 42K 
were described in Section 3.1.5. To determine if either of 
these polypeptides was related to the G proteins 
[3H]-glucosamine labelled lysates of PVM infected cells were 
immunoprecipitated with the monoclonal antibody 19/1/e9. The 
samples were run on the same gel as samples 
immunoprecipitated with the anti-PVM serum in order to 
distinguish between the 42K and 44K polypeptides. The 
results are shown in Figure 37, the exposure of the 
polypeptides immunoprecipitated by the antiserum being too 
short to reveal the 44K polypeptide. A polypeptide was 
immunoprecipitated by the monoclonal antibody that 
co-migrated with the 42K polypeptide. The low intensity of 
this band meant that the possibility that the 44K 
polypeptide was also related to the G protein could not be 
excluded. 
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Figure 37 [3H]-glucosamine labelled polypeptide 
immunoprecipitated by the anti G monoclonal antibody 
The monoclonal antibody 
immunoprecipitate [3H]-glucosamine 
from PVM and mock infected cell 
19/1/e9 was used to 
labelled polypeptides 
lysates. Labelling was 
carried out in the presence or absence of tunicamycin (2.5 
pgmi- 1 ) or monensin (O.8pM). [3H]-glucosamine labelled PVM 
and RS virus polypeptides irnrnunoprecipitated with the 
homologous antisera were run on the same gel as controls. 
19/1jC9-
Antisera-
PVM-
RS-
MI-
T-
M-
C-
Samples irnrnunoprecipitated with 
monoclonal antibody 19/1/e9 
Samples irnrnunoprecipitated 
homologous antisera 
Samples immunoprecipitated 
infected cell lysates 
with the 
from PVM 
Samples irnrnunoprecipitated from RS virus 
infected cell lysates 
Samples immunoprecipitated from mock 
infected cell lysates 
Samples irnrnunoprecipitated from lysates 
of tunicamycin treated cells 
Samples immunoprecipitated from lysates 
of monensin treated cells 
Samples Immunoprecipitated from lysates 
of untreated cells 
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3.3.1. Demonstration of a possible F like glycoprotein b7 
labelling with [3H]-glucosamine. 
The results described in Sections 3.3.2 and 3.3.3 
showed that the two glycoproteins of PVM described by others 
(Cash et aJ., 1919a) represented two forms of a single 
protein. This protein probably represented the 
haemagglutinin since haemagglutination was inhibited by the 
monoclonal antibody directed against the Gl/G2 protein. 
Other members of the family Paramyxoviridae possess two 
major glycoproteins the haemagglutinin or 
haemagglutinin-neuraminidase in paramyxoviruses or the G 
glycoprotein in RS virus and a fusion protein. The latter 
protein is typically cleaved to give a large and a small 
fragment which are linked by disulphide bonds. PVM showed 
two glycosylated bands in the 45K region of the gel (the 44K 
and 42K polypeptides which were described in Section 3.1.5). 
In order to establish if there was an F like protein in this 
region of the gel samples labelled with [3H]-glucosamine and 
immunoprecipitated with anti-PVM serum were run under 
reducing and non-reducing conditions along with the RS F 
protein as a control. The result is shown in Figure 38. It 
was found that the bands in the 45K region were reduced in 
intensity under non-reducing conditions and a band of lower 
mobility was observed (Fl,2). The band labelled Fl may 
represent some reduced Fl or a glucosamine labelled band in 
this region of the gel that is not related to the F protein. 
No evidence of a glycosylated F2 like polypeptide was 
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Figure 38 [3B]-glucosamine labelled PVM polypeptides 
observed under reducing and non-reducing conditions 
PVM infected RS virus infected and mock infected cells 
were incubated for 48 hours at 33°C and ~hen labelled for 24 
hours with [3H]-glucosamine (100uCi per ml). Cell lysates 
and PEG precipitates of the supernatants were 
immunoprecipitated using anti-PVH serum for the samples from 
PVM and mock infected cells and the anti-F monoclonal 
antibody 43.1 for the samples from RS virus infected cells. 
The immunoprecipitates were divided into two parts and one 
part boiled in sample buffer containing 2-mercaptoethanol 
(+2ME) and the other in sample buffer lacking 
2-mercaptoethanol (-2ME). A fluorograph of the samples 
analysed by SDS-PAGE using a 6-15 per cent gradient gel is 
shown in the figure. Samples immunoprecipitated from cell 
lysates are labelled cell lysate whilst those 
immunoprecipitated from PEG precipitates of cell 
supernatants are labelled PEG. The'PVM specific polypeptides 
are labelled on the left and the RS virus specific 
polypeptides are labelled on the right. 
PVH Samples derived from PVH infected cells 
RS Samples derived from RS virus infected cells 
HI Samples derived from mock infected cells 
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3.3.15 Identification of an F like polypeptide by 
immunoprecipitation of polypeptides expressed on the cell 
surface 
It was possible that the F like polypeptide produced 
in PVM infected cells was poorly glycosylated and could be 
more readily labelled with [35 S]-methionine. A candidate for 
such a protein existed in the form of the F1 polypeptide 
described in Section 3.1.4 which migrated in a similar 
position to the Fl polypeptide of RS virus. Virus envelope 
glycoproteins are expressed at the cell surface so it was of 
interest to find out which PVM polypeptides were expressed 
on the surface of infected cells. To do this the approach of 
Morrison & Ward (1984) was used. PVM infected cells labelled 
with [ 35 S]-methionine were incubated with antibody·, the 
unreacted antibody washed off, the cells lysed and the 
antibody adsorbed with Immuno-Precipitin which could then be 
washed and the proteins eluted in the usual way. Only 
proteins present on the cell surface would be expected to be 
immunoprecipitated. The results of such an experiment are 
shown in Figure 39. Surprisingly relatively little of the Gl 
or G2 polypeptides were ever detected on the cell surface in 
these experiments despite the strong cell surface 
immunofluorescence that was observed using the monoclonal 
antibody recognizing this polypeptide. This was probably due 
to the poor labelling that was obtained with this 
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Figure 39 Immunoprecipitation of PVH polypeptides expressed 
on the cell surface 
PVM infected RS virus infected and mock infected cells 
were labelled with (35SJ-methionine as described in Section 
3.5.12. Polypeptides were immunoprecipitated from the cell 
surface by incubation of the cells with a 100 fold dilution 
of ascitic fluid in PBS for 30 minutes on ice and washing 
five times with PBS prior to lysis of the cells as described 
in Section 2.5.12. The antibody-antigen complexes were 
precipitated using Immuno-Precipitin as described in Section 
2.5.15. PVM polypeptides were then immunoprecipitated from 
the remaining lysate. One half of each immunoprecipitate was 
boiled in sample buffer with 2-mercaptoethanol (+2ME) and 
the other half boiled in sample buffer without 
2-mercaptoethanol (-2ME). The figure shows a fluorograph of 
the immunoprecipitates analysed by SDS-PAGE using a 6-15 per 
cent gradient gel. The PVM specific polypeptides are 
labelled on the left and the RS virus specific polypeptides 
are labelled on the right. 
Cell lysate Polypeptides immunoprecipitated from cell 
lysates 
Cell surface Polypeptides immunoprecipitated from the 
surface of infected cells. 
PVM Polypeptides immunoprecipitated from PVM 
infected cells using anti-PVM serum 
RS 
MI 
Polypeptides immunoprecipitated from RS 
virus infected cells using anti-RS virus 
serum 
Polypeptides 
mock infected 
serum. 
immunoprecipitated from 
cells using anti-PVM 
+ 2 ME -2ME 
CELL CELL CELL CELL 
LYSATE SURFACE SURFACE LYSATE 
PVMRSMI PVMRS MI PVM RS MI PVM R 
L L L 
FO F1,2 
F1.2 
F 39:~ Fl N N P 
P 
M 
M 
M2 M2 
22K 22K 
19K 19K 
12K 12K 
polypeptide. Two major bands were obtained in cell surface 
immunoprecipitates, N/39K and Fl. The polypeptide designated 
Fl showed some similarity to the Fl polypeptide of RS virus, 
becoming reduced in intensity if non-reducing conditions 
were used with a concommitant ,increase in the intensity of a 
50K polypeptide designated F1.2 by analogy with the RS F1,2 
polypeptide observed under the same conditions. 
Precipitation of the N/39K polypeptide was later shown 
to be an artefact (Section 3.4.4), not being 
immunoprecipitated if a lower salt concentration was used in 
the immunoprecipitation buffer. The 39K polypeptide was 
also not detected by FACS analysis using the anti-39K 
protein monoclonal antibody 26/4C4 (Section 3.4.3). An F2 
like polypeptide could not be clearly identified, possible 
candidates would be the 9K polypeptide observed occasionally 
(Section 3.1.2) and the 12K polypeptide. The latter 
polypeptide was observed to be expressed on the cell surface 
but was not clearly reduced in intensity under non-reducing 
conditions. Both of these polypeptides would appear to be 
too large to account for the mobility difference between 
Fl,2 and Fl although this could have been due to aberrant 
migration. Attempts to demonstrate a polypeptide of the 
predicted size for F2, (Mr of 5,000) using 14C labelled 
protein hydrolysate and the gel system of Swank & Munkres 
(1971) failed although this could have been due to 
insufficient label incorporation. On the gel shown in Figure 
39 the RS virus infected cells were probably disrupted 
during the cell surface immunoprecipitation since all of the 
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Figure 40 The effect of tunicamycin on PVH and RS virus 
polypeptides expressed on the cell surface 
PVM and RS virus infected cells were incubated for 48 
hours at 33°C in the presence or absence of tunicamycin 
(2.5~g per ml) or monensin (O.8~M) and then labelled for 24 
hours with [35SJ-methionine (50~Ci per ml). The virus 
specific polypeptides present on the cell surface and in 
total cell lysates were immunoprecipitated by homologous 
antisera as described in the legend to Figure 39. An 
immunoprecipitation of the cell surface polypeptides was 
also carried out in the absence of antibody. A fluorograph 
of the gel of the immunoprecipitates of cell surface and 
cell lysate polypeptides is shown in the figure. 
PVM- Polypeptides immunoprecipitated from samples of 
PVM infected cells. 
RS- Polypeptides immunoprecipitated from samples of 
RS virus infected cells. 
+Ab- Immunoprecipitation carried out with homologous 
antiserum. 
-Ab- Control immunoprecipitation carried out without 
antibody. 
T-
M-
e-
Cells were incubated 
tunicamycin. 
in the presence of 
Cells were incubated in the presence of monensin. 
Cells were incubated in the absence of 
glycosylation inhibitors. 
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3.3.16 Effect of tunicamycin on PVM and RS polypeptides 
expressed on the cell surface. 
Figure 40 shows the effect of tunicamycin and monensin 
on polypeptides of PVM and RS virus that were expressed on 
the surface of infected cells. The effect of" monensin is 
described in the following section. The RS G polypeptide was 
not identified since the samples were labelled with 
[ 35 S]-methionine and this polypeptide has a low methionine 
content. The RS virus Frelated proteins observed in the 
presence of inhibitors were not expressed at very high 
levels on the surface of infected cells. The unglycosylated 
forms of FO and Fl. (FOu and Flu) were observed in 
immunoprecipitates of total cell 1ysates but not to a very 
great extent in the cell" surface samples. The reason for 
this was not clear and the result differs from that observed 
with the forms of the PVM glycoproteins synthesized in the 
presence of tunicamycin described below. 
Cells infected with PVM and labelled in the presence 
of tunicamycin showed two noticeable differences from 
control PVM infected cells. Gl and Fl were not apparent 
whilst two new bands. G1t and Flt were observed. Both of the 
polypeptides were expressed on the surface of infected 
cells. Since Glt was known to be related to G1 (Sections 
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3.3.9 and 3.3.10), the presence of F1t and absence of Fl in 
tunicamycin treated cells suggested that F1t was an 
unglycosylated form of Fl· and 'that despite the apparent 
absence of an F like polypeptide in (3 H] -gl,ucosamine 
labelled gels there was ~n Fl polypeptide containing 
N-linked sugars. The difference in mobility between the Fl 
and Flt polypeptides of PVM was less than that between the 
F1 and Flu polypeptides of RS virus suggesting that F1 in 
PVM was less highly glycosylated than F1 in RS virus. 
Whatever the nature of the 12K polypeptide expressed on the 
cell surface it did not appear to have N-linked sugars. 
3.3.17 The effect of monensin OD PVM and RS virus 
polypeptides expressed on the cell sur£ace 
PVM and RS polypeptides expressed on the surface of 
cells treated with monensin are shown in Figure 40. There 
was a slight increase in the mobility of the F1 protein of 
RS virus observed in cell lysates and this polypeptide was 
not observed on the cell surface. No PVM specific 
polypeptides could be detected on the surface of monensin 
treated PVM infected cells and only a few feint bands in the 
Fl region were observed in the immunoprecipitated cell 
lysate ,these possibly being due to forms of Fl showing 
heterogeneous glycosylation. The L, G1, N, 35K and 12K 
polypeptide bands were also reduced in intensity in monensin 
treated cells. The expression of the M, 20K and 19K 
polypeptides 
treatment. 
was relatively 
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Figure 41 Partial proteolytic digestion of Fl and FIt with 
chymotrypsin 
PVM infected cells were incub~ted for 48 hours at 33°C 
in the presence or absence of tunicamycin C2.5ug per ml) and 
then labelled for 24 hours with [ 35 S]-methionine (SOOuCi per 
ml). The polypeptides were immunoprecipitated from the cell 
lysates with anti-PVM serum and run on a 6-15 per cent 
gradient gel. The Fl and Flt polypeptide bands were excised 
from the gel and digested during stacking in a second gel as 
described in Section 2.S.22. The resolving gel of the second 
gel was a 15 per cent acrylamide single concentration gel. 
The figure shows a fluorograph of this gel. the 
concentration of chymotrypsin used being indicated above 
each track in ug per mI. The circles indicate bands common 
to both digests whilst the crosses indicate bands unique to 
the digest of one of the polypeptides. 
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Figure 42 Comparison of partial proteolytic digests of Gl, 
Fl, Git and Fit 
PVM infected cells were incubated for 48 hours at 33°C 
in the presence or absence of tunicamycin (2.5~g per ml) and 
then labelled for 24 hours with [ 35 S]-methionine (50QuCl per 
ml). The polypeptides were immunoprecipitated from the cell 
lysates with anti-PVM serum and run on a 6-15 per cent 
gradient gel. The Gl, Fl, Glt and Flt polypeptide bands were 
excised from the gel and digested during stacking in a 
second gel as described in Section 2.5.22. The resolving gel 
of the second gel was a 15 per cent acrylamide single 
concentration gel. The figure shows a fluorograph of this 
gel, the concentration of chymotrypsin used being indicated 
above each track in ug per mI. 
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3.3.16 Partial proteolysis of the F related polypeptides 
Comparison of digests of Fi 'and Fit with 
(Figure 41), revealed several differences 
chymotrypsin 
be~ween the 
polypeptides (indicated by. crosses), perhaps due to 
glycosylated peptides in the digest of F1 or an increase in 
the sensitivity of the non-glycosylated polypeptide to 
digestion. These differences do not rule out a relationship 
between these polypeptides since there were eight bands 
common to digests of both polypeptides but they did not 
provide clear evidence for such a relationship. Figure 42 
shows that there was no similarity between the F and G 
related polypeptide digests suggesting that these 
polypeptides were distinct. 
3.3.19 Tryptic peptide maps of F related polypeptides 
F1 and F1t were not conclusively shown to be related 
by the partial proteolysis experiments described above so 
they were subjected to analysis by two dimensional tryptic 
peptide mapping. The results obtained with digests of F1, 
Fit and a mixture of the two digests are shown in Figure 43. 
In the case of the mixture poor resolution was obtained in 
the fi~st dimension so not all the spots could be resolved. 
It can be seen that the three patterns show considerable 
similarity and the two polypeptides were therefore related. 
The unlabelled spots were not adequately labelled or 
'resolved on some of the fluorographs to determine whether or 
not they were common to all the peptide maps. The point of 
193 
\ 
Figure 43 Tryptic peptide maps of PVM F related polypeptides 
PVM infected cells were labelled for 48 hours in the 
presence or absence of tunicamycin (2.5ug 'per ml) and then 
labelled for 24 hours with [ 35 S]-methionine (500uCi per ml), 
and 4,5-[3H]-leucine (750uCi per ml). The PVM specific 
polypeptides were immunoprecipitated with anti-PVM serum and 
separated by SDS-PAGE using a 6-15 per cent gradient gel. 
The Fl and F1t bands were excised and digested with trypsin 
as described in Section 2.5.24. The peptides were analysed 
by two dimensional thin layer electrophoresis/thin layer 
chromatography. Fluorographs of the tlc plates are shown in 
the figure. Spots common to all the fluorographs are 
indicated by small circles. A large circle on each 
fluorograph indicates the point at which the samples were 
applied. 
(a) Fluorograph of chromatograph of tryptic peptide 
digest of Fl. 
(b) Fluorograph of chromatograph of tryptic peptide 
digest of Flt. 
(c) Fluorograph of tryptic peptide digests of Fl and 
Flt analysed on the same chromatograph. 
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3.3.20 Pulse chase experiment' using anti-PVM serum 
No antibody specific for the the PVM F protein was 
available so studies on the F,protein had to be carried out 
using the murine anti-PVM serum. The results of a pulse 
chase experiment carried out using this serum are shown in 
Figure 44. Most of the polypeptides showed a decreasing 
intensity in the cell lysate as the chase periods became 
longer with a corresponding increase in intensity of the 
polypeptide band in the PEG precipitate samples. This would 
be expected to occur as the polypeptides were incorporated 
into the virus. There did appear to be some label 
incorporation during the early chase periods in this gel, 
the L polypeptide becoming more heavily labelled up to 60 
minutes of chase but this could not account for the more 
abrupt appearance of Gl and the 12K polypeptide. The 35K 
polypeptide did not alter much in intensity during the chase 
periods until after a 25 hour chase period when this band 
was fainter. The fate of this polypeptide was not clear 
since it has not been observed in polyethylene glycol 
precipitates of culture supernatants and there was no 
obvious increase in intensity of any other band at this 
time. It may have simply been degraded or changed to a form 
that was obscured by other bands. The significance of a 17K 
polypeptide observed only after the pulse period was not 
clear. A 17K polypeptide was observed in ~/itro 50 this may 
represent a primary gene product although it is not possible 
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to tell if it was modified to give one of the other 
polypeptides or if it was simply degraded. No FO to Fl 
change was observed only Fl being detected after the pulse 
period. This could mean that no such change actua~ly occurs 
and that F1 is synthesized as ,such in vivo, that the change 
occurs more rapidly than the pulse period could detect or 
that cleavage occurred iTI vitro during the sample 
processing. In addition to the changes involving Gl and G2 
described in Section 3.3.4 the 12K polypeptide was observed 
not to be a primary gene product appearing only after about 
60 minutes of the chase period. The precursor of this 
polypeptide was not clear. The absence of FO at earlier 
times after the pulse argues against this polypeptide 
representing F2 whilst its relatively early appearance 
argues against it being related to the G polypeptides. The 
size of the polypeptide would be more consistent with it 
being derived from cleavage of Gl than from cleavage of FO. 
It is shown later however (Section 3.3.26) that the 12K 
polypeptide did not share tryptic peptides with Gl and it 
was therefore not derived from Gl. 
3.3.21 Pulse chase experiment carried out in the presence of 
tunicamycin 
Two exposures of a gel showing the results of a pulse 
chase experiment carried out in the presence of tunicamycin 
are shown in Figure 45. The pattern was similar to that 
observed in the pulse chase experiment carried out in the 
absence of tunicamycin described above. The Glt and G2t 
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Figure 45 Pulse chase experiment carried out in the presence 
of tunicamycin using immunoprecipitation with anti-PVH serum 
PVM infected and mock infected cells were incubated in 
the presence of tunicamycin (2.5~g per ml) for 48 hours at 
33°C before labelling for 10 minutes with [35 S]-methionine 
(400~Ci per ml) and chasing for various lengths of time in 
the absence of labelled methionine as described in Section 
2.5.13. The pulse labelling and chase periods were carried 
out in the presence of tunicamycin. The cell lysates and PEG 
precipitates of the supernatants were immunoprecipitated 
with anti-PVM serum and analysed by SDS-PAGE using a 6-15 
per cent gradient gel. Two fluorographs showing different 
exposures of the gel are shown (a and b). The PVM specific 
polypeptides are labelled on the left and the ~s of the 
marker polypeptides (X10- 3 ) are indicated in the centre. 
Samples immunoprecipitated from mock infected cells are 
indicated by HI above the track all other tracks 
representing polypeptides immunoprecipitated from PVM 
infected cells. The length of the chase period is indicated 
above each track in minutes except for the 22 hour chase 
period (22h). P indicates that the samples were harvested 
immediately following the pulse label. Polypeptides 
immunoprecipitated from cell lysates are on the left of the 
marker track (labelled cell lysate) and polypeptides 
immunoprecipitated from PEG precipitates of cell 
supernatants are shown on the right (labelled PEG). The 
shorter exposure (b) shows immunoprecipitates of 
lysatea only. 
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polypeptides were observed in place of the Gl and G2 
polypeptides and there were differences in the region of the 
Fl polypeptide. A band occurring in a similar position to Fl 
was observed to become reduced in intensity after t~e longer 
chase periods and an additional polypeptide migrating 
slightly slower than N became apparent. This is more 
apparent in the short exposure shown i? Figure 45b. Although 
some of the polypeptide with a mobility similar to Fl, 
(designated FOt), was released into the supernatant this was 
matched by a greater release of the faster mobility 
polypeptide F1t so it would appear that Flt was derived from 
FOt no other suitable precursor being identified. These 
bands therefore may represent the unglycosylated forms of FO 
and Fl, the latter being derived from the former during the 
chase period. The conversion of FO to F1 was not observed in 
the experiments described in Section 3.3.20 so the cleavage 
of FOt must occur more slowly than that of the native 
polypeptide FO. An alternative explanation would be that Fl 
was the initial product produced but that this was sensitive 
to protease activity in the presence of tunicamycin. If a 
modification of Fl rendering it protease sensitive did occur 
it was not reflected by any change in mobility. 
3.3.22 Pulse chase experiment using [3B]-glucosamine 
labelling 
A pulse chase experiment was carried out using 
C3 H]-glucosamine labelling to find if the F like polypeptide 
could be observed in this manner. The gel obtained is shown 
199 
\ 
Figure 46 Pulse chase experiment carried out using 
[3B]-glucosamine labelling 
PVM and RS virus infected cells were incubated for 48 
hours at 33°C and then labelled for 10 minutes with 
[3H]-glucosamine (400uCi per ml) and'incubated in medium 
without [3H]-glucosamine for 3 hours as described in Section 
2.5.13. PVM specific polypeptides are labelled on the left 
whilst RS virus specific polypeptides are labelled on the 
right. Molecular weights (X10- s ) of the marker proteins are 
shown to the right of the marker track. 
Lysate-
PEG-
anti-PVM-
43.1-
111.2a-
P-
c-
Polypeptides immunoprecipitated from cell 
lysates. 
Polypeptides immunoprecipitated from PEG 
precipitates of cell supernatants. 
PVM polypeptides immunoprecipitated using 
anti-PVM serum. 
RS virus infected polypeptides 
immunoprecipitated using the anti-F 
monoclonal antibody 43.1. 
RS virus polypeptides immunoprecipitated 
using the anti G monoclonal antibody 
111.2a. 
Polypeptides immunoprecipitated from 
pulse labelled samples. 
Polypeptides immunoprecipitated from 
samples pUlse labelled and then chased 
for 3 hours in the absence of label. 
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Figure 47 Pulse chase experiment using [3H]-glucosamine, 
densitometer traces. 
Tracks from the gel shown in Figure 46 were scanned 
with a densitometer in order to show some of the weaker 
bands more clearly. 
(a) Immunoprecipitates of the RS virus F protein 
related polypeptides occurring after a pulse 
labelling (black) and pulse labelling followed by 
a chase period (green). 
(b) Immunoprecipitates of the RS virus G protein 
(c) 
related polypeptides occurring in RS virus 
infected cell lysates after a pulse labelling 
(black) and pulse labelling followed by a chase 
period (green). 
Immunoprecipitates of the PVM glycoproteins 
occurring in cell lysates of PVM infected cells 
after a pulse labelling (black) and pulse 
labelling followed by a chase period (green). 
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in Figure 46 and since the labelling of the polypeptides 
during the pulse period was poor densitometer traces of the 
gel tracks are shown in Figure 47. The equivalent peaks did 
not exactly overlap probably due to distortion on the gel. 
There was a considerable increase in the degree of labelling 
observed after the chase period compared to that observed 
immediately following the pulse. This may have been due to 
relatively low levels of glucosamine in intracellular pools 
compared to amino acids which was made more noticeable by 
the absence of a high level of cold glucosamine in the 
medium used to wash the cells. Additional glucosamine was 
not added to the medium since this was reported to be an 
inhibitor of glycosylation at high concentrations and may 
have altered the results (Klenk et al., 1912; Koch et al .• 
1979; Schwartz & Klenk, 1974). The pulse labelled samples 
were weakly labelled, no labelling at all being observed in 
the supernatants of pulse labelled samples as would be 
expected. RS virus infected cell samples immunoprecipitated 
with anti-F and anti-G monoclonal antibodies are also shown 
in Figures 46 and 47. The RS virus F polypeptide related 
bands showed similar relationships to those described by 
Fernie et al. (1985) and Gruber & Levine (1983). Bands of 
low intensity were observed in the pulse labelled sample 
that corresponded to FO and Fl. The chase sample revealed an 
FO band of similar intensity to that observed after the 
chase period probably due to continuing incorporation of 
label into this polypeptide during the chase period. Strong 
Fl and F2 bands were observed in the chase sample in 
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agreement with the results of the authors mentioned above 
who showed that FO was converted to Fl and F2 during the 
chase period. The high mobility peaks observed in Figure 47a 
corresponded to marks on the autoradiograph a~d did not 
represent genuine polypeptide,peaks. The supernatant did not 
contain detectable levels of F related polypeptides after 
the pulse period but RS F1 and F2 polypeptides appeared in 
the supernatant after the chase period. Two RS G related 
polypeptides were observed. The peak labelled X in Figure 
47b was due to an artefact on the fluorograph not a virus 
specific band. In contrast to the results of Fernie et aI. 
(1985) and Gruber & Levine (1985b) but in agreement of those 
, of Routledge et aI. (1986) there was no obvious precursor 
product relationship between the p45 polypeptide and G. This 
might be expected since [3H]-glucosamine would be 
incorporated directly into Gl if it was derived from a less 
highly glycosylated precursor. 
The polypeptides observed in the cell lysates of PVM 
infected cells are shown in Figure 47c. The peak labelled X 
was due to a mark on the fluorograph. Three virus specific 
peaks could be identified on the track of pulse labelled 
samples, the smaller two not being well resolved on the 
densitometer trace. The 50K polypeptide may be FO. The 42K 
polypeptide band may represent F1 and/or the 42K polypeptide 
with a similar mobility that is related to Gl and G2. After 
the chase period the polypeptide marked C which was a 
cellular polypeptide immunoprecipitated by the anti-PVM 
serum, became apparent as did G2 (not fully resolved in 
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Figure 47d but clearer in Figure 46), whilst the 50K 
polypeptide disappeared. The SOK polypeptide could have been 
a precursor to Gl.1 the cellular polypeptide or a 
glycosylated Fl polypeptide that would co-migrate with the 
42K polypeptide. No detectable PVM specific polypeptides 
were released into the supernatant during the pulse period, 
whilst the pattern observed following the chase period was 
similar to that observed in the cell lysate samples obtained 
after the chase period. The G2 polypeptide was relatively 
more abundant in the supernatant as was usually observed. 
3.3.23 Association of Gl, G2 and Fl with a particulate 
fraction in PVM infected cell supernatants. 
Figure 48 shows that when the supernatant of PVM 
infected cell cultures was pelleted at lOO,OOOg for 60 
minutes the pellet and supernatant showed different 
polypeptide profiles following immunoprecipitation with 
anti~PVM serum. The supernatant fractions contained a high 
level of background host cell polypeptides that were 
virtually absent from the pellet. The supernatant fractions 
also contained PVM 
low level of G2. The 
Gi, Nand M polypeptides and perhaps a 
polypeptides observed were probably 
soluble protein released from disrupted cells or virions. 
The experiment was originally performed in an attempt to 
demonstrate the presence or absence of a soluble non-virion 
glycoprotein, but the high levels of several polypeptides in 
the supernatant suggested that widespread disruption of 
cells or virions had occurred so it was not possible to tell 
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Figure 48 Polypeptides associated with soluble and 
particulate fractions of PVH infected cell supernatants 
Clarified supernatant of PVM infected BS-C-l and 
BHK-21 cells and mock infected BS-Cl cells was pelleted at 
100,000g for 60 minutes and the pellet and supernatant 
fractions immunoprecipitated with anti-PVM serum. The 
immunoprecipitates were analysed by SDS-PAGE using a 6-15 
per cent gradient gel. A fluorograph of the gel is shown in 
the figure. The PVM specific polypeptides are labelled on 
the left. 
Pellet Immunoprecipitates of the pellet fraction. 
Supernatant Immunoprecipitates of the supernatant 
fraction. 
BS-C-l 
BHK-21 
HI 
Immunoprecipitates of polypeptides in 
samples derived from the supernatants of 
BS-C-l cells. 
Immunoprecipitates of 
samples derived' from 
BHK-21 cells. 
polypeptides in 
the supernatant of 
Immunoprecipitates 
samples from the 
. infected cells. 
Immunoprecipitates 
samples from the 
infected cells. 
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if any particular protein was secreted. The pellet appeared 
to be relatively enriched in Gl, G2 and Fl suggesting that 
these polypeptides may have been' associated in some common 
structure, and also contained the other virus ~tructural 
polypeptides. Insufficient material precluded assaying the 
fractions for infectivity so it is not clear if the pellet 
did in fact represent virions or disrupted membranes. 
, 
3.3.24 The effect of Glycopeptidase F on PVH and RS virus 
glycoproteins 
Glycopeptidase F cleaves the bond between asparagine 
residues and the carbohydrate chain of N-linked 
glycoproteins. This enzyme was used to demonstrate directly 
the effect on mobility of removing N-linked carbohydrate 
from the Gl, G2, Glt, G2t, Fl and Flt glycoproteins of PVM 
and the Fl and F2 glycoproteins of RS virus. The PVM 
glycoproteins were labelled with either [35 S]-methionine 
(Figure 49) or [3H]-glucosamine (Figure 50). The RS virus 
polypeptides were labelled with [3H]-glucosamine (Figure 
50). It can be seen that the RS virus Fl and F2 
glycoproteins were deglycosylated by this enzyme under the 
conditions used (Figure 50). Unfortunately insufficient 
label . was incorporated into the RS virus G polypeptide in 
this experiment to stUdy the effect of the enzyme on this 
polypeptide. The PVM Gl polypeptide was observed to show an 
increase in mobility following digestion with glycopeptidase 
'F, the polypeptide co-migrating with the Glt polypeptide 
(Figure 49) as would be expected if Glt represented the Gl 
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Figure 49 The effect of glycopeptidase F on PVH 
glycoproteins 
PVM infected cells were labelled 48 hours after 
infection, in the presence or absence of tunicamycin (2.5ug 
per ml) for 24 hours with [ 35 S]-methionine (lOOue! per mI. 
The polypeptides were immunoprecipitated with anti-PVM serum 
and separated by SDS-PAGE using a 6-15 per cent gradient 
gel. The PVM Gl, G2, G1t, G2t and F1 polypeptides were 
excised from the gel using a fluorograph as a template. The 
polypeptides were eluted and concentrated as described in 
Section 2.5.25. samples of each polypeptide equivalent to 
one band on the gel were digested with glycopeptidase F or 
incubated in buffer without enzyme as described in Section 
2.5.25. The samples were boiled with sample buffer and the 
polypeptides analysed on a 6-15 per cent gradient gel. The 
figure shows a fluorograph of this gel. The polypeptide 
indicated above each pair of tracks was either digested with 
glycopeptidase F (N) or undigested (U). The MrS of the 
markers are indicated to the right of the marker track. 
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Figure 50 Digestion of [3S]-glucosamine labelled PVM and RS 
virus polypeptides with glycopeptidase F 
PVM and RS virus infected cells were labelled 48 hours 
after infection, in the presence or absence of tunicamycin 
(2.5ug per ml) with (3H]-glucosamine (lOQuei per ml) for 24 
hours. The labelled polypeptides were immunoprecipitated 
with homologous antisera and separated by SDS-PAGE using a 
6-15 per cent gradient gel. The Gl polypeptide of PVM and 
the Fl and F2 polypeptides of RS virus were excised from the 
gel, digested or mock treated and analysed on a second gel 
as described in Section 2.5.25. A fluorograph of the gel is 
shown in the figure. The polypeptide indicated above each 
pair of tracks was digested with glycopeptidase F (N) or 
undigested (U). 
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polypeptide without its N-linked carbohydrate. A similar 
result was obtained by digestion of the [3H]-glucosamine 
labelled Gl polypeptide (Figure 50). The other PVM 
glycoproteins were not sufficiently well labelled to study 
the effect of glycopeptidase F on the [3H]-glucosamine 
labelled polypeptides. Digestion of G2 gave a band with a 
mobility similar to G2t (Figure 49). The Glt and G2t 
polypeptides did not show any mobility change after 
digestion as would be expected since these polypeptides 
should not have possessed N-linked carbohydrate. The other 
higher mobility polypeptides observed in each track were 
probably breakdown products of the major bands described 
above. These results provided further evidence that a band 
with the mobility of Glt represented Gl without its N-linked 
oligosaccharides and a band with the mobility of G2t 
represented G2 without its N-linked oligosaccharides. 
Digestion of Fl did not result in a mobility change which 
does not support the result obtained using tunicamycin when 
a polypeptide of increased mobility was observed. The reason 
for this is not known, the enzyme may have failed to act on 
the Fl protein or the presence of Flt rather than Fl in 
tunicamycin treated PVM infected cells may have been due to 
some effect other than failure to add N-linked 
oligosaccharides. 
3.3.25 Digestion of PVH and RS virus glycoproteins with 
Endo-«-N-acetylgalactosaminidase 
Endo-«-N-acetylgalactosaminidase cleaves the bond 
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Figure 51 Digestion of PVH glycoprotein. with 
Endo-«-N-acetylgalactosamlnldase 
PVM infected cells were labelled, in the presence of 
tunicamycin (2.5ug per ml), with ~5S]-methionine as 
described in the legend to Figure 49. The PVM G1t and G2t 
polypeptides were excised from a gel of polypeptides 
immunoprecipitated with anti-PVM serum, eluted and 
concentrated as described in Section 2.5.25. All of the 
samples of the polypeptides were di,ested with a mixture of 
exoglycosidases. In addition one sample of each polypeptide 
was digested with Endo-«-N-acetylgalactosaminldase and one 
sample with both Endo-«-N-acetylgalactosamlnidase and 
glycopeptidase F (Section 2.5.25.). The di,ests were 
analysed by SDS-PAGE using a 6-15 per cent gradient ,el. A 
fluorograph of this gel is shown in the figure. The 
polypeptide indicated above each track was di,ested with the 
exoglycosidases only (E) , with exo,lycosidases and 
Endo-«-N-acetylgalactosamlnldase (0) , or with 
exo,lycosidases, Endo-«-N-acetylgalactosaminidase and 
,lycopeptidase F (N+O). The Krs of the markers (X10- s ) are 
indicated to the right of the marker track. 
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Figure 52 Dige5tion of PYM polypeptlde5 labelled with 
[3H]-glucosamine with Endo-«-N-acetylgalactosaminidase. 
PVM polypeptides were labelled 48 hours after 
infection with [3H]-glucosamine (100~Cl per ml) for 24 
hours. The polypeptides were immunoprecipitated with 
anti-PVM serum and separated by SDS-PAGE using a 6-15 per 
cent gradient gel. The bands were excised, the polypeptides 
eluted and samples digested with various combinations of 
enzymes as described in the legend to Figure 51. The samples 
were analysed on a 6-15 per cent gradient gel a fluorograph 
of which is shown in the figure. The polypeptide indicated 
above each group of three tracks was digested with 
exoglycosidases only, (E) , exoglycosidases and 
Endo-u-N-acetylgalactosaminidase (0) or exoglycosidases, 
Endo-«-N-acety!galactosaminidase and g!ycopeptidase F (N+O). 
The Mrs of the markers (XIO- 3 ) are shown on the left of the 
marker track. 
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Figure 53 Digestion of RS virus polypeptides labelled with 
(3B]-glucosamine with Endo-a-N-acetylgalactosamlnldase. 
RS virus polypeptides were labelled 48 hours after 
infection with [3H]-glucosamine, (lOOuei per ml) for 24 
hours. The polypeptides were immunoprecipitated with anti-RS 
virus serum and separated by SDS-PAGE using a 6-15 per cent 
gradient gel. The bands were excised, the polypeptides 
eluted and samples digested with various combinations of 
enzymes as described in the legend to Figure 51. The samples 
were analysed on a 6-15 per cent gradient gel a fluorograph 
of which is shown in the figure. The polypeptide indicated 
above each group of three tracks was digested with 
exoglycosidases only, (E), exoglycosidases and 
Endo-«-N-acetylgalactosamin1dase (0) or exoglycosidases, 
Endo-u-N-acetylgalactosaminidase and glycopeptidase F (N+O). 
The Mys of the markers (X10- 3 ) are shown on the right of the 
marker track. 
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between the core disaccharide Gal(81-3)GalNAc and serine or 
threonine residues of O-glycanes. The enzyme does not 
function· if the disaccharide is substituted by other sugars 
(Endo & Kobata, 1976). Due to this latter observation and 
ignorance of the nature of apy O-linked oligosaccharides 
that might exist in the PVM glycoproteins digestion with 
this enzyme was carried out in the presence of 
exoglycosidases to remove oligosaccharides from the core 
disaccharide. The exoglycosidases used were neuraminidase 
from Clostridium perfringens and a mixture of enzymes from 
Turbo cornutus. These enzymes alone were also used to digest 
the polypeptides as a control so that any mobility change 
could be associated with the action of 
Endo-«-N-acetylgalactosaminidase. The results of digestion 
of PVM glycoproteins labelled with [ 35 SJ-methionine or 
[3HJ-glucosamine are shown in Figures 51 and 52 
respectively. The results of digestion of RS virus 
polypeptides labelled with [3H]-glucosamine with these 
enzymes are shown in-Figure 53. In each Figure the result 
of digestion with both these enzymes and Glycopeptidase F is 
also shown. The RS G protein did not label adequately to be 
detectable after digestion (considerable losses of label 
occurred during the preparation of the proteins for 
digestion, probably due to non-specific binding of the 
glycoproteins to dialysis tubing or leakage of the dialysis 
tubing). The RS virus F1 and F2 glycoproteins did not show 
any specific changes in mobility due to treatment with 
Endo-«-N-acetylgalactosaminidase (Figure 53). This was 
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expected since these polypeptides are known to have only 
N-linked oligosaccharides (e.g. as was shown in Figure 50 
and by Gruber & Levine 1983). When glycopeptidase F was 
included amongst the enzymes used to digest the RS virus Fl 
and F2 polypeptides no band was observed as expected for the 
reason mentioned above. 
The [35 S]-methionine labelled Gl and G2 glycoproteins 
of PVM digested with Endo-«-N-acetylgalactosamlnldase are 
not shown since no digestion was observed for unknown 
reasons since the [3H]-glucos~mine labelled Gl and G2 
polypeptides were digested under identical conditions. 
Figure 51 shows G1t and G2t digested with exoglycosidases, 
exoglycosidases and Endo-«-N-acetylgalactosaminidase or 
these enzymes plus glycopeptidase F. The mobilities of G1t 
and G2t suggest that they were digested to some extent by 
the exoglycosidases alone. In the case of Glt a similar 
mobility was observed for the protein digested with all the 
enzymes (tracks labelled N+O) although for G2t there is no 
evidence of even exoglycosidase activity when all the 
enzymes were used in combination. The Glt and G2t 
polypeptides digested with exoglycosidases and 
Endo-«-N-acetylgalactosaminidase (tracks labelled 0) showed 
evidence of digestion by Endo-«-N-acetylgalactosaminidase. 
Although it is possible that the increased mobility was due 
to contaminating protease or glycosidase activities in the 
enzyme preparation the results suggest that there were some 
O-linked oligosaccharides on the Glt and G2t polypeptides. 
[3B]-glucosamine labelling of Glt and G2t did not give 
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adequate label incorporation to carry out glycosidase 
digestions so it is not known if the forms of Glt and G2t 
observed following digestion with 
Endo-«-N-acetylgalactosaminidase represent the fully 
deglycosylated forms of the G+ and G2 proteins. The failure 
to detect a similar mobility change when glycopeptidase F 
was included in the digestion mixture suggests that the 
compromise conditions used inhibited the action of 
Endo-«-N-acetylgalactosaminidase. 
Figure 52 shows that the G1 and G2 glycoproteins could 
also be digested with Endo-«-N-acetylgalactosaminidase. 
Some undigested polypeptide remained in each case. The 
mobility of Gl appeared to have been unaffected by the 
exoglycosidase treatment judging by comparison of Mr 
estimates with those of undigested Gl protein. There was 
however an increase in the mobility of G2 when it was 
digested with exoglycosidases. The mobilities of Gl and G2 
when digested with all the enzymes (tracks labelled N+O) 
were similar to those observed with the [ 35 S]-methionine 
labelled glycoproteins digested in the same way. Since there 
was no evidence of the action of 
Endo-«-N-acetylgalactosaminidase on the [ 35 S]-methionine 
labelled polypeptides the mobility change in Gl and G2 when 
digested with all the enzymes was probably due to the action 
of glycopeptidase F. The failure of 
Endo-«-N-acetylgalactosaminidase to digest the proteins in 
combination with glycopeptidase F would be consistent with 
the results observed for digestion of Glt and G2t described 
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above. It can be seen that digestion of both Gl and G2 by 
Endo-«-N-acetylgalactosamlnldase occurred (compare tracks 
labelled E and O).Taken together the results suggest that 
the PVM Gl and G2 glycoproteins have Q-linked 
oligosaccharides with Gl prob~bly having a larger extent of 
O-linked glycosylation than G2. 
Calculation of the amounts of 
carbohydrate was complicated by several 
each type 
factors. 
of 
The 
efficiency of the action of 
Endo-«-N-acetylgalactosaminidase is not known and the Hrs of 
the carbohydrate components of the glycoproteins calculated 
from glycoprotein mobilities are not valid (but useful in a 
descriptive manner). In addition the exoglycosidases removed 
oligosaccharides from both Q-linked and N-linked chains so 
for G2 where both types of oligosaccharides were present, a 
mobility change due to the action of exoglycosidases could 
not be apportioned between the two types of 
oligosaccharides. A final caveat to the validity of the 
calculations is that there were not any undigested 
glycoproteins on these gels 50 calculation of the amount of 
carbohydrate removed by the exoglycosidases was less 
accurate than calculation of removal of N-linked 
carboh~drate and O-linked disaccharides. The purpose of the 
calculations was to enable rough estimates of the 
contributions of the N-linked and Q-linked oligosaccharides 
to the glycoprotein ~s to be obtained and to estimate the 
sizes of the unglycosylated forms of the polypeptides. The 
amount of N-linked carbohydrate (represented by the ~ of 
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Table 14 Carbohydrate of the G related glycoproteins 
Protein 
(RMM) 
Gl (76.2) 
(BO.3) 
G2 (60.3) 
(65.9) 
(64.9) 
Glt (58.2) 
(62.8) 
G2t (46.5) 
(49.4) 
Protein Mr after 
digestion with 
46.5 
58.2 
46.5 
61.5 80.3 
54.9 
57.3 
46.2 52.2 
40.9 44.0 
Sizel due to Sizel due to 
N-linked O-linked 
Carbohydrate Carbohydrate 
1B.O 
13.8 
0.0 
0.0 
18.8 (0.0) 
3.4-11.0 
(7.6) 
16.6 (10.6) 
8.5 (5.4) 
1) The size is the calculated molecular weight of protein 
causing a similar change in mobility to the removal of 
the carbohydrate. In the case of G2 an interval of sizes 
for the O-linked carbohydrate from a minimum based on 
all the carbohydrate removed by exoglycosidases being 
N-linked to a maximum based on all such carbohydrate 
being O-linked is given. The figures in brackets after 
the size due to O-linked oligosaccharide are the 
calculated sizes of carbohydrate removed by 
exoglycosidases. 
2) N- Glycopeptidase F 
0- Endo-«-N-acetylgalacto3aminida3e + mixed 
exoglycosidases 
E- Mixed exoglycosidases 
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Table 15 Calculated ~ of G glycoproteins without 
N-linked and/or Q-linked carbohydrate 
Protein t\ following removal of : -
Nothing N-linked Q-linked N- and Q-
carbohydrate carbohydrate linked 
carbohydrate 
G1 76.4 58.4 57.6 39.6 
G2 62.0 48.2 51-58.61 37.2-44.81 
G1t 60.9 60.9 44.3 44.3 
G2t 49.8 49.8 41. 3 41.3 
1) Lower estimate based on the higher estimate of the 
amount of Q-linked oligosaccharide given in Table 3.3.1. 
Upper estimate based on the lower estimate of the amount 
of O-linked carbohydrate given in Table 14. 
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protein giving an equivalent mobility change) was estimated 
by subtracting the Mr of the protein observed after 
digestion by glycopeptidase F from that of the undigested 
polypeptide (Table 14). The amount of a-linked carpohydrate 
was calculated for Gl, Glt and G2t by subtracting the Mrs of 
the polypeptide observed after digestion by exoglycosidases 
and Endo-«-N-acetylgalactosaminidase from those of the 
undigested polypeptides. This was possible because the G1 
protein was not digested by exoglycosidases alone and the 
G1t and G2t polypeptides lacked N-linked oligosaccharides so 
the exoglycosidases would only be digesting a-linked 
oligosaccharides. G2 had both Q-linked . and N-linked 
oligosaccharides and was digested by the exoglycosidases so 
the amount of a-linked carbohydrate could not be determined. 
Limits for the amount of Q-linked oligosaccharide were 
obtained by considering all of the sugars removed by the 
exoglycosidases to be N-linked (giving a minimum estimate 
for the amount of Q-linked carbohydrate) and by considering 
all of the carbohydrate· removed by exoglycosidases to be 
Q-linked 
Q-linked 
(giving a maximum 
oligosaccharide).The 
estimate for the 
calculated ~s 
amount of 
of the G 
related glycoproteins without N-linked, Q-linked or N-linked 
and Q~linked oligosaccharides are shown in Table 15. These 
figures suggest that the difference in size of the G1 and G2 
proteins is at least partly due to differences in the extent 
of Q-linked glycosylation and if the action of 
Endo-«-N-acetylgalactosaminidase on Glt was incomplete there 
may not be any difference in the polypeptide chain of G1 and 
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Figure 54 Tryptic peptide maps of Gl and the 12K polypeptide 
The Gl and 12K polypeptide bands were excised from 
gels of PVM polypeptides labelled· with [ 35 S]-methionine 
(500~Ci per ml) and 4,5-[3H]-leucine. (750uCi per ml) and 
immunoprecipitated with anti-PVM serum. The polypeptides 
were digested with trypsin as described in Section 2.5.24 
and the peptides analysed by two dimensional thin layer 
electrophoresis (left to right)/thin layer chromatography 
(bottom to top). Spots due to Gl peptides are indicated by 
small circles and spots due to 12K polypeptide peptides are 
indicated by ovals. Large circles indicate the point of 
application of the samples. 
(a) Fluorograph of a tryptic peptide map of Gl. 
, 
(b) Fluorograph of a tryptic peptide map of the 12K 
polypeptide. 
(c) Fluorograph of a tryptic peptide map of mixed Gl 
and 12K polypeptides. 
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3.3.26 Tryptic peptide map of the 12K polypeptide 
The 12K polypeptide was observed to be expressed on 
the cell surface (Figure 39) and to appear during chase 
periods in pulse chase experiments (Figure 44). The 
intensity of the polypeptide band under non-reduced 
conditions and failure to detect an FO polypeptide in pulse 
chase experiments argued against this polypeptide being 
related to the F protein. The 12K polypeptide could have 
been derived from Gl during its change into G2. To 
investigate this possibility tryptic peptide maps of G1 and 
the 12K polypeptide were compared. In Figure 54 the Gl 
peptide spots are indicated by circles and the 12K 
polypeptides by ovals. It can be seen that the polypeptides 
did not share common peptides and were therefore not 
related. 
3.3.27 Identification of a 31K glycosylated PVH polypeptide 
Figure 55 is a reproduction of Figure 30 and a longer 
exposure of Figure 29. This figure reveals the presence of a 
glycosylated 31K polypeptide. This band was observed to 
exist as a broad smear and was only observed after prolonged 
exposure of heavily labelled samples. No equivalent 
polypeptide has been reported in RS virus infected cells 
labelled with [3H]-glucosamine and immunoprecipitated with 
anti-RS virus serum. An antiserum raised against a synthetic 
peptide corresponding to the carboxy-terminus of the RS NSIA 
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Figure 55 Identification of a 31K PVH glycoprotein 
This figure shows a longer exposure of the gel shown 
in Figure 29 
polypeptides 
labelled cell 
and a reproduction 
immunoprecipitated 
lysates and PEG 
of Figure 30. PVM 
from [3H]-glucosamine 
precipitates of cell 
supernatants using anti-PVM serum are shown on these 
fluorographs. The PVM specific polypeptides are labelled on 
the left and the 31K polypeptide indicated by a circle to 
the right of the tracks in which it is visible. 
T- Polypeptides immunoprecipitated from samples of 
cells labelled in the presence of tunicamycin. 
M- Polypeptides labelled in the presence of monensin 
prior to immunoprecipitation. 
c- Polypeptides labelled in the absence of 
inhibitors prior to immunoprecipitation 
PViM- Polypeptides immunoprecipitated from samples from 
PVH infected cells 
MI- Polypeptides immunoprecipitated from samples from 
mock infected cells. 
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a glycoprotein from protein did immunoprecipitate 
[3H]-glucosamine labelled cell lysates which gave a very 
diffuse band of about 30K when artalysed by SDS-PAGE and 
fluorography (c. Caravokyri, R. Olmsted, . personal 
communications). A similar polypeptide was identified in 
immunoprecipitates of 3H-glucosamine labelled TRT virus 
polypeptides, (Section 3.5.8). This polypeptide was reduced 
in intensity when cells were labelled in the presence of 
monensin. This effect was probably just due to a reduction 
in the overall level of protein synthesis in monensin 
treated cells. This polypeptide was not observed in 
tunicamycin treated cells suggesting that the 
oligosaccharides were all N-linked. An equivalent broad band 
was never observed in [35 S]-methionine labelled 
immunoprecipitates of PVM infected cells. This could mean 
that no polypeptide was actually associated with this band 
or simply that the methionine content was low or the 
quantity of the polypeptide insufficient to be detectable 
above the background of non-specifically precipitated 
polypeptides. 
3. 3.28 Summary 
T~e results presented in this section describe the 
glycoproteins of PVM, the effect of inhibitors of N-linked 
and Q-linked glycosylation on their synthesis and precursor 
product relationships observed during pulse chase 
experiments. The previously reported glycoproteins Gl and G2 
were shown to have both N-linked and non-N-linked 
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oligosaccharides. These polypeptides were also shown to 
represent different forms of a single glycoprotein, G2 being 
derived from Gl during the course of pulse chase 
experiments. The totally deglycosylated forms of the two 
proteins were not identified so it was not possible to 
determine if the difference resided in the polypeptide 
moiety, the carbohydrate moiety or both. The mobility 
difference between the two forms of the G protein was 
preserved in the absence of N-linked carbohydrates so these 
were probably not involved in determining the mobility 
differences of Gl and G2. The absence of any effect of the 
presence of «2-macroglobulin on the relative intensities of 
the G1 and G2 bands suggested that endoproteolytic cleavage 
of Gl during 
the labelling 
sample preparation or extracellularly during 
period was unlikely to account for the 
presence of G2. If intracellular endoproteolytic cleavage of 
Gl occurred a small fragment would be produced in addition 
to G2. This fragment could have been digested or remained 
intact. The 12K polypeptide was observed to appear during 
pulse chase experiments at about the same time as Gl. The 
intensity of this band did not correlate with that of G2 
suggesting that it was not a product of cleavage of Gl. 
EXQprotease activity would be expected to give a continuous 
distribution of polypeptide sizes and so is unlikely to 
account for the apparent modification of Gl to give G2 
during pulse 
endoproteolytic 
chase experiments. An intracellular 
cleavage or differences in the non-N-linked 
oligosaccharides therefore appear to be the most likely 
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explanations of the relationship between Gl and G2. 
In pulse chase experiments no G related polypeptide 
could be identified until about 60' minutes after labelling 
with [35 S]-methionine. In a pulse chase experiment with 
[3H]-glucosamine Gl was observed after the pulse period but 
this could have been due to incorporation of 
oligosaccharides into carbohydrate of a polypeptide that had 
already undergone some processing. The nature of the 
precursor to Gl is therefore unknown. A small conformational 
change could change the protein from a form not recognized 
by antibody to one that is. The PVM G protein may however 
have a precursor with a lower Hr as i3 the case with the RS 
virus G protein. The RS virus G protein has a series of 
precursors which are believed to represent forms with no 
Q-linked oligosaccharides and varying amounts of N-linked 
oligosaccharides. The major precursor observed, p45, 
acquires the a-linked oligosaccharides relatively slowly to 
give the mature G protein (Fernie et al. 1985). The failure 
to identify the precursor to G in PVM prevented the 
demonstration of a similar or different mechanism of 
processing for the PVM G protein. 
The possibility of a glycoprotein equivalent to the F 
polypeptide of RS virus occurring in PVM was considered. The 
evidence presented for such a polypeptide suggested that it 
was poorly glycosylated being more readily labelled with 
[ 35 S]-methionine than with [3H]-glucosamine. The difference 
in mobility of this polypeptide under reducing and 
non-reducing conditions suggested that if it exists as two 
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disulphide bonded fragments then the smaller fragment would 
only have a Mr of 5,000. No polypeptide. with a ~ of this 
size was detected po.ssibly due to poor labelling or aberrant 
mobility. The 12K polypeptide was expressed on the cell 
surface but although it a~peared after a chase period in 
pulse chase experiments this did not correlate with a 
conversion of a FO to a F1 polypeptide (the only possible 
band that could have represented FO was a 50K polypeptide 
observed during a pulse chase experiment carried out with 
3H-glucosamine as the 
observed to be present 
label). The Fl polypeptide was 
in a particulate fraction of PVM 
infected cell supernatants along with the Gl and G2 
polypeptides. 
A PVM glycoprotein producing a very diffuse band was 
observed which was similar to a protein of similar mobility 
in TRT virus and to a glycosylated form of the RS virus 
protein NS1A. 
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3.4 Non-glycosylated PVH polypeptides 
3.4.1 Introduction 
Most of the work described has concerned studies on 
the glycoproteins of PVM. This section describes some 
studies carried out on the non-glycosylated PVM 
polypeptides. These experiments fell into three main 
categories: experiments on the Nand 39K polypeptides of 
PVM, comparison of the relationships of the other 
non-glycosylated PVM polypeptides by partial proteolysis, 
and protein phosphorylation in viruses of the genus 
Pneumovirus. 
Studies on the nucleocapsid polypeptide of PVM 
addressed two questions. Firstly, experiments described in 
~ 
the preceding section described the presence of a 
polypeptide with the mobility of the PVM nucleocapsid or 39K 
polypeptide on the surface of infected cells. Experiments 
described in this section showed that the detection of this 
polypeptide was an artefact due to the conditions used for 
the immunoprecipitation. Secondly, Cash et ai. (1979b) 
observed a 38K polypeptide of RS virus migrating slightly 
faster than the nucleocapsid polypeptide that was related to 
it, so it was of interest to find out if the 39K polypeptide 
of PVM showed a similar relationship to the nucleocapsid 
polypeptide. 
The PVM polypeptides were analysed by partial 
proteolysis with chymotrypsin to look for any possible 
relationships between them. The relatively large number of 
PVM associated polypeptides identified in Section 3.1 
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compared with the number of polypeptides associated with RS 
virus suggested that some of the PVM polypeptides may have 
been related. The results of the partial digests suggested 
that 39K and 35K and the 20K and 19K proteins ar~ related. 
The M polypeptide and the two M2 like polypeptides of RS 
virus were also subjected to partial proteolysis to obtain 
evidence that the two H2 polypeptides were in fact related. 
RS virus has been reported to possess one major 
phosphorylated polypeptide. 
reported for one subgroup 
polypeptides of PVM 
This however has only been 
B strain. The phosphorylated 
have not been described. 
Immunoprecipitation of 32phosphorous labelled polypeptides 
of the RSS-2 strain of RP virus (a subgroup A strain) and of 
PVM was carried out to identify the phosphorylated 
polypeptides of these viruses. 
3.4.2 Immunoprecipitation of polypeptides expressed on the 
cell surface using monoclonal antibodies 
Monoclonal antibodies were-used to immunoprecipitate 
radio labelled polypeptides from the surface of virus 
infected cells. The results are shown in Figure 56. All of 
the antibodies immunoprecipitated the N/39K polypeptide from 
total cell lysates. In the case of monoclonal antibody 
26/4/C4 this was due to the antibody recognizing the 39K 
polypeptide and the Land 35K polypeptides were 
co-precipitated as previously described (Section 3.2.4). 
·Antibody i9/l/C9 immunoprecipitated Gl (G2 was not apparent 
on this gel probably due to poor labelling) and the N/39K 
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Figure 56 Polypeptides immunoprecipitated by monoclonal 
antibodies following binding to intact cells 
Monoclonal antibodies 19/1/C9, 26/4/C4 and 26/1/Ell 
directed against the G, 38K and M proteins respectively of 
PVM were used to immunoprecipitate polypeptides from intact 
or lysed PVH or mock infected cells. The cells were labelled 
with [ 35 S]-methionine (lOOuCi per ml). The figure shows the 
immunoprecipitates analysed by SDS-PAGE using a 6 to 15 per 
cent gradient gel followed by fluorography. The antibodies 
used are indicated above each pair of tracks and PVM 
specific polypeptides labelled on the left. The positions of 
marker polypeptides (Mrs X10- 3 ) is indicated in the centre 
track. 
Cell surface- Polypeptides expressed on the cell 
surface were immunoprecipitated as 
described in the legend to Figure 39. 
Cell lysates- Cell lysates were immunoprecipitated as 
described in Section 2.6.15. 
PVM- Immunoprecipitates of PVH infected 
cella. 
HI- Immunoprecipitates 
cella. 
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polypeptide. Antibody 26/l/Ell immunoprecipitated the M 
polypeptide and the N/39K polypeptide. The M polypeptide 
appeared not to be expressed on the cell surface since much 
less label was associated with this polypeptide precipitated 
from the surface of the cells than from total cell lysates. 
Monoclonal antibody 19/1/C9 failed to immunoprecipitate Gl 
or G2 from the cell surface probably due to poor labelling 
of these polypeptides. Antibody 19/1/C9 did 
immunoprecipitate the N/39K polypeptide probably due to 
co-precipitation with an undetectable amount of Gl. The 39K 
polypeptide was immunoprecipitated from the surface of 
infected cells by monoclonal antibody 26/4/C4. However the 
results described in the following two sections revealed 
that this was an artefactual result, non-specific 
precipitation of the N/39K polypeptide occurring when a 
buffer with a high salt concentration was used. The results 
obtained using this approach must therefore be interpreted 
with care. 
3.4.3 Absence of evidence for expression of the PVK 39K 
polypeptide on the cell surface by FACS analysis 
In order to study the expression of the polypeptide 
recognized by monoclonal antibody 26/4/C4 on the cell 
surface by an alternative procedure to that described above, 
FACS analysis was used. This procedure was used to determine 
the mean fluorescence intensity of cells following 
incubation with monoclonal antibodies followed by 
fluorescein conjugated anti-mouse immunoglobulins. Three 
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Table 16 FACS analysis of PVH polypeptides expressed OD the 
surface of infected cells 
Antibody Dilution Mean fluorescence with 
PVM infected cells mock infected cells 
anti-PVM 1/10 214.14 33.26 
1/50 81.46 12.48 
1/250 24.14 4.24 
19/1/C9 1110 157.14 10.13 
(anti-G1/G2) 1/50 145.36 9.46 
1/250 126.56 2.42 
26/4/C4 1110 10.07 7.89 
(anti-39K) 1/50 8.10 5.15 
1/250 4.35 2.74 
., 
26/1/A2 1/10 9.20 14.83 
(anti-N/39K) 1/50 5.87 9.02 
1/250 3.96 8.19 
26/1;El1 1110 14.70 13.46 
(anti-M) 1/50 5.43 6.08 
1/250 3.06 2.93 
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different antibody concentrations were used to determine if 
the antibody level was saturating. The results are shown in 
Table 16. Positive results are indicated in bold type. The 
anti-PVM serum and monoclonal antibody 19/1/C9 were used as 
positive controls and the anti-M monoclonal antibody 
26/l/Ell as a negative control. Antibody 19/1/C9 was used as 
a positive control since although it did not precipitate 
polypeptides from the cell surface it did give a positive 
reaction in immunofluorescence experiments (Figure 17). It 
can be seen that the negative control (using monoclonal 
antibody 26/l/E1l) did not give significant levels of 
fluorescence. The anti-PVM serum control did not appear to 
reach saturating levels of antibody, the mean fluorescence 
~ 
increasing with increasing antibody concentration. The 
19/1/CS monoclonal antibody gave similar mean fluorescence 
levels at each concentration and so may have been saturating 
although the conjugate concentration could have been 
limiting. (The slight increase in fluorescence with 
increasing antibody concentration was less than 1.5 fold for 
a 25 fold increase in antibody concentration and was not 
considered significant.) It can be seen that neither 
antibody 26/4/C4 nor antibody 26/1/A2 gave levels of 
fluorescence above those for the negative control so the 39K 
polypeptide did not appear to be expressed on the cell 
surface. 
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3.4.4 Immunoprecipitation of cell surface polypeptides using 
a low salt buffer 
A systematic study of the use of buffers with 
different pH values and salt concentrations was carried out 
during an attempt to optimise immunoprecipitation with the 
monoclonal antibody 19/1/e9. This antibody was found not to 
immunoprecipitate any polypeptides on many occasions. This 
was subsequently found to correlate with the virus stocks 
used and was probably due to some stocks giving insufficient 
multiplicities of infection to enable the G polypeptides to 
be labelled adequately. The experiment revealed that the 
background level of label incorporation decreased with 
increasing sal~ concentration of the buffer. However a PVM 
... 
polypeptide (either N or the 39K polypeptide) showed 
anomalous behaviour and the band intensity increased with 
increasing salt concentration. This suggested that the use 
of buffer with a high salt concentration might affect the 
results of immunoprecipitation experiments. Anomalous 
precipitation could account for the apparent expression of 
the N/39K polypeptide on the cell surface when 
immunoprecipitation of intact cells was used. A cell surface 
immunoprecipitation using a buffer with a lower salt 
concentration was therefore carried out. The result is shown 
in Figure 57, the composition of the buffer being 10mM 
Tris-Hel (pH7. 4), SDS (0.1 per cent w/v), Sodium 
deoxycholate (1 per cent w/v) , Triton Xl00 (1 per cent v/v) 
and Sodium chloride (O.15M). It can be seen that the N/39K 
polypeptide is not precipitated from the surface of intact 
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cells under these conditions. Similarly only Fl and a 22K 
polypeptide (which may represent a fragment of F1 like that 
described with viruses of RS virus by Norrby et al .. 1986) 
were immunoprecipitated from the surface of RS virus 
infected cells. It was concluded from these data that only 
the Fl polypeptide of PVM and the F1 related polypeptides of 
RS virus could be considered to be genuinely expressed on 
the cell surface in these immunoprecipitation experiments. 
The figure also shows immunoprecipitates of TRT virus 
polypeptides that are considered later (Section 3.5.6). 
3.4.5 The absence of mobility changes of the 39K polypeptide 
during pulse chase experiments 
~ 
Figure 58 shows immunoprecipitates of a pulse chase 
experiment using the monoclonal antibody 26/4/C4. 
Insufficient label incorporation was achieved to detect this 
polypeptide in the supernatant. Two polypeptides of similar 
mobility can be observed, the lower mobility band probably 
representing co-precipitating N polypeptide. There is no 
evidence from this data of any processing as was observed 
with the Nand 38K polypeptides of RS virus (Cash et al. 
1979b). 
3.4.6 Identification of 39K related polypeptides by analysis 
of partial chymotryptic digests of PVH polypeptides 
All of the PVM polypeptides that could be sufficiently 
well labelled with were digested with 
chymotrypsin and the products analysed by SDS-PAGE as 
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Figure 58 Pulse chase experiaent- i..unoprecipitatioo with 
anti-39K .000010081 antibody 
PVM infected (PVM) and mock infected (HI) BS-C-l cell. 
were pulse labelled 48 hour. after infection with 
(35SJ-methionine (400uC1 per mIl. Pulse labelled samples <P 
in the figure) were then harve.ted whilst the other .ample. 
were chased in the ab •• nce of labelled methionine a. 
described in Section 2.5.13 tor the tim •• indicated (in 
minutes). Cell ly •• te. were immunoprecipitated with 
monoclonal antibody 26/4/C4. The immunoprecipitat •• were 
analysed by SOS-PAGE and tluoro,raphy. The fluoro,raph is 
shown in the ficure. The 39K polypeptide i. labelled on the 
left. The Hrs of the markers (XIO· a ) are shown in the 
figure. 
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Figure 59 Partial digests of the Fl, N, 39K and 35K 
polypeptides of PVM 
PVM infected cells were labelled from 48 to 72 hours 
post infection with [3sSJ-methionine (400uCi 
immunoprecipitated as described in Section 
polypeptides were synthesized in vitro as 
per ml) 
2.5.15. 
described 
and 
PVM 
in 
Section 2.5.27) and some of the samples immunoprecipitated 
whilst others were boiled in sample buffer. The samples were 
analysed by SDS-PAGE and the bands excised. The bands were 
digested during stacking in a second gel using chymotrypsin 
(lmg per ml) as described in Section 2.5.22. This gel had a 
15 per cent resolving gel. The polypeptide used is indicated 
above each track. Si~ilar polypeptide profiles are indicated 4 
by similar letters to the right of each band. Two prints are 
shown to enable bands of different intensities to be 
identified. 
IC- Polypeptide derived from immunoprecipitate of 
infected cell lysate. 
IV-
IVI-
mAb-
Polypeptide derived from irl vitro translation 
of RNA from PVM infected cells. 
Polypeptide derived from immunoprecipitate 
using anti-PVM serum of PVM polypeptides 
labelled in vitro. 
Polypeptide immunoprecipitated using 
monoclonal antibody 26/4/C4. 
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described in the legend of Figure 59. The results are shown 
in Figures 59 and 60. The Nand 39K polypeptides could not 
be clearly separated when immunoprecipitated from samples 
labelled in vivo. However the polypeptides could be more 
readily separated when they were labelled irl vitro. The 
reason for this difference is not clear. The digests of the 
Nand 39K polypeptides labelled in vitro (IV) show different 
peptides (peptides associated with N are labelled a and 
those associated with the 39K protein are labelled b in 
Figure 59). A digest of the N/39K band observed when the 
polypeptides were labelled iTI ~/i~/(.) (IC) shows the peptides 
associated with digests of both the Nand 39K proteins 
labelled in vitro. The two polypeptides were therefore 
.. 
considered to be distinct. The polypeptide 
immunoprecipitated by monoclonal antibody 26/4/C4 (mAb in 
Figure 59) showed a polypeptide pattern similar to that of 
the 39K polypeptide and the antibody was considered to be 
specific for the 39K polypeptide on this basis. It was not 
possible to determine- the specificity of this antibody 
unequivocally on the basis of mobility since the Nand 39K 
polypeptides had such similar mobilities. It was observed 
that the 35K polypeptide also shared peptides with the 39K 
polypeptide and may therefore be related to it in some way. 
The nature of the relationship if it is genuine is not 
clear. The 25K polypeptide labelled irl vitro showed a 
single band that may have corresponded to the major 
digestion product of the 39K polypeptide (Figure 60) but 
this was run on a different gel so this was not clear. In 
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Figure 60 Partial proteolysis of the PVH M 25K 24K 20K , , , 
and 19K polypeptides. 
PVM polypeptides were labelled and separated and 
digested with chymotrypsin as described in the legend to 
Figure 59. Two prints are shown to enable bands with 
different intensities to be identified. 
mAb 
IC-
IV-
IVI-
Polypeptide immunoprecipitated with 
monoclonal antibody 26/1/Ell. 
Polypeptide labelled i TI vivo and 
immunoprecipitated with anti-PVM serum. 
Polypeptide labelled in vitro. 
Polypeptide labelled in vi tr () and 
immunoprecipitated with anti-PVM serum. 
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contrast to the situation with RS virus the Nand 39K 
polypeptides are not related. Polypeptides of 35K and 25K 
may be related to the 39K polypeptide. 
3.4.7 Identification of other possible relationships between 
PVM polypeptides with different mobilities 
Figure 60 shows that digestion of the M polypeptide of 
PVM with chymotrypsin gave a similar peptide pattern 
regardless of whether the labelling was carried out ir, vivo 
(Ie) or in vitro (IV). Digestion of the M polypeptide 
labelled in vitro and immunoprecipitated with monoclonal 
antibody 26/1/El1 (mAb) gave a similar peptide pattern to 
that observed with the M polypeptide immunoprecipitated 
using anti-PVM serum (IVI). Partial digests of the 24K 
polypeptide and the M polypeptide shared peptides of similar 
mobilities suggesting that the polypeptides may have been 
related although the peptide patterns were not identical. 
The 20K polypeptide and the 19K polypeptide shared a similar 
pattern of peptides and may therefore not be unique 
polypeptides. The possibility exists in this case that the 
bands were not sufficiently well resolved to cut each one 
out without extensive cross contamination with labelled 
protein from the other. 
3.4.8 Labelling of pneumovirus polypeptides with 
32 phosphorous 
RS virus has been shown to have one major 
phosphorylated polypeptide, the P protein (Cash.t al. 
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Figure 61 I .. unoprecipitation of pneumovirus polypeptides 
labelled with 32 phosphorous. 
PVH. RS virus. TRT virus and mock infected cells were 
incubated in phosphate free medium from 48 to 52 hours post 
infection. The cells were then incubated overni,ht in 
similar medium containin, 32phosphorous (500~Cl per ml). The 
cells and supernatants were harvested as described in 
Section 2.5.12 and immunoprecipitated with the homolo,ous 
antiviral sera. The samples were analysed by SDS-PAGE 
followed by autoradio,raphy usin, an intensifyin, screen. 
The autoradio,raph is shown in the fi,ure. The sizes of the 
markers (~sXl0-3) are indicated in the centre. PVH specific 
polypeptides are labelled on the left, RS virus polypeptides 
on the ri,ht and TRT virus polypeptides on the far ri'ht. 
Cell lysate-Samples immunoprecipitated from cell lysates 
PEG- Polypeptides immunoprecipitated from PEG 
preCipitates of cell supernatants 
PVM-
RS-
TRT-
HI-
Immunoprecipitates of 
infected cells. 
.amples from PVH 
Immunoprecipitates of samples from RS virus 
infected cells. 
Immunoprecipitates of samples from TRT virus 
infected cell •. 
Immunopreeipitate. of samples from mock 
infeeted eell. carried out uain. all of the 
antiviral .era to.ether. 
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1979b). Phosphoproteins of PVM and TRT virus have not been 
described. In order to identify any phosphorylated 
polypeptides of PVM and TRT virus and to confirm the result 
observed for RS virus using a more sensitive and specific 
technique immunoprecipitation was used. PVM, RS virus and 
TRT virus infected cells were labelled with 32phosphate and 
the cell lysates and PEG precipitates of the supernatants 
were then immunoprecipitated with the appropriate antisera. 
The phosphoproteins of TRT virus are described in Section 
3.5.7. Mock infected cells were immunoprecipitated with all 
the antisera in combination as a control. The polypeptides 
immunoprecipitated were analysed by SDS-PAGE and the results 
are shown in Figure 61. Label migrating at the top of the 
~ 
gel may have represented phosphorylation of the L 
polypeptide of RS virus but it was very diffuse and probably 
represented non-specifically precipitated material. The 
label at the bottom of the gel may also have represented 
non-specifically precipitated material. In the case of RS 
virus a band at the bottom of the PEG precipitate track had 
no counterpart in the tracks of PEG precipitates of 
supernatants of the other cells. Label in the 60K to 150K 
region of the gel could not be correlated with RS virus 
polypeptides except possibly for the G polypeptide. A band 
occurred in the region of the RS virus Fl polypeptide 
although this band was not clearly virus specific since 
there was a band in a similar position on the-~rack of 
immunoprecipitates of mock infected cells. The P protein of 
RS virus was the most heavily labelled band in 
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immunoprecipitates of cell lysates. A polypeptide migrating 
in the position of the M polypeptide of RS virus was 
phosphorylated. A low intensity band was observed in the 
region of the 22K RS virus polypeptide which was not 
detected amongst the polypeptides in the PEG precipitate. A 
polypeptide of 19K was observed that could have represented 
F2. A polypeptide of 11K may have represented the 11K 
non-structural protein of RS virus. However this polypeptide 
was present in the supernatants of infected cells in this 
experiment. As described above it was not clear if the band 
at the bottom of the gel was virus specific. This band would 
represent a polypeptide with an Mr of only about 1,000. This 
would be smaller than any of the reported RS virus 
polypeptides and so the band may represent a fragm;nt of a 
larger polypeptide or non-specifically precipitated 
material. 
Only two PVM specific bands were observed. One of the 
phosphoproteins was the Nand/or 39K polypeptide whilst the 
other was the 20K or 19K polypeptide. 
The mobilities of PVM and RS virus phosphoproteins are 
therefore different. The nature of the phosphoproteins of 
higher mobility than P is not known. Experiments with 
monoclonal antibodies would be required to determine which 
of the higher mobility polypeptides is phosphorylated. The 
26/4/C4 monoclonal antibody binds to both the PVM 39K 
polypeptide and the RS virus P protein so these polypeptides 
could be analogous proteins. 
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3.4.9 Summary 
The results presented in this section describe some of 
the properties of the non-glycosylated polypeptid~s of PVM. 
It was not possible to distinguish the Nand 39K 
polypeptides of PVM in many experiments. The two polypeptides 
appeared to be distinct giving different patterns of 
peptides after digestion with chymotrypsin and trypsin. The 
39K polypeptide could be distinguished from the N 
polypeptide when the monoclonal antibody 26/4/C4 was used 
(Section 3.4.6. The similar mobility of the Nand 39K 
polypeptides has prevented the unambiguous determination of 
which of these polypeptides is phosphorylated. Results 
described in the previous section (3.3.15) suggested that 
either the N or the 39K polypeptide was expressed on the 
cell surface. This result was shown to be an artefact due to 
the salt concentration used during the immunoprecipitation. 
The 39K and 35K polypeptides appeared to be related. The 35K 
polypeptide did not appear to be phosphorylated so if the 
39K polypeptide is the phosphoprotein the 35K polypeptide 
may represent its unphosphorylated form. There may be 
differences in the epitope recognized by monoclonal antibody 
26/4/C4 between the 39K and 35K polypeptides since the 
latter polypeptide was only weakly precipitated by the 
monoclonal antibody and was not detected on Western blots. 
The antibody may recognize an epitope involving phosphate 
groups since it also binds to the RS virus phosphoprotein 
(Section 3.2.5). It is not known if the antibody 
immunoprecipitates any TRT virus polypeptides. If the 39K 
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and 35K polypeptides are in fact related the absence of the 
35K polypeptide in PVM infected BHK-21 cells (Cash f?t al 
1979) may be due to . the absence of that form of the 
polypeptide in these cells. 
The M protein of PVM did not appear to be 
phosphorylated unlike the RS virus M protein which had a 
similar mobility and charge. The 25K and 24K PVM 
polypeptides synthesized iTI ~'itro may not represent unique 
polypeptides. One of the bands shared peptides with the 39K 
polypeptide whilst the other shared peptides with the M 
polypeptide following digestion with chymotrypsin. 
The second phosphoprotein observed with PVM had no 
cle~r counterpart in RS virus. This polypeptide may have 
.. 
been either the 20K or the 19K polypeptide (or both since 
they were not always well resolved). A 19K phosphoprotein 
was observed with RS virus but the only protein in this area 
of the gel was F2 and there is no evidence that the 20K and 
19K were F2-like proteins. The 20K/19K phosphoprotein of PVM 
was not therefore considered to be analogous to the 19K 
polypeptide of RS virus. The 20K and 19K polypeptides 
appeared to show similar peptide patterns after digestion 
with chymotrypsin but the difficulty in separating these 
polypeptides may have resulted in their being heavily cross 
contaminated. The 18K, 16K and 12K polypeptides of PVM could 
not be compared with the other PVM polypeptides 
satisfactorily by partial proteolysis due to their high 
'mobilities and poor labelling. 
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3.5 Polypeptides of TRT virus 
3.5.1 Introduction 
The polypeptides of TRT virus have not been 
characterized in any detail. The polypeptides observed on 
stained gels of partially purified virus have been described 
(Collins & Gough 1988). To obtain additional information on 
the viral polypeptides radiolabelling was used to identify 
the polypeptides synthesized in infected cells. This 
approach was hindered by the high background of cellular 
protein synthesis even in the presence of actinomycin D. The 
study was therefore extended using in vitro translation of 
RNA from TRT virus infected cells. A murine antiserum was 
also produced to enable immunoprecipitation of virus 
specific polypeptides to be carried out. The use of 
[32 phosphate] and [3H]-glucosamine labelling combined with 
immunoprecipitation enabled the phosphorylated and 
glycosylated viral polypeptides to be identified. 
3.5.2. TRT virus induced polypeptides observed in infected 
cells 
Figure 62 shows that five virus specific polypeptides 
with calculated ~s of 38K, 35K, 3DK, 19K and 15K could be 
identified in [ 35 S]-methionine labelled TRT virus infected 
cell lysates. The cells were infected as described in the 
legend to Figure 62. These three polypeptides were probably 
equivalent to the 49K, 45K and 39K polypeptides described by 
Collins et al. (198Gb). The relative molecular mass 
estimates given by these authors were subsequently revised 
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Figure 62 PolYPeptides of TRT virus synthesi~ed in infected 
cella. 
Conflu@nt monolayers of BS-C-l cells were infected at 
a multiplicity of infection of 2 and incubated at 33°C for 
48 hours befor@ labellin, for 24 hours with r35 S]-methionine 
in the presence of actinomycin D (2.5u, per ml). A 
fluoro,raph of the TRT virus polypeptides synthesized in 
infected BS-C-l cells analysed on a 6-15 per cent .radient 
resolvin, ,el is shown. 
TRTV Samples from TRT virus infected culture. 
HI Samples from mock infected cell cultures 
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downwards (Collins & Gough 1988). The pattern of mobilities 
was similar but their relative molecular mass estimates 
differed due to the. use of different molecular weight 
standards. 
3.5.3. Analysis of TRT virus polypeptides using two 
dimensional polyacrylamide gel electrophoresis 
[ 35 S]-methionine labelled lysates of TRT virus 
infected BS-C-l cells were analysed by two dimensional gel 
electrophoresis as described in the legend to Figure 63. The 
two dimensional gels of RS virus (a), PVM (b), and mock 
infected (c) cell lysates are included in the same figure as 
that of TRT virus infected cell lysates Cd) for comparison. 
. ~ 
The positions of the virus specific polypeptides are shown 
superimposed on the autoradiograph of the polypeptides from 
mock infected cells on the right of each autoradiograph. 
Acidic polypeptides of 38K, 35K and 15K and a basic 
polypeptide of 30K were identified in the TRT virus infected 
cell lysates. These had similar mobilities and charge 
properties to the N, P, M and 15K polypeptides of RS virus. 
Like the nucleocapsid proteins of PVM and RS virus some 
streaking of the TRT virus 38K polypeptide was observed. 
3.5.4 TRT virus polypeptides synthesized in vitro 
TRT virus polypeptides were synthesized iTi vitro using 
a rabbit reticulocyte lysate system with RNA extracted from 
·TRT virus infected cells incubated in the presence of 
actinomycin D as described in Sections 2.5.26 and 2.6.27. 
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Figure 63 Analysis of pneu.ovirus polypeptides in infected 
cell lysates OD two dimensional gels. 
BS-C-l cells were infected and labelled as described 
in the legend to Figure 82. The cells were lysed and 
analysed by non-equilibrium pH gradient electrophoresis 
followed by SDS-PAGE as described in Section 2.5.17. NEPHGE 
was carried out in the horizontal direction with the acidic 
end to the right. Dia,rams of the virus specific 
polypeptides overlaid on the mock infected cell polypeptides 
are shown adjacent to each autoradio,raph. 
a) Autoradiograph of ,el of RS virus infected cell lysate . 
• 
b) Autoradiograph of gel of PVM infected cell lysate. 
c) Autoradio,raph of gel of mock infected cell lysate. 
d) Autoradio,raph of eel of TRT virus infected cell lysate. 
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The [ 35 S]-methionine labelled polypeptides separated by 
SDS-PAGE are shown in Figure 64 along with PVM and RS virus 
polypeptides translated iTi vitro, Xhe significance of the 
faint unmarked bands in the PVM and RS virus tracks is not 
known. It can be seen that the polypeptide profile of TRT 
virus differs from that of PVM and RS virus to a larger 
extent than the polypeptide profiles of these two viruses 
differ from each other. Four of the five TRT virus 
associated polypeptides identified iTi vivo the 38K, 35K, 30K 
and 19K polypeptides could be identified iTI vitro. A 
polypeptide not observed amongst the polypeptides labelled 
irl vi 110 (the 23K polypeptide) was observed amongst theiTi 
vitro translation products of RNA from TRT virus infected 
.. 
cells. This may have been due to the 23K polypeptide being 
of low abundance in infected cells or due to it being 
processed in some way. The 15K polypeptide observed amongst 
TRT virus specific polypeptides labelled iTi vi~/o was not 
observed amongst the polypeptides synthesized iTi vitro on 
single dimension gels ~uggesting that it may not have been a 
primary translation product. 
The products of iTi vitro translation of RNA from TRT 
virus infected cells were also analysed by two dimensional 
NEPHGE/SDS-PAGE. The results are shown in Figure 65 along 
with the two dimensional gels of PVM and RS virus 
polypeptides synthesized iTi vitro using RNA extracted from 
RS virus (a), PVM (b) and mock infected cells. As had been 
·observed for a polypeptide of similar mobility observed in 
infected cells (Section 3.5.3.) the 38K polypeptide was 
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Figure 64 Polypeptides of TRT virus synthesized in vitro 
RNA was extracted from PVM, RS virus, TRT virus and 
mock infected cells as described in Section 2.5.26. The RNA 
was used to direct the synthesis of virus specific 
polypeptides in vitro as described in Section 2.5.27. The 
figure shows a fluorograph of the polypeptides analysed by 
SDS-PAGE. The PVM polypeptides are labelled on the left, the 
TRT virus polypeptides are labelled on the right and the RS 
virus polypeptides are labelled on the far right. The 
positions of the polypeptides are indicated by circles to 
the right of each track. Molecular weight markers (~Xl0-3) 
are indicated on the left . 
.. 
PVM- Polypeptides synthesized i rl Ilitro using RNA from 
PVM infected cells. 
RS- Polypeptides synthesized i rl Ilitro using RNA from 
RS virus infected cells. 
MI- Polypeptides synthesized in vitro using RNA from 
uninfected cells. 
TRT- Polypeptides synthesized iTI vitro using RNA from 
TRT virus infected cells. 
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Figure 65 Analysis of pneu.ovirus polypeptides synthesized 
in vitro on two dl.eD~loDal gels. 
Polypeptides synthesized i~ vltro as described in 
Section 2.5.26 were analysed by NEPHGE/SDS-PAGE as described 
in Section 2.5.27. NEPHGE was carried out in the horizontal 
direction with the acidic end to the ri,ht. 
a) Fluorocraph of PVH polypeptides synthesized in 
vitro analysed by NEPHGE/SDS-PAGE 
b) Fluorograph of RS polypeptides synthesized in 
vitro analysed by NEPHGE/SDS-PAGE 
~) Fluoro,raph of mock infected cell polypeptides 
• 
synthesized i~ vitro analysed by NEPHGE/SDS-PAGE 
d) Fluoro,raph of TRT virus infected cell 
polypeptides synthesized in vitro analysed by 
NEPHGE/SDS-PAGE 
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observed to streak in the first dimension. The 35K and 30K 
polypeptides were acidic and basic respectively as has been 
described for polypeptides of similar mobility in infected 
cells (Section 3.5.3). The 30K polypeptide, like the H 
polypeptide of RS virus was observed to have a similar 
mobility to a series of more acidic polypeptides. The 23K 
and 19K polypeptides were observed to be highly basic. The 
15K polypeptide observed amongst iTI ~/i tro translation 
products of RNA from TRT virus infected cells was more basic 
than the 15K polypeptide observed in infected cells (Figure 
63). This suggests that either these two polypeptides are 
distinct or that some form of processing occurs iTI vivo 
altering the charge on this polypeptide. 
3.5.5. Cross neutralization tests with antiviral sera 
Murine antisera were raised against two types of TRT 
virus giving different plaque morphologies and -used in cross 
neutralization tests with both types of TRT virus and PVH 
and RS virus. The two variants of TRT virus produced focal 
plaques (TRTf) and syncytial plaques (TRTs) as described by 
Ling & Pringle (1988). Anti-PVM and anti-RS virus sera were 
also used. The results are shown in Table 17. It can be seen 
that the murine anti-PVM and bovine anti-RS virus sera 
showed high neutralizing activity with the homologous virus 
and no neutralizing activity with heterologous viruses. The 
murine anti-TRT virus sera showed relatively low 
neutralizing titres. The anti-TRTf virus serum had higher 
titres against both forms than the anti-TRTs virus serum. 
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Table 17 Cross neutralization tests with anti-pneumovirus 
sera 
Antiserum Neutralization titre with:-
PVM RS virus TRT(F) virus TRT(S) virus 
anti-PVM 27,000 <20 <20 <20 
anti-RS <20 25,000 <20 <20 
virus 
anti-TRT(F) 120 <20 940 390 
virus 
anti TRT(S) 180 <20 560 240 
virus 
Pre-immune 11 90 ND2 <20 <20 
Pre-immune 21 90 ND2 <20 <20 
1 Pre-immune 1 serum was taken from mice subsequently 
.. immunized with TRT(F) virus and pre-immune 2 serum was 
't 
taken from mice subsequently immunized with TRT(S) virus 
2 not done 
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Both anti-TRT virus sera neutralized the focus forming 
variant more effectively than the syncytium forming variant. 
These results suggested that the two viruses were 
antigenically similar. The sera did not neutralize RS virus 
but did show very low neutralizing activity with PVM. This 
low level of anti-PVM activity was also present in 
pre-immune sera and the level in the anti-TRT virus sera did 
not correlate with the titres of the two sera against TRT 
virus. This indicated that there was no cross reactivity 
between antisera to TRT virus and PVM. 
The results show that the two types of TRT virus were 
related in neutralization tests. PVM, RS virus and TRT virus 
do not show any cross neutralization reactions. 
3.5.6 Immunoprecipitation of TRT virus polypeptides with 
murine anti-TRT virus serum 
The anti-TRTf serum described in the preceding section 
was used to immunoprecipitate TRT virus polypeptides from 
[ 35 S]-methionine labelled TRT'virus infected cell lysates 
(Figure 66, which is a longer exposure of Figure 57). Eight 
major polypeptides were immunoprecipitated by the anti-TRTf 
serum the l29K, 58K, 45K, 38K, 30K, 23K, 19K and 15K 
polypeptides. A band of similar mobility to the l29K 
polypeptide was immunoprecipitated from labelled uninfected 
cells so this polypeptide may not have been virus specific. 
There also appears to be a lOOK polypeptide below the l29K 
polypeptide. The 19K polypeptide appeared to consist of two 
closely migrating bands on this gel (only apparent in the 
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Figure 66 Immunoprecipitation of TRT virus polypeptides with 
a murine antiserum 
Polypeptides were labelled with [ 35 S]-methionine and 
immunoprecipitated from intact or lysed cells as described 
in the legend to Figure 57. The polypeptides were 
immunoprecipitated with the corresponding antiviral sera, 
the samples from mock infected cells being 
immunoprecipitated with antisera to all of the viruses. The 
figure shows a fluorograph of the polypeptides analysed by 
SOS-PAGE using a 6-15 per cent gradient gel. The PVM 
specific polypeptides are labelled on the left, the TRT 
virus polypeptides on the right and the RS virus specific 
~ 
polypeptides on the far right. The positions of the markers 
(Mrs X10- 3 ) are indicated in the centre. 
Cell surface- Polypeptides immunoprecipitated after 
binding antibody to intact cells. 
Cell lysates- Polypeptides 
cell lysates. 
immunoprecipitated from 
PVM-
~-
TRT-
MI-
Polypeptides immunoprecipitated from PVM 
infected cells. 
Polypeptides immunoprecipitated from RS 
virus infected cells. 
Polypeptides immunoprecipitated from TRT 
virus infected cells. 
Polypeptides immunoprecipitated from 
mock infected cells. 
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shorter exposure Figure 57) similar to the 20K and 19K 
polypeptides of P~. Figure 57 shows that 
immunoprecipitation of poly,pepticies expressed on the cell 
surface did 'not clearly reveal any TRT virus specific 
polypeptides although the 45K and 38K polypeptides may have 
been present on the cell surface. The TRT virus 35K 
polypeptide detected in infected cell lysates (e.g. Section 
3.5.2) was not precipitated by this antiserum. 
If the 129K polypeptide is virus specific it has no 
counterpart of similar mobility in RS virus or PVM. No G 
like polypeptide was ever observed in [ 35 S]-methionine 
labelled cell lysates. The 45K polypeptide has a similar 
mobility to the Fl polypeptides of PVM and RS virus . 
. 
Evidence is presented in Sections 3.5.8 and 3.5.9 that this 
polypeptide and a 58K polypeptide that may represent an 
FO-like protein are glycosylated. The 38K polypeptide of TRT 
virus has a similar mobility to the N polypeptides of PVM 
andRS virus and like them may be associated with 
nucleocapsids (data not-shown). 
3.5.1 Phosphorylated polypeptides of TRT virus 
32 Phosphate labelled TRT virus polypeptides were 
immunoprecipitated from infected cell lysates and PEG 
precipitates of the culture supernatants using the murine 
anti-TRTf virus serum. The polypeptides were analysed by 
SDS-PAGE along with the PVM and RS virus phosphoproteins 
immunoprecipitated with homologous antisera. The results are 
shown in Figure 61. Three possible phosphoproteins were 
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immunoprecipitated from samples from TRT virus infected 
cells. A polypeptide of about 43K was observed to be a 
stronger band in samples from TRT virus infected cells than 
a corresponding band in mock infected cells. This 
polypeptide did not appear to be specifically precipitated 
from PEG precipitate samples. The other TRT virus 
phosphoproteins were the 35K and 19K polypeptides. Two 
polypeptides were identified in the region of the 19K 
polypeptide as described above (Section 3.5.6). These 
polypeptides could only be clearly observed in the PEG 
precipitate sample. 
The results of the phosphate labelling studies did not 
reveal a common pattern of phosphorylation or pneumovirus 
.. 
polypeptides. PVM and RS virus showed a totally distinct 
pattern of phosphoproteins whilst the pattern with TRT virus 
contained bands or similar mobility to those of each of the 
other viruses. The Nand 39K polypeptides of PVM were 
difficult to distinguish due to their similar mobilities. It 
is likely that the 39K polypeptide is similar to the RS 
virus P protein because they both bind to monoclonal 
antibody 26/4/C4. TRT virus has a phosphorylated polypeptide 
of about 35K that could be analogous to the phosphorylated P 
protein of RS virus that has a similar mobility. TRT virus 
also had a possible phosphorylated polypeptide of 43K as did 
RS virus although a co-migrating polypeptide in uninfected 
cells precluded a definite identification ~£ these 
,polypeptides as being virus specific. Analysis of 
32phosphorous labelled samples under non-reducing conditions 
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might establish whether or not the F1 protein or RS virus 
and the 45K protein of TRT were in fact phosphorylated 
because the label would then be e~pected to occur in the FO 
and 58K polypeptides. Both PVM and TRT virus had 
phosphoproteins in the 19K region of the gel which could be 
equivalent polypeptides. 
3.5.8 Identification of TRT virus glycoproteins 
Figure 67 shows the proteins present in cell lysates 
and PEG precipitates of supernatants of TRT virus infected 
cells labelled with C3 H]-glucosamine and immunoprecipitated 
with murine anti-TRTf virus antiserum. It can be seen that a 
very high background or cellular glycoproteins made 
~ 
identification of TRT virus specific glycoproteins difficult 
in immunoprecipitates of cell lysates. This was 'due to low 
multiplicities of infection and the low titre of the 
antiserum. Putative viral glycoproteins or 95K, 31K and 15K 
were identified. The situation was clearer with the 
immunoprecipitates of PEG precipitates of the supernatants. 
Virus specific polypeptides of 45K, 31K and 15K were readily 
identified whilst an 83K glycoprotein had a greater 
intensity than a polypeptide of similar mobility in samples 
from mock infected cells. The glycoproteins of TRT virus 
therefore show a similar pattern to those of other 
pneumoviruses. 
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Figure 67 Polypeptides of TRT virus labelled with 
[3B]-glucosamine 
TRT virus infected and uniniected BS-C-l cells were 
labelled with [3H]-glucosamine (50uCl per ml) from 48 hours 
to 72 hours post infection. TRT virus iniected cells were 
also incubated in the presence of tunicamycin (2.5ug per ml) 
and labelled in the presence of the antibiotic in a similar 
way to the untreated samples. Samples of cell lysates and 
PEG precipitates of the supernatants (PEG) were 
immunoprecipitated with murine anti-TRT virus serum as 
described in Section 2.5.15 and analysed by SDS-PAGE 
followed by fluorography (Sections 2.5.16. and 2.5.23). The 
samples were run under both reducing and non-reducing 
conditions. The ficure shows the fluorograph obtained. The 
positions of the markers are indicated by their MrS (X10- a ). 
TRT virus specific polypeptides are indicated by circles and 
labelled on the left (for samples run under reducing 
conditions) and on the right (for samples run under 
non-reducing conditions) using their ~s. 
Cell lysates- Immunoprecipitates of cell lysate. 
PEG- Immunoprecipitates of PEG precipitates 
of cell supernatants 
TRT-
HI-
T-
C-
Samples from TRT virus infected cells 
Samples from mock infected cells 
Sample. immunoprecipitated from 
tunicamycin treated cells 
Samples immunoprecipitated from 
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150K 
95K 
83K 
58K 
45K 
31K 
Reduc i19 conditions 
I Cell lysate PEG I TRT IMI TRT IMI C T C C T C 
o 
15K 0 o 
Non-reducin, condition5 
I Cell lysate PEG I TRT 1M I TRT 1M I 
C T C T C 
200 
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3.5.9 TRT virus glycoproteins observed under non-reducing 
conditions 
The glycoproteins of TRT virus labelled and 
immunoprecipitated as described in the preceding section 
were analysed under non-reducing conditions to identify 
possible disulphide bonded proteins. The results are shown 
in Figure 67. Polypeptides of 95K in the cell lysate sample 
(even less distinct than in samples run under reducing 
conditions) and 83K in the PEG precipitate showed similar 
mobilities to those under reducing conditions. The 45K, 31K 
and 15K polypeptides were all reduced in intensity when the 
samples were run under non-reducing conditions. Additional 
virus specific bands of 150K and 58K were observed under 
-
non-reducing conditions. The 150K polypeptide may represent 
aggregates or disulphide bonded multimers of the other viral 
glycoproteins. The 58K protein may represent an Fl,2 like 
protein, this suggestion being supported by the reduction in 
intensity of the 45K and 15K polypeptides. Figure 68 shows 
the results of a similar experiment carried out using 
[ 35 S]-methionine labelled TRT virus infected cells. It was 
again observed that the 58K polypeptide band was increased 
in intensity under non-reducing conditions whilst the 45K 
polypeptide band was reduced in intensity. The 58K band 
observed under reducing conditions could, by analogy with 
the RS virus F protein, have represented the uncleaved FO 
like protein of TRT virus. 
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3.5.10 The effect of tunicamycin on TRT virus glycoprotein 
synthesis 
The effect of tunicamycin .treatment of TRT virus 
infected cells on TRT virus glycoproteins is also shown in 
Figure 67. It can be seen that no TRT virus specific 
glycoproteins could be identified in immunoprecipitates of 
samples from cells incubated in the presence of tunicamycin. 
This suggests that all of the TRT virus polypeptides have 
only N-linked oligosaccharides. No unglycosylated 
[ 35 S]-methionine labelled forms of the 58K or 45K 
polypeptides could be detected in immunoprecipitates of 
samples from tunicamycin treated cells (Figure 68). This 
suggests that they may be unstable in the absence of their 
- ~ 
N-linked oligosaccharides as was observed for the F protein 
of subtype B strains of RS virus (Norrby et al. 1986). 
3.5.11 Effect of monensin treatment on synthesis of 
[ 35 S]-methionine labelled TRT virus specific polypeptides 
Immunoprecipitates of [ 35 S]-methionine labelled TRT 
virus polypeptides immunoprecipitated with murine anti-TRT 
virus antiserum were analysed by SDS-PAGE and fluorography 
(Figure 68). The polypeptides were labelled in the presence 
of tunicamycin (2.5~g per ml), monensin (O.8~M) or in the 
absence of these inhibitors. The bands indicated by circles 
were considered to be virus specific since they were more 
intense than bands in the mock infected tracks. The 38K 
polypeptide unlike co-migrating host cell polypeptides were 
detected when cells were labelled in the presence of 
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Figure 88 [3s S ]-methioDiDe labelled TRT virus polypeptides 
sTDthesi~ed in the preseDce and abseDce of tunic .. yciD or 
aODeDsiD 
TRT virus infected and mock infected BS-C-l cells were 
incubated for 48 hours in the presence or absence of 
tunicamycin <2.5ui per ml) or monen~1n (O.SuM). The cells 
were then labelled for 24 hours with ( 35 S]-methionine (SOuCl 
per ml). Immunoprecipitation with murine anti-TRT virus 
serum (SOul per lX10' cells) was used to precipitate TRT 
virus specific polypeptides that were then resolved by 
SDS-PAGE under reducin, or non-reducin, conditions. 
TRT- Immunoprecipitates of TRT virus infected 
cell lysates. 
MI 
T-
M-
C-
Immunoprecipitates of mock infected cell 
lysates. 
Samples from tunicamycin treated cells. 
Samples from monensin treated cells. 
Samples from untreated cells. 
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tunicamycin. The apparent resolution of the 38K, 31K and 19K 
polypeptide bands into two bands each was considered to be 
an artefact, probably being due to. overloading the gel since 
it was most commonly observed when large amounts of 
antiserum were used to precipitate viral polypeptides. Two 
distinct polypeptides were observed in the region of the 38K 
polypeptide under non-reducing conditions. The relationship 
between these bands and the polypeptides observed under 
reducing conditions is not known. The nature of the 36K and 
26K polypeptides observed under non-reducing conditions was 
not. clear. The effect of tunicamycin on the viral 
polypeptides was considered above (Section 3.5.10). 
Monensin treatment of TRT virus infected cells only 
• 
affected the synthesis of the F-like polypeptides. The 58K 
polypeptide band of TRT virus showed an increased intensity 
relative to the 45K polypeptide band under reducing 
conditions. The 58K band was much stronger than the 45K 
polypeptide band under non-reducing conditions. These 
results could be explained if a 58K polypeptide was the 
precursor to a disulphide bonded dimer of a 45K polypeptide 
and a 15K polypeptide as suggested above (Section 3.5.9). 
Under non-reducing conditions only a 58K polypeptide would 
then be observed, whereas under reducing conditions both the 
58K and the 46K and 16K polypeptides would be observed if 
cleavage or reduction of the 58K polypeptide was incomplete. 
A 15K polypeptide was not observed on fluorographs of the 
gel shown in Figure 68 even after longer exposures. The 
relative increase in intensity of the 58K polypeptide band 
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relative to the 45K polypeptide band when polypeptides were 
labelled in the presence of monensin could indicate that 
cleavage of the 58K polypeptide occurred at a site distal to 
the site of action of monensin as has been observed with the 
RS virus F protein (Fernie et al. 1985). If this was the 
case the inhibition of glycoprotein processing by monensin 
in this experiment was incomplete. 
3.5.12 Summary 
The results presented in this section describe the 
identification of the proteins of TRT virus and a partial 
characterization of their properties. TRT virus like PVM and 
RS virus probably has a glycoprotein with a high glucosamine 
content and a low methionine content. This polypeptide had 
an estimated Mr of 83K and could only be identified in PEG 
precipitates of cell supernatants and not in cell lysates. 
The existence of a co-migrating host cell glycoprotein 
prevented the virus specificity of this polypeptide being 
confirmed. This polypeptide had N-linked oligosaccharides 
since it could not be detected when TRT virus infected cells 
were labelled in the presence of tunicamycin. The presence 
of other types of oligosaccharides on this protein was not 
ruled out by this result since the polypeptide may have been 
unstable when synthesized in the presence of tunicamycin. A 
specific antibody against this polypeptide was not available 
preventing further studies on this polypeptide such as pulse 
chase studies or identification of the size of the 
unglycosylated polypeptide. 
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TRT virus has an F-like polypeptide with disulphide 
bonded 45K and 15K glycosylated polypeptides. The 
oligosaccharides appeared to be .N-·linked as was observed for 
the PVM and RS virus F proteins (Section 3.3.7). In contrast 
to the situation with the PVM and subgroup A RS virus F 
proteins no unglycosylated form of the TRT virus 58K or 45K 
polypeptides could be identified when infected cells were 
labelled in the presence of tunicamycin. This could have 
been due to failure of the antiserum to recognize the 
unglycosylated polypeptide or instability of the 
unglycosylated polypeptide. 
TRT virus also had a 31K glycoprotein similar to that 
of PVM described in Section 3.3.27. This glycoprotein was 
.. 
not detected by radiolabelling with [3s SJ-methionine and 
produced a very diffuse band. The oligosaccharides of this 
polypeptide appeared to be N-linked. No equivalent 
polypeptide has been demonstrated in RS virus infected cells 
after labelling with [3H]-glucosamine and 
immunoprecipitation with anti-RS virus serum. However 
immunoprecipitation of [3HJ-glucosamine labelled RS virus 
polypeptides with an antiserum raised against a synthetic 
peptide corresponding to the carboxy terminus of the NS1A 
polypeptide does precipitate a similar polypeptide (C. 
Caravokyri, personal communication). 
The TRT virus specific 58K, '45K, 38K, 3DK, 23K, 19K 
and 15K polypeptides were identified by immunoprecipitation 
of [3sSJ-methionine labelled infected cell lysates using a 
murine anti-TRT virus antiserum. The 35K protein was not 
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identified in immunoprecipitates of [35 S]-methionine 
labelled samples but was identified in immunoprecipitates of 
32p labe~led samples. The 35K polypeptide could be analogous 
to the P protein of RS virus. The 30K polypeptide has 
similar mobility and charge properties to the PVM and RS 
virus M polypeptides charge heterogeneity being observed for 
all three polypeptides synthesized in vitro. Like the PVM M 
protein but unlike the RS virus M protein the 30K 
polypeptide of TRT virus was not phosphorylated. The 19K 
polypeptide could sometimes be resolved into two 
phosphorylated bands. The two 19K polypeptides had similar 
properties to the PVM 20K and 19K of PVM but had no obvious 
counterparts in RS virus. The TRT virus polypeptides 
identified are compared with those observed by Collins & 
Gough (1988) in Table 18 and the results summarized in Table 
19. 
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Table 18 Comparison of TRT virus polypeptides observed with 
the data of Collins & Gough (1988) 
Col,lins & Gough (1988) Present results 
TRT virus ~ TRT virus Mr 
protein (XtO- 3 ) protein (X10- 3 ) 
200K 200 
129K 129 
95K 95.4 
84K 84 83K 82.9 
58K 58.0 
54K 54 
45K 45.4 
42K 42 38K 38.5 
37K 37 35K 35.3 
., 
31K 31.0 
31K 31 30K 30.3 
23K 22.7 
19K 19.6 
14K 14 15K 15.5 
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Table 19 Polypeptides of TRT virus 
TRT virus Mr (X10- a ) Polypeptide Acidic Identified 
protein identified . or basic by immuno-
iTI vivo iTi vitro precipitation 
129K 129 + + 
95K 95.4 + + 
83K 82.9 + + 
58K 58.0 + + 
45K 45.4 + + 
38K 38.5 + + acidic + 
35K 35.3 + + acidic 
31K 31. 0 + + 
30K 30.3 + + basic + 
.. 
23K 22.7 + + basic + 
19K 19.6 + + basic + 
15K 15.5 + + acidic + 
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DISCUSSION 
4 DISCUSSION 
The polypeptides of RS virus. PVM and TRT virus are 
listed in Table 20 along with their major properties or 
suggested functions. In most instances the functions are 
based on the roles of proteins with similar properties in 
terms of location in the virion or nucleocapsids, charge and 
post-translational modifications in other paramyxoviruses or 
rhabdoviruses. Polypeptides with similar properties are 
shown in the same row of the table. The number of PVM and 
TRT virus encoded polypeptides has not been established 
since some of the less well labelled polypeptides may prove 
not to be virus encoded and others may be related to each 
other. The low titres of TRT virus stocks and the anti-TRT 
~ 
virus serum may have prevented the identification of poorly 
labelled TRT virus polypeptides. Molecular cloning of viral 
genes and analysis of transcripts will be required to 
identify the primary gene products. This may not be 
sufficient to identify all of the viral polypeptides present 
in infected cells however since some of the polypeptides 
detected probably arise from post-translational 
modifications. Monospecific antibodies, possibly raised 
against synthetic peptides may be required to establish the 
relationships between the polypeptides observed iTl v i ~/O. The 
classification of PVM and TRT virus into the genus 
Pneumovirus was initially based on morphological data 
(Berthiaume et al., 1974; Collins et al., 19S5b). The 
mobilities of the three major non-glycosylated polypeptides 
of these viruses also show some similarity (Cash et al., 
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TABLE 20 Summary of pneumovirus polypeptides 
Polypeptide designation Possible function 
PVM 
L 
G 
F1 
N 
39K 
M 
23K 
20K/19K 
18K 
17K 
16K 
31K 
RS virus 
L 
G 
FO,Fl,F2 
N 
P 
M 
M2 
NSIB 
NS1C 
NSIA 
TRT virus 
200K RNA polymerase~ transcriptase 1 
83K Attachment glycoprotein 
58K,45K,15K Fusion glycoprotein 
38K Nucleocapsid protein 
35K 
30K 
22K 
19K 
31K 
Phosphoprotein 
Matrix protein 
Second matrix protein 
? 
Second phosphoprotein 
., ? 
? 
? 
? 
? 
Glycosylated protein 
1) Functions/properties in italics are speculative, otherwise 
they are based on properties observed for the polypeptides 
of one or more of the viruses 
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1977; Collins et al., 1986b). Subsequently antigenic 
relationships have been identified between the Nand 39K 
polypeptides of PVM and the Nand P proteins of RS virus 
(Gimenez et al., 1984; Sections 3.1.10 and 3.2.5). Recently 
part of the sequence of the putative N gene of PVM has been 
shown to have a similar sequence to the N gene of human RS 
virus (J. Barr, P. Chambers & A. J. Easton, personal 
communication). 
The characterization of the PVM and TRT virus 
polypeptides are discussed separately followed by 
suggestions for further work on these viruses. 
4.1 Polypeptides of PVH 
A total of 20 virus specific polypeptides were 
identified in experiments on PVM proteins synthesized in 
vivo and in vitro (Table 9). Some of these polypeptides (G1, 
G2, F1, N, 39K, H, 20K and 19K) have been studied in more 
detail than the others. In the case of these polypeptides 
their possible equivalence to RS virus polypeptides is 
discussed. The large number of polypeptides identified on 
gels compared with the number of genes of human RS virus 
suggests that some of these polypeptides are related to each 
other. Recent analysis of the PVM transcripts using cDNA 
clones suggests that PVM may have 11 genes (P. Chambers, 
personal communication). 
The G protein of PVM appears to be processed in a 
different way to other viral glycoproteins. Processing of a 
glycoprotein to give a higher mobility form has been 
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obzerved for other viral glycoproteinz for example the 
influenza A virus haemagglutinin (Lazarowitz et al., 1973), 
the gp160 glycoprotein of the human immunodeficiency virus 
(McCune et aI., 1988) and corresponding env gene products 
of other retroviruses (e.g. Pinter & Fleissner, 1977) and 
the fusion proteins of the viruses in the family 
Paramyxoviridae (Sato et al., 1988; Scheid & Choppin, 1977; 
Fernie et al., 1985). These proteins however have disulphide 
bonds linking the two parts of a cleaved protein whereas 
experiments with the PVM G protein analysed under 
non-reducing conditions (Section 3.3.14) failed to detect 
any reduction in the intensity of the G2 polypeptide band. 
The HN glycoprotein of some strains of Newcastle disease 
virus has been observed to have a precursor' (HNo) but this 
protein has only N-linked oligosaccharides (Nishikawa et 
aJ., 1986). The only virus in the family Paramyxoviridae 
that has been observed to have non-N-linked oligosaccharides 
is RS virus which is believed to have extensive O-linked 
glycosylation of the G protein. A further similarity of the. 
PVM Gl protein to the RS virus G protein is the delayed 
appearance of these polypeptides in pulse chase experiments. 
In RS virus a 45K precursor (p45) has been identified that 
appears to undergo further processing to give the RS virus G 
protein probably due to addition of Q-linked sugars since 
this step is blocked by monensin (Appendix 1). In PVM no 
such precursor has been identified and monensin inhibits Gl 
production without any alternative form of the G protein 
accumulating so it is not clear if the processing of the PVM 
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and RS virus G proteins are similar at this stage. If the 
processing of the PVM and RS virus G proteins was similar 
the failure to detect either a precursor to G1 or a form of 
G1 devoid of Q-linked oligosaccharides could have been due 
to the instability of the polypeptide or failure of the 
monoclonal antibody to bind to it. A 42K G related 
glycosylated protein was observed but there was no evidence 
for it being a precursor to the G1 protein or becoming 
relatively abundant in monensin treated cells. 
The PVM G glycoprotein like the RS virus G protein 
does not form disulphide bonded oligomers under non-reducing 
conditions (Ding et al., 1987; Gruber & Levine, 1983). This 
differs from the situation with the large (HN) glycoproteins 
of Sendai virus and Newcastle disease virus that form 
disulphide bonded dimers or trimers (Ozawa et al., 1976; 
Hardwick & Bussell, 1979; Markwell & Fox, 1980). The large 
(H) glycoproteins of measles virus and CDV also form 
disulphide bonded dimers (Hardwick & Bussell, 1978; Lund & 
Salmi, 1981; Shapshaket al., 1982). The possibility that 
the PVM Gl protein represented a dimer of the 42K protein as 
has been suggested with the RS virus G and p45 proteins 
(Fernie et al., 1985) cannot be ruled out. 
The difference between the G1 and G2 proteins of PVM 
may have been largely or even entirely due to differences in 
the extent of glycosylation. The G1 and G2 glycoproteins 
synthesized in the presence of tunicamycin or digested with 
glycopeptidase F showed mobility increases corresponding to 
reductions in ~ of 18K and 13.8K. The difference in extent 
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of a-linked glycosylation was even more marked, the 
increases in mobility of the Glt and G2t proteins following 
digestion 
corresponding 
respectively. 
with endo-«-N-acetylgalactosaminidase 
presence of 
to 
The 
reductions in Mr 
Mrs of G1 and 
of 
G2 
16.6K and 8.5K 
synthesized in the 
tunicamycin and digested with 
endo-«-N-acetylgalactosaminidase differed by only about 5K 
(Table 14) . Since the action of 
endo-«-N-acetylgalactosaminidase may not remove all of the 
Q-linked oligosaccharides there may be no difference in the 
size of the polypeptide of G1 and G2. 
Absence of the N-linked oligosaccharides had no effect 
on the stability of the PVM G protein in contrast to the 
situation with some viral glycoproteins such as the 
influenza A virus haemagglutinin (Schwarz et ai., 1976) and 
the F and G glycoproteins of subgroup B strains of human RS 
virus (Norrbyet a1., 1986; C. Caravokyri J personal 
communication). The Gl protein was also expressed at the 
cell surface normally in the presence of tunicamycin in 
contrast to the behaviour of some glycoproteins such as the 
measles virus fusion protein (Sato et a1., 1988). Processing 
of the G1 protein to give the G2 protein was also unaffected 
by the absence of N-linked oligosaccharides in contrast to. 
for example. the measles virus fusion protein where 
cleavage of the unglycosylated polypeptide does not occur 
(Sato et a1'J 1988). The subtype A RS virus proteins are 
processed normally when synthesized in the presence of 
tunicamycin (Fernie et ai., 1985; Gruber & Levine 1985a). 
The F proteins of subgroup B strains of human RS virus are 
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unstable in the presence of tunicamycin however so the 
properties of glycoproteins without their N-linked 
carbohydrates can vary between strains of the same virus. 
Processing of G1 to give G2 appeared to be a late 
event since monensin appeared to cause some reduction in the 
intensity of the G2 band relative to the G1 band and G2 
appeared only after several hours of incubation in the 
absence of label in pulse chase experiments. 
The high haemagglutination inhibition titre of the 
G-specific monoclonal antibody suggests that the G protein 
is involved in the haemagglutinating activity of the virus. 
Several monoclonal antibodies or monospecific antisera to 
each of the viral proteins would be necessary to confirm 
that this was the case since an antibody binding to the G 
protein could sterically inhibit haemagglutination involving 
another protein. Respiratory syncytial virus lacks a 
haemagglutinating activity and no such activity has been 
reported for TRT virus. In the Paramyxovirus and 
l1()rbillivirus genera haemagglutinating activity is 
associated with the larger of two viral glycoproteins so the 
G protein of PVM appears to be a likely candidate for the 
viral haemagglutinin. In all the viruses of the family 
Paramyxoviridae the large glycoprotein has been suggested to 
be the attachment protein. This has been demonstrated for 
the SV5 HN protein by Merz et al. (1981) and the RS virus G 
protein by Levine et al. (1987) using polyclonal sera 
directed against these proteins. Antibodies that inhibit 
attachment of the virus would be expected to neutralize the 
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virus. Orvell (1984) identified a group of monoclonal 
antibodies against one antigenic site of the mumps virus HN 
protein that could neutralize the virus but did not inhibit 
haemagglutination. Orvell & Grandien (1982) did not observe 
any antibodies to the Sendai virus HN protein that showed 
either HI or neutralizing activity independently of the 
other. The relationship between sites involved in 
haemagglutination and susceptibility of the viruses to 
neutralization by antibodies may therefore vary between 
viruses. The monoclonal antibody directed against the PVM G 
protein inhibited haemagglutination but did not neutralize 
the virus so if this protein is the viral attachment protein 
and the viral haemagglutinin these two functions must 
involve distinct sites on the protein. 
The PVM F protein was not identified by Cash et al. 
(1977, 1979a) probably due to a co-migrating host cell 
polypeptide in their samples that were not 
immunoprecipitated. The expression of the Fl protein on the 
cell surface and its association with the Gl and G2 
polypeptides in a pelleted fraction of the supernatant of 
PVM infected cells suggest that this polypeptide is a second 
major glycoprotein analogous to the F proteins of other 
paramyxoviruses. The RS virus F2 protein was readily 
labelled with [3H]-glucosamine but not with [ 35 S)-methionine 
and is more heavily glycosylated than the F1 protein as is 
the case with Sendai virus (Scheid & Choppin, 1977). In 
morbilli viruses only the 
glycosylated (Campbell et 
F2 
al .• 
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subunit 
1980; 
appears to be 
Hardwick & Bussell, 
1978; Mountcastle & Choppin, 1977; Orvell (1980); Tyrell & 
Norrby, 1978). With PVM the F1 protein was poorly 
glycosylated and no F2.subunit was detected by labelling 
with [3H]-glucosamine, [35 SJ-methionine or [1 4 C]-protein 
hydrolysate. If PVM has an F2 protein [ 35 S]-cysteine may be 
a suitable label to use since it would be expected to 
contain this amino acid. The predicted size of a PVM F2 
protein is much smaller than that of the F2 proteins of 
other paramyxoviruses. The failure to detect an FO-like 
polypeptide in pulse chase experiments argues against the 
existence of an F2 protein. The apparent alteration in 
mobility of the Fl protein under non-reducing conditions 
could be due to internal disulphide bonding . 
. 
When a pulse chase experiment was carried out with 
cells labelled in the presence of tunicamycin a polypeptide 
with a similar mobility to Fl, (designated FOt), disappeared 
and the Fit polypeptide appeared during the chase periods. 
There are three possible interpretations of this result. The 
disappearance of Fot and appearance of Fit may have been 
coincidental although this seems unlikely. FOt may have 
represented an unglycosylated form of FO that was detected 
in the absence of glycosylation due to slower processing. 
Finally, the FOt polypeptide may have represented Fl that 
was sensitive to, for example, protease activity giving rise 
to the higher mobility Fit band during chase periods. A lack 
of N-linked carbohydrate might account for the instability 
·of the FOt polypeptide. Although Fl and FOt had similar 
mobilities the extent of glycosylation of Fl appeared to be 
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low so this might be expected. This is supported by the 
failure to observe any mobility change when Fl was digested 
with glycopeptidase F. Increases in the mobility of Fl 
synthesized in the presence of tunicamycin could also have 
been due to altered cleavage of a signal peptide in the 
absence of glycosylation or altered translocation leaving 
part of the protein on the cytoplasmic side of the membrane 
that could subsequently be removed by proteases. The nature 
of the F protein of PVM is therefore unclear but it appears 
to differ from that of other viruses in the family 
Paramyxoviridae in that it has a very small Fl subunit or 
none at all and it is very poorly glycosylated. 
The 48K polypeptide synthesized in vitro was not 
~ 
observed in immunoprecipitates of PVM infected cell lysates 
or PEG precipitates of the supernatants of PVM infected 
cells. It was possible that this polypeptide represented an 
unglycosylated form of one of the glycoproteins. It was too 
large to represent an unglycosylated form of the PVM G 
protein. This was the only potential glycoprotein identified 
by labelling in vitro which favours the possibility that it 
was related to the F protein of PVM since this protein was 
more readily labelled with amino acid labels than the G 
protein. Labelling of the 48K polypeptide to a higher 
specific activity followed by a comparison of the tryptic 
peptide map of this polypeptide to those of PVM polypeptide 
synthesized in vivo would probably be the best way of 
resolving this difficulty. 
The N polypeptide of PVM was identified as the 
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nucleocapsid polypeptide by Cash et aJ. (1979&). Either the 
N or the 39K polypeptide was phosphorylated. The 
nucleocapsid proteins of canine distemper virus (Hall et 
aI .• 1980), measles virus (Robbins & Bussell, 1979), mumps 
virus (Rima et al., 1980) and Sendai virus (Lamb & Choppin, 
1977) are phosphorylated. The N protein of Sendai virus also 
exists in a non-phosphorylatea form (Lamb & Choppin. 1977) 
and the nucleocapsid protein of RS virus is not 
phosphorylated. There are therefore precedents for both 
phosphorylated and non-phosphorylated nucleocapsid proteins. 
The N protein of PVM shows a similar streak when identified 
by two dimensional NEPHGE/SDS-PAGE to the N protein of RS 
virus (Figure 7) suggesting that it may have similar 
properties to the N protein of RS virus. 
The 39K polypeptide of PVM may be analogous to the RS 
virus P protein. The 39K polypeptide may represent the 
phosphorylated polypeptide, the 35K polypeptide which gives 
a similar peptide profile to the 39K protein after digestion 
with chymotrypsin (Figure 7) representing an 
unphosphorylated form of the protein. In Sendai virus the P 
protein has been observed to be relatively more abundant in 
infected cells than in virions (Lamb et al., 1976; Portner & 
Kingsbury, 1976). The 39K polypeptide was observed to be 
more readily immunoprecipitated from cell lysates than from 
dissociated PEG precipitates of culture supernatants 
suggesting that the 39K polypeptide is also more abundant in 
infected cells than in the culture supernatants. The 
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unphosphorylated 35K polypeptide was only detected in cell 
lysates and has not been identified in partially purified 
virus (Cash et al., 1979a). There i5 no evidence of a 
progression of label from the 35K polypeptide to the 39K 
polypeptide during pulse chase experiments. This suggests 
that either no interchange between the forms of the 39K 
protein occurs or that an equilibrium is reached with only 
the 39K form being .tncorporated into virions. The 
significance of the 35K polypeptide is not clear since it 
has not been detected in lysates of PVM infected BHK-21 
cells in which PVM is able to multiply (Cash et al., 1979&). 
The cross reaction of the anti-39K polypeptide monoclonal 
antibody 26/4/C4 with the RS virus P protein provides 
further evidence that these polypeptides may have similar 
functions. Immunoprecipitation of 32phosphorous labelled PVM 
proteins with the anti-39K polypeptide 26/4/C4 would 
determine if the 39K polypeptide was in fact phosphorylated. 
The M protein of PVM has not been shown to be envelope 
associated since insufficient quantities of radiolabelled 
virus could be obtained. The M proteins of PVM and RS virus 
do however share a similar basic nature. On two dimensional 
NEPHGE/SDS-PAGE gels minor spots with the same mobility as 
the M protein were observed with both PVM and RS virus 
polypeptides. The spots may represent conformational 
variation of the M protein such as different disulphide bond 
arrangements. Different forms of M have been observed under 
non-reducing conditions with both PVM (data not shown) and 
RS virus (Gruber & Levine, 1983). Although the NEPHGE sample 
buffer contained 2-mercaptoethanol it did not contain SDS 
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and the samples were not heated so not all of the disulphide 
bonds may have been disrupted. The matrix proteins of Sendai 
virus and measles virus have an affinity for lipid and 
nucleocapsids suggesting that they may be involved in 
assembly of the virus (Shimizu & Ishida, 1975; Tyrell et 
a1.J 1980; Yoshida et al., 1976). As described in the 
introduction the RS virus matrix protein remains associated 
with subviral particles. The M protein of PVM was 
co-precipitated with the 39K polypeptide suggesting that 
these polypeptides may be associated. 
There was some evidence that the 20K and 19K 
polypeptides may have been related but this was only from a 
partial proteolysis experiment and the 20K and 19K 
.. 
polypeptides may not have been sufficiently well resolved to 
excise the bands cleanly. One or both of these polypeptides 
was phosphorylated. If the polypeptides are related the 
mobility difference between them could have been due to 
different degrees of phosphorylation. This might also 
account for differences in the intensity of the 20K and 19K 
polypeptides observed in vitro. There was no obvious 
counterpart of the 20K or 19K polypeptides in RS virus 
although an 18K phosphorylated polypeptide of unknown origin 
was identified. The 20K and 19K polypeptides were readily 
detected in PEG precipitates of PVM infected cells 
suggesting that they were probably structural polypeptides 
of the virus. 
Little is known about the L, 25K, 24K, 23K, 18K, 17K, 
16K, and 12K PVM polypeptides or the 31K glycosylated 
282 
\ 
polypeptide. Since the 18K and 17K polypeptides were only 
regularly identified when synthesized in vitro they probably 
represent primary translation products that are modified to 
give other proteins in infected cells. A 17K polypeptide was 
in fact identified in infected cells after a pulse labelling 
period (Section 3.3.20). The 12K protein was not a primary 
gene product appearing only after a chase period (Section 
3.3.20). 
4.2 TRT virus polypeptides 
The TRT virus polypeptides identified are summarised 
in Table 19 and compared with those described by Collins & 
Gough (1988) in Table 18 and with those of the pneumoviruses 
in Table 20. The 200K polypeptide described by Collins & 
Gough (1988) in preparations of partially purified virus was 
not observed probably due to low levels of label 
incorporation. A 200K polypeptide was immunoprecipitated by 
a chicken anti-TRT virus serum but the result was difficult 
to interpret since the only other polypeptides 
immunoprecipitated by this serum were the 38K TRT virus 
polypeptide and the RS virus N protein. All of the other 
polypeptides described by Collins & Gough (1988) were 
observed in infected cell lysates or PEG precipitates of 
culture supernatants. 
The 83K glycoprotein was not observed in cell lysates 
suggesting that it may be derived from an intracellular 
precursor of different mobility. The 95K glycoprotein 
observed only in cell lysates was a possible candidate for a 
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precursor of the 83K polypeptide. Pulse chase experiments 
would be required to determine if the 95K and 83K 
polypeptide did show such a relationship. Ideally an amino 
acid label would be used along with immunoprecipitation by a 
specific antibody to carry out such an experiment. If the 
protein was very difficult to label with amino acid labels 
[3H]-glucosamine could probably be used because although 
label incorporation continues during the chase period the 
appearance of the PVM G2 protein after a chase period could 
be detected in this way. Labelling of TRT virus infected 
cell with [3H]-glucosamine in the presence of tunicamycin 
showed that all the TRT virus glycoproteins had N-linked 
oligosaccharides. This did not exclude the possibility that 
other types of oligo saccharides occurred since the 
glycoproteins devoid of N-linked oligosaccharides may have 
been unstable. This could be examined further by digesting 
the glycoprotein bands excised from gels with glycosidases. 
The label incorporation achieved with TRT virus polypeptides 
was low compared with the label incorporation into PVM 
polypeptides. To avoid the losses of label observed during 
digestion of PVM and RS virus glycoproteins it would 
probably be better to digest the glycoproteins in the gel 
slices after washing them in a similar way to that described 
for the tryptic peptide mapping experiments. The gel slice 
and any fluid could then be boiled with sample buffer and 
loaded into the gel slots avoiding any significant loss of 
labelled glycoprotein. The nature of the 95K and 83K 
polypeptides if they represent distinct proteins is not 
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clear although either or both proteins could represent 
aggregates of lower molecular weight polypeptides. The 
function of the 83K polypeptide is not known, no 
haemagglutinating or neuraminidase activity has so far been 
demonstrated for TRT virus. By analogy with the G protein of 
RS virus which has a similar mobility it could be the 
attachment protein of the virus. 
The 45K and 15K glycosylated polypeptides had similar 
properties to the F1 and F2 polypeptides of RS virus. Under 
non-reducing conditions these bands were reduced in 
intensity and a band of 58K was detected. The most likely 
explanation of this is that the 45K and 15K polypeptides are 
disulphide bonded. To demonstrate that they are derived by 
cleavage of a precursor polypeptide a pulse chase experiment 
would need to be carried out to show the passage of labelled 
amino acid from a precursor of about 58K to the 45K and 15K 
polypeptides. An attempt to demonstrate this was 
unsuccessful due to inadequate label incorporation into 
pulse labelled polypeptides immunoprecipitated with the 
anti-TRT virus serum. 
The 38K polypeptide was one of the two most readily 
detected TRT virus polypeptides. Its mobility was similar to 
that of the nucleocapsid proteins of PVM and RS virus and it 
was acidic although it did not show such pronounce streaking 
during NEPHGE as the nucleocapsid proteins of PVM and RS 
virus. Like the nucleocapsid protein of RS virus it does not 
appear to be phosphorylated. It was present in material 
isolated using a method designed for the isolation of RS 
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virus nucleocapsids (Ward et al. 1983) and which gave 
material containing predominantly the N polypeptide of PVM 
when used with lysates of PVM infected cells. However, the 
35K and 30K polypeptides were also present in the material 
isolated from TRT virus infected cells (data not shown). 
The 35K polypeptide of TRT virus had a similar 
mobility and charge to the P protein of RS virus and the 35K 
polypeptide of PVM. Like the P protein of RS virus the 35K 
polypeptide of TRT virus is phosphorylated. The 35K 
polypeptide of PVM is not phosphorylated but as discussed 
above is related to the 39K polypeptide that may be 
phosphorylated. The 35K polypeptide synthesized iTi lIitro is 
indistinguishable on the basis of mobility and charge from 
• 
the 35K polypeptide synthesized iTI ~I i 110 suggesting that it 
may be phosphorylated in villo. 
The 30K polypeptide of TRT virus has been identified 
in radiolabelled cell lysates, amongst the products of iTi 
vitro experiments and on stained gels of partially purified 
virus (Collins & Gough,. 1988 i Ling & Pringle, 1988). It is 
readily detected and appears to be basic like the M proteins 
of PVM and RS virus. The 30K polypeptide co~migrates with 
several minor spots revealed on two dimensional gels. The 
different spots could represent polypeptides with different 
arrangements of disulphide bonds, two dimensional SDS-PAGE 
using non-reducing conditions for the first dimension and 
reducing conditions for the second dimension would enable 
.this to be established. The 30K polypeptide of TRT virus 
migrates with a lower mobility than the PVM and RS virus M 
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proteins. The relative position and intensity of the 30K 
polypeptide band does however resemble that of the PVM and 
RS virus M proteins. It seems likely that the 3DK 
polypeptide of TRT virus is a matrix-like protein. 
The 23K and 19K polypeptides of TRT virus were not 
observed in preparations of partially purified virus by 
Collins & Gough 
polypeptides. The 
(1988) 
19K 
and may be non-structural 
polypeptide could however be 
identified in PEG precipitates of culture supernatants. The 
23K polypeptide was however basic like the RS virus M2 
protein and resembling this protein in its location on two 
dimensional gels more than any other pneumovirus 
polypeptide. The 19K polypeptide did not clearly resemble 
any pneumovirus polypeptide being phosphorylated and having 
a similar mobility to the PVM 20K and 19K polypeptides but 
being basic when identified on two dimensional gels. 
4.3 Suggestions for further work 
There are several experiments .that could be performed 
to further characterize the polypeptides of PVM, TRT virus 
and RS virus. Digestion with glycosidases could be used to 
determine the extent of N-linked and O-linked glycosylation 
on the viral glycoproteins directly. This would be most 
informative for the TRT virus glycoproteins where all that 
is known is that some N-linked oligosaccharides are present 
on the glycoproteins. The digestion of the G1tand G2t 
~olypeptides of PVM with endo-«-N-acetylgalactosaminidase 
could usefully be repeated since it is not known how 
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reproducible or complete this digestion is. The use of sugar 
labelling and/or different enzyme concentrations would give 
an indication of whether all the carbohydrate is removed. 
The use of G1t and G2t rather than G1 and G2 would remove 
the complication of the digestion of N-linked carbohydrate 
by the exoglycosidases or the requirement to obtain 
conditions under which the proteins could be digested by 
both glycopeptidase F and endo=«-N-acetylgalactosaminidase. 
Digestion with both enzymes would be required to study the 
TRT virus glycoproteins because they appear to be unstable 
when synthesized in the presence of tunicamycin. Digestion 
of the RS virus G protein synthesized in the presence of 
tunicamycin would be useful to give a direct indication of 
the degree of a-linked glycosylation on this protein. Pulse 
chase experiments to determine the relationships between TRT 
virus glycoproteins have already been mentioned. Studies on 
the non-glycosylated proteins mainly require the resolution 
of closely migrating bands such as the 20K and 19K 
polypeptides and increased label incorporation in the minor 
polypeptides such as the various bands observed in the 
20-25K region of the gel and the polypeptides with apparent 
~s of less than 19K. These polypeptides need to be studied 
by peptide mapping along with the major viral polypeptides 
to determine which of them represent unique viral proteins 
and which of them are related to other viral proteins. 
Radiolabelling of polypeptide bands with iodine -125 would 
.enable higher specific activities to be obtained for tryptic 
peptide mapping. This approach was not attempted in the 
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experiments described in Section 3.3 because of the 
immunoglobulin bands of 45-50K and 22-24K regions of the 
gel. This problem could be overcome by using a two 
dimensional gel with a non-reducing first dimension that 
would separate the immunoglobulin, migrating as an intact 
150K molecule under these conditions), from the viral 
polypeptides. The viral polypeptides could then be identified 
from their mobilities on the dimension gel. Alternative 
methods of preparing TRT virus nucleocapsids and detergent 
and salt treatment of partially purified virus could be used 
to determine the location of the viral polypeptides in 
virions. The possibility of determining whether the N or 39K 
polypeptide of PVM was phosphorylated by immunoprecipitation 
with the anti-39K protein monoclonal antibody 26/4/C4 has 
already been mentioned. An interesting observation was the 
low background of cellular polypeptides observed when 
polypeptides were synthesized in vitro using RNA from 
infected cells treated with actinomycin D. This could have 
been due to the RNA being synthesized for an extended period 
in the presence of actinomycin D prior to labelling of 
polypeptides. Actinomycin D apparently had no effect on the 
background of cellular polypeptides synthesized in infected 
cells but labelling in this case was begun only one hour 
after treatment with actinomycin D. The effect of treatment 
with actinomycin D 12 to 24 hours prior to labelling for 1 
hour might reveal if timing of the labelling would explain 
the discrepancy between the results obtained in vitro and in 
vivo. Another explanation might be that a protein bound to 
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the viral mRNA molecules and inhibited translation which 
could then take place after the RNA had been extracted and 
added to an in vitro translation system. This possibility 
could easily be tested by adding extracts of uninfected and 
PVM infected cells to in vitro translation reactions. This 
would reveal whether translation of the viral mRNA was 
inhibited by a cellular or a viral protein. 
~ The results presented in this thesis describe the 
first detailed study of PVM glycoproteins and a preliminary 
study of the TRT virus proteins. Further characterization of 
these viruses awaits molecular cloning of the viral genomes 
and production of additional specific antibodies to the 
viral proteins. Some progress on molecular cloning of these 
viruses has already been made in the same laboratory by P. 
Chambers, J. Barr and A. J. Easton, the PVM clones being 
prepared from the cellular RNA extracted from PVM infected 
cells that was used in the in vitro translation experiments 
described in Sections 3.1.7-9 and 3.5.4. The 
characterization of the viral genomes will show the number 
of primary gene products and enable the relationship of 
these viruses to RS virus to be more clearly established. 
eDNA clones will enable studies of both transcription of 
viral genes and identification of polypeptides synthesized 
in vitro to be carried out. In addition sequence data would 
enable synthetic peptides to be produced. Such peptides 
would provide convenient antigens for raising antisera for 
studying polypeptide synthesis in vivo. eDNA clones and 
specific antibodies would be useful for attempts to identify 
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any PVM related viruses 
patients. Further isolates 
in clinical samples from human 
of PVM would be required to 
establish if significant strain variation occurs. 
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APPENDICES 
.. 
APPENDIX 1 
Glycosylation of polypeptides 
Two types of oligosaccharides occur in glycoproteins, 
distinguished by the nature of the linkage to the 
polypeptide chain. Many oligosaccharides are linked to 
asparagine residues and are described as being N-linked. 
Other oligosaccharides may be linked to serine, threonine or 
~ 
less commonly hydroxylysine or hydroxyproline residues. 
These are referred to as O-linked oligosaccharides. 
N-linked oligosaccharides are initially synthesized 
and added to the polypeptide in the rough endoplasmic 
reticulum (Katz et al o , 1977; Rothman & Lodish, 1977; 
Sefton, 1977; Tonezuzzo & Ghosh, 1977, 1978). 
N-acetylglucosamine is transferred from 
N-acetylglucosamine-UDP to dolichol phosphate followed by 
the transfer of a further N-acetylglucosamine residue, 9 
mannose residues and 3 glucose residues from 
glycosyl-nucleoside diphosphates to the oligosaccharide 
chain (reviewed by Kornberg & Kornberg, 1980; Waechter & 
Lennarz, 1976). Figure 69 shows a diagram of the synthesis 
and processing of N-linked carbohydrates. This precursor 
oligosaccharide is then transferred to an asparagine residue 
of a newly synthesized polypeptide chain at the sequence 
Asn-X-Ser(Thr) where X can be any amino acid. This sequence 
is required for attachment of the oligosaccharides but not 
every sequence of this type is glycosylated. The precursor 
oligosaccharide is processed during transport to the Golgi 
apparatus by removal of the glucose and a variable number of 
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FIGURE 69 Synthesis of N-linked oligosaccharides 
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the mannose residues to give a high mannose oligosaccharide. 
The oligosaccharide may then be further processed by the 
addition of N-acetylglucosamine, galactose, neuraminic acid 
and fucose residues within the Golgi apparatus to give a 
complex form. The involvement of the Golgi apparatus in 
processing of complex carbohydrates has been indicated by 
the enrichment of the glycosyltransferases in fractions 
\) 
enriched in this organelle (Munro et a1., 1975) and by 
autoradiography (Haddad et a1., 1971). A single glycoprotein 
may have both high mannose and complex carbohydrates, for 
example thyroglobulin (Arima & Spiro, 1972) and IgM (Hickman 
et a1., 1972; Shimizu et a1., 1971). A single glycoprotein 
may also possess both complex and O-linked oligosaccharides, 
for example fetuin (Spiro, 1973) and human IgA (Baenziger & 
Kornfield, 1974a and b). 
Tunicamycin is an antibiotic that inhibits transfer of 
sugars to dolichol phosphate and as a result inhibits 
addition of N-linked oligosaccharides to polypeptides 
(Waechter & Lennarz, 1976). It does not inhibit attachment 
of Q-linked oligosaccharides to glycoproteins (Holmes et 
1981; Shida & Dales, 1981) . 
Endo-8-N-acetylglucosaminidase H cleaves between the two 
N-acetylglucosamine residues proximal to the polypeptide 
chain in high mannose but not complex carbohydrates (Arakawa 
& Muramatsu, 1974; Tarentino et a1 . , 1974). 
Endo-J-N-acetylglucosaminidase D catalyses a similar 
cleavage with a specificity for complex oligosaccharides 
without side chains and with a Man3GlcNAc2-Asn sequence or 
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complex oligosaccharides with one side chain and one 
terminal mannose residue (Ito et a 1 . , 1975) . 
Endo-~-N-acetylglucosaminidase F (Endo F) cleaves N-linked 
oligosaccharides without specificity for the nature of the 
carbohydrate. Glycopeptidase F is similar to Endo F but 
cleaves between the asparagine and the first glucosamine 
residue. These enzymes have 
.. 
been used to determine the 
nature of N-linked oligosaccharides of glycoproteins. 
O-linked oligosaccharides are synthesized in the Golgi 
apparatus by transfer of individual oligosaccharides from 
glycosyl-nucleoside diphosphates to serine or threonine 
residues or other sugars attached to such residues. They 
vary in complexity from simple disaccharides in submaxillary 
mucins to complex branched structures such as those of blood 
group antigens (reviewed by Kornfield and Kornfield, 1980). 
No common amino acid sequences have been identified around 
glycosylated serine/threonine residues and it has been 
suggested that acceptor regions have little secondary 
structure making them accessible to the 
UDP-N-acetylgalactosamine:polypeptide «-N-acetyl-
galactosaminyl transferase (Hill et al., 1977). Serine and 
threonine linked oligosaccharides are normally identified by 
their susceptibility to removal by alkaline borohydride 
treatment but this procedure results in destruction of the 
polypeptide chain and so cannot be used for studying the 
polypeptide. Other O-linked oligosaccharides are attached to 
hydroxyproline or hydroxyproline but these appear to be 
restricted to limited types of glycoproteins. Hydroxylysine 
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attached oligosaccharides occur in collagens (Morgan et al., 
1970) and hydroxyproline attached oligosaccharide5 occur in 
proteins in plant cell walls known as extensins (Lamport et 
al., 1973). Another type of O-linked oligosaccharide has 
been described in which single N-acetylglucosamine residues 
are attached to the polypeptide and in which the 
monosaccharides are added in the cytoplasm (Davis & Blobel, 
1987). 
.~ 
Only one 
oligo saccharides 
enzyme 
appears 
Endo-«-N-acetylgalactosaminidase 
specific for O-linked 
to be available. 
cleaves unsubstituted 
galactose disaccharides from serine and threonine residues 
but does not work if either galactose residue is substituted 
50 additional sugars need to be removed with 
exoglycosidases. Monensin, an ionophore specific for 
monovalent cations, has been used as an inhibitor of Golgi 
apparatus functions including addition of O-linked 
oligosaccharides to polypeptides (Alonso & Compans, 1981; 
Johnson & Schlesinger, 1980; Johnson & Spear, 1982, 1983; 
Niemann et al., 1982; Pressman 1976). 
Tunicamycin, monensin, Endo H, Endo D and Endo F have 
been used in the study of RS virus glycoproteins. 
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APPENDIX 2 
Suppliers names and addresses 
Amersham International plc, Aylesbury, Bucks. ,UK 
Amplify 
Biotinylated anti-mouse Ig, general purpose screening 
reagent 
Biotinylated peroxidase plus streptavidin 
Biotinylated protein A 
D-(1-3 H]-glucosamine hydrochloride 5.8Ci mmol- l 
L-(4,5-3 H]-leucine 
L-[ 35 S]-methionine 1490Ci mmol- l 
Rabbit reticulocyte lysate 
Streptavidin-biotinylated peroxidase complex 
Bantin & Kingman Ltd, Grimston, Hull, UK 
Balb/c mice, female 6-8 weeks old 
BDH Chemicals Ltd, Atherstone, Warwks., UK 
Citric acid 
Glutaraldehyde solution (50%) 
2-Mercaptoethanol 
Nonidet P-40 
Orthophosphoric acid 
Phenol 
Polyethylene glycol 1500 
Polyethylene glycol 6000 
Potassium chloride 
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Potassium dihydrogen orthophosphate 
Sodium hydroxide 
di-Sodium hydrogen orthophosphate 
Beckman RIIC Ltd., High Wycombe, UK 
Ready-solv EP liquid scintillation fluid 
Bio-rad Laboratories Ltd., Watford, Herts., UK 
BRP colour development reagent 
Trans blot apparatus 
Boehringer-Mannheim (BCL) , The Boehringer Corporation Ltd, 
Lewes, East Sussex, UK 
Polyethylene glycol (50% solution in HEPES) 
Tunicamycin 
Glycopeptidase F 
Endo-«-N-acetylgalactosaminidase 
BRL (Bethesda Research Laboratories) Ltd., Renfrew Road, 
Paisley, OK 
Ammonium persulphate 
Carbon-14 labelled molecular weight markers 
Immunoprecipitin 
297 
Chance Propper Ltd., Smethwick, Warley, UK 
Cover glasses, 17mm diameter, No.l.5 
Microscope slides, 76X26Xl.0-l.2mm 
Fisons PLC (Services), Crawley, Sussex, UK 
Acrylamide, specially purified for electrophoresis 
Ammonium hydrogen carbonate 
., 
Butan-l-ol 
Calcium chloride 
Chloroform 
Diaminoethanetetra-acetic acid,disodium salt 
Diethyl ether 
Dimethyl sulphoxide 
2,5-Diphenyloxazole 
Glycerol 
Glycine 
Hydrogen peroxide (100 vols;) 
Lithium chloride 
Magnesium chloride 
Magnesium sulphate 
Nitric acid 
Sodium chloride 
Sodium lauryl sulphate, 
biochemical work 
Trichloroacetic acid 
Urea 
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specially 
.. 
purified for 
Flow Laboratories Inc., Rickmansworth, Herts., UK 
Foetal calf serum 
Glasgow modification of Eagles medium 
HLA plates, 60 well 
Round bottomed 96 well plates 
Fuji Photo film Co. (UK) Ltd., 125 Finchley Road, London, UK 
RX medical X-ray film 
Gibco Europe Ltd., Paisley, Scotland 
Foetal calf serum 
Glutamine (200mM) 
Leucine (200mM) 
Methionine (200mM) 
Non-essential amino acids (lOOX ) 
Tryptose phosphate broth 
Valine (200mM) 
Kodak Chemicals Ltd., Kirby, Liverpool, UK 
N,N-methylene bis-acrylamide 
LKB Instruments Ltd., Milton Keynes, Bucks., UK 
Ampholines pH3.5-10 
Ampholines pH5-7 
May and Baker Ltd., Eccles, Manchester, UK 
Acetic acid, (glacial) 
Ethanol 
299 
\ 
Hydrochloric acid 
Methanol 
Miles Laboratory Ltd., Stoke Poges, Slough, UK 
Mixed glycosidases from Turbo cornutus 
Nordic Immunological Reagents Ltd., Maidenhead, Berks., UK 
Rabbit anti-mouse immunoglobulins-FITC conjugate 
Northumbria Biologicals Ltd., Nothumberland, UK 
Costar 6,12, and 24 well tissue culture clusters 
Costar 25cm2 ,50cm2 and 150cm2 tissue culture flasks 
ESG hybridoma growth factor 
Schleicher and Schuell, Dassel, West Germany 
BA8S membrane filter 
Cellulose thin layer chromatography plates (20X20cm) 
Sigma chemical Company, .Poole, Dorset, UK 
Acid fuchsin 
Actinomycin D 
Aminopterin 
Bovine serum albumin 
Crystal violet 
Diethyl pyrocarbonate 
Freunds complete adjuvant 
Freunds incomplete adjuvant 
HAT medium supplement 
300 
HEPES 
HT medium supplement 
Hypoxanthine 
L-methionine 
Monensin 
Neuraminidase 
Orange G 
Orthophenylenediamine 
Paraformaldehyde 
Phenylmethylsulphonylfluoride 
Polyoxyethylene sorbitan monolaurate (Tween 20) 
Ponceau S 
2,6,10,14-Tetramethylpentadecane 
Thymidine 
Triton X-100 
Trizma base 
va protease 
. Sera lab, Crawley Down, Sussex, UK 
Foetal calf serum 
Sterilin, Teddington, Middlesex, UK 
96 well tissue culture plates 
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